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Abstract 
Clostridium difficile is the most common cause of antibiotic-associated diarrhoea and 
the severity and incidence of C. difficile infections (CDIs) have risen dramatically in the last 
decade. C. difficile is only able to cause disease once the microbiota of the gut has been 
damaged, usually through the use of broad spectrum antibiotics. CDIs are treated using 
antibiotics which further damage the microbiota, resulting in high rates of recurrence. This 
highlights the need for more specific CDI therapies that do not damage the natural flora.  
Avidocin-CDs are a potential alternative therapy for CDI that resemble the R-type 
Pyocins of Pseudomonas aeruginosa, and kill C. difficile by inserting a needle like core through 
the bacterial cell envelope. We have demonstrated that these complexes bind SlpA, the major 
component of the S-layer. Spontaneous mutants resistant to Avidocin-CDs, that lacked a 
functional S-layer, were isolated. These S-layer mutants, and a strain in which functional slpA 
was returned to the chromosome of these mutants, provided a unique opportunity to study the 
function of the S-layer. We have now demonstrated that the S-layer affects the growth and 
morphology of cells, sporulation efficiency, resistance to innate immune effectors and CwpV 
expression. Interestingly, we also demonstrated that the S-layer mutants are avirulent in the 
hamster model of infection, although maintain the ability to persist in the gut. Sequencing of 
the S-layer mutant genome also allowed the identification of a new phase variable promoter.  
In addition to studying S-layer function we also investigated S-layer biogenesis and the 
role of SecA2. Using pull-down experiments, we have identified potential SecA2 binding partners 
including members of the Cell Wall Protein family and the cell wall synthesis machinery 
components MreB and FtsZ. We provide evidence that S-layer biogenesis is localised to areas of 
cell wall growth and suggest a model in which SecA2 interacts with MreB or FtsZ to localise the 
secretion of SlpA to these areas.  
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Chapter I 
Introduction 
1.1 Clostridium difficile  
Clostridium difficile is a Gram-positive, spore forming, obligate anaerobe and is the 
major cause of antibiotic-associated diarrhoea. Originally named Bacillus difficilis due to the 
difficulty in culturing this organism, C. difficile was first isolated in 1935 from the stool of a 
healthy infant (Hall and O'Toole, 1935). Although pseudomembranous colitis, one of the most 
severe complications of C. difficile infection (CDI), was first described in 1893 (Bartlett, 1994), it 
wasn’t until 1978 that C. difficile was associated with human disease, being identified as the 
cause of the majority of antibiotic-associated diarrhoea cases (Bartlett et al., 1978; George et 
al., 1978). C. difficile has now been recognised as the leading cause of nosocomial diarrhoea and 
is being increasingly associated with community acquired disease (Freeman et al., 2010). 
Asymptomatic carriage of C. difficile occurs in 2-18% of healthy adults, with rates higher in 
hospital settings compared to the community, and 25-35% in children under 1 year old (Smits et 
al., 2016). Despite this frequent asymptomatic carriage, C. difficile can cause disease ranging in 
severity from mild, self-limiting diarrhoea to the more severe cases characterised by severe 
diarrhoea, abdominal pain, and leucocytosis (Burke and Lamont, 2014).  These diseases can 
progress into the more severe inflammatory complication, pseudomembranous colitis, which 
can, in turn, progress to toxic megacolon (Fig.1.1). Such severe CDIs are associated with high 
rates of mortality (Martin et al., 2016).  
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Fig.1.1: Manifestations of severe CDI. (A) Colonoscopic examination of a healthy colon, showing normal 
mucosa. (B) Sigmoidoscopy of a 74-year-old man showing symptoms of severe CDI. Notable are the 
‘volcanic’ yellow lesions present on the mucosa, characteristic of pseudomembranous colitis. (C) 
Computed tomography (transverse plane) of the patient’s abdomen showing clear dilation of the colon 
(white arrow), characteristic of toxic megacolon. Modified from (Gweon et al., 2015).  
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1.1.1 Epidemiology of C. difficile Infection 
From its identification as a pathogen in the 1970s, CDI was considered a common, easily 
managed complication of antibiotic use. Before 2003, no systematic surveillance on circulating 
C. difficile types was performed. However, since 2003 a large increase in the severity and 
incidence of CDI was observed in North America, several European countries including the UK, 
and, after 2008, Australia, Asia, and Central America. This was associated with emergence of the 
epidemic PCR ribotype 027 strains, and to a lesser extent ribotype 078 (Goorhuis et al., 2008; 
He et al., 2013).  
This increase in incidence and mortality due to CDI continued in the UK until 2007, when 
more than 55,000 cases of CDI resulting in 8,324 deaths were reported, more than five times 
the number of deaths caused by MRSA infection (https://www.ons.gov.uk/).  Due to the huge 
threat posed by CDI, increased surveillance and mandatory reduction targets for CDI were 
implemented and the incidence has fallen steadily since 2007 in England and Wales, with only 
1,646 deaths involving CDI reported in 2012 (Wilcox et al., 2012) (https://www.ons.gov.uk/).  
Despite these infection control successes in the UK, the European Centre for Disease 
Prevention and Control (ECDC) 2011 and 2012 point-prevalence survey estimated that within 
the European Union approximately 124,000 individuals develop nosocomial CDI each year and, 
as many cases are overlooked, this figure is probably an underestimate (ECDC, 2013). Although 
the accuracy of the approximation is uncertain, the US Centres for Disease Control and 
Prevention (CDC) estimated that there were approximately 500,000 cases of CDI, resulting in 
29,000 deaths, in the US in 2011 (Lessa et al., 2015). C. difficile poses such as threat to human 
health that in 2013 the CDC labelled the risk posed as ‘urgent’ (CDC, 2013). 
CDI typically occurs in health-care settings due to the abundance of antibiotic use, high 
concentrations of elderly patients with compromised immune systems, abundance of spores in 
the environment, and poor health care provider hygiene. For these reasons, elderly, hospitalised 
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patients undergoing prolonged treatment with antibiotics are the most common sufferers of 
CDI. Broad spectrum antibiotic treatment increases the risk of CDI as it disrupts the intestinal 
microbiota allowing C. difficile to establish and cause disease. C. difficile is the most common 
cause of antibiotic associated diarrhoea, estimated to cause 15-39% of cases (Viswanathan et 
al., 2010). Although many antibiotics have been associated with CDI, cephalosporins, 
clindamycin and fluoroquinolones carry a higher risk compared to others (Johnson et al., 1999; 
Pepin et al., 2005). Unlike cephalosporins and clindamycin, to which almost all C. difficile strains 
are resistant, the risk of fluoroquinolone use is more recent due to the increased incidence of 
fluoroquinolone resistant ribotype 027 strains (Pepin et al., 2005). 
Although CDI is typically a nosocomial infection, community-acquired disease is 
increasingly observed and, atypically, these infections occur in individuals lacking the classic risk 
factors, including prior antibiotic exposure (Gupta and Khanna, 2014). In North America and 
Europe, it is estimated that 20-27% of CDI cases are community-associated (Gupta and Khanna, 
2014). A recent study of over 15,000 CDI cases in the USA concluded that community-acquired 
infection occurred in 30-120 individuals per 100,000 (Lessa et al., 2015). In the Netherlands, 
community-acquired CDI alone is estimated to occur in 390–730 individuals per 100,000, making 
it more common than Salmonella infection (Bouwknegt et al., 2015). Individuals with community 
acquired CDI are less likely to have been exposed to antibiotics prior to infection compared to 
nosocomial infections (78% and 98% respectively) (Khanna et al., 2012). In addition, it seems 
that community acquired CDI occurs more often in younger patients, with the median age of 
community-acquired CDI patients being 50, compared with 72 for patients with nosocomial 
infections (Khanna et al., 2012). 
1.1.2 Tools Available for C. difficile Genetic Manipulation 
 C. difficile research has been hampered due to the lack of tools available for the genetic 
modification of this organism. Recently however, several methods for manipulation of the C. 
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difficile genome have been described. The first was ClosTron, which allowed the inactivation of 
genes through targeted insertion of a group II intron (Heap et al., 2007). However, the use of 
ClosTron carries several disadvantages, including an inability to precisely manipulate the 
genome, make clean knock-outs, and polar effects due to the insertion of the group II intron.  
These problems were overcome with the development of pseudosuicide homologous 
recombination vectors (Cartman et al., 2012). Areas of homology flanking the genomic site to 
be modified are introduced into these vectors and the genome is then modified via two 
homologous recombination events with the vector, a process known as allele exchange.  These 
vectors contain sub-optimal origins of replication that limit the plasmid replication rate. Under 
antibiotic selection, the growth rate of C. difficile bearing these plasmids is limited by the rate 
of plasmid replication. Upon the first recombination event, the plasmid is incorporated into the 
genome; the replication of the plasmid DNA is therefore no longer dependent on the origin of 
replication, and the growth rate of the bacterium becomes normal. Cells in which the first 
recombination event has occurred can therefore be selected by their increased growth rate 
relative to those in which the plasmid has not yet recombined with the genome. The second 
recombination event, which results in the excision of the plasmid from the genome and 
subsequent plasmid loss, can then be selected by growth of the bacteria on media containing 5-
fluorocytosine. The recombination vectors contain a gene encoding the cytosine deaminase 
CodA, an enzyme that converts cytosine to uracil. Plasmid-bearing bacteria cannot grow on 
plates containing 5-fluorocytosine as CodA converts it into the toxic 5-fluorouracil (Cartman et 
al., 2012). Therefore, bacteria that grow on this media have lost the plasmid and either reverted 
to WT or contain the desired mutation, theoretically a 50% chance either way. The use of allele 
exchange allows for precise manipulation of the genome, including insertion, deletion, and 
substitution of sequences.  
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1.1.3 C. difficile Sporulation and Germination 
C. difficile is transmitted by the faecal-oral route with oxygen-tolerant endospores 
acting as the transmissive agent (Deakin et al., 2012). These spores are highly resistant to 
environmental stresses including high temperatures and many disinfectants. As spores are 
metabolically inactive, they are also unaffected by antibiotic treatment. Despite the clinical 
importance of C. difficile, our understanding of sporulation by this organism is relatively poor (as 
reviewed in (Paredes-Sabja et al., 2014)). Although the sporulation pathways of C. difficile and 
B. subtilis are mechanistically similar, little homology is shared by the spore-coat proteins of 
these organisms. Components in the sporulation pathway shared between these two species 
also appear to be regulated differently. The stimuli leading to sporulation initiation in C. difficile 
are yet to be identified, although the cascade is likely to respond to similar stimuli as in other 
organisms, such as nutrient starvation and quorum sensing (Higgins and Dworkin, 2012). As in 
B. subtilis, initiation of sporulation in C. difficile is caused by the activation of the master 
regulator Spo0A. This leads to the activation of RNA polymerase sigma factors σF, σE, σG, and σK 
(Fimlaid et al., 2013). Although the activation of these sigma factors is regulated differently in C. 
difficile relative to B. subtilis, they do display compartment-specific activation with σF and σG 
being localised to the forespore, and σE and σK to the mother cell (Pereira et al., 2013). These 
sigma factors control the expression of proteins involved in spore formation and mother cell 
lysis. The overall structure of the C. difficile spores shows great similarity to the spores of other 
organisms (Fig.1.2).  
Once ingested, the spore interacts with bile salts initiating germination (Sorg and 
Sonenshein, 2008). Primary bile salts, notably cholate conjugated with either taurine or glycine, 
are produced by the liver and are secreted into the duodenum. They then pass into the jejunum 
and ileum, where they are largely absorbed and recycled (Ridlon et al., 2006). However, some 
passes into the anaerobic environment of the caecum, where members of the microbiota 
expressing bile salt hydrolases remove the bile salt from its conjugated amino acid (Ridlon et al., 
 Chapter I. Introduction 
 7 
 
2006). The unconjugated bile salts are then converted to secondary bile salts such as 
deoxycholate by members of the microbiota (Ridlon et al., 2006). Some secondary bile salts can 
initiate germination of spores, but prevent the outgrowth of vegetative cells (Sorg and 
Sonenshein, 2008). In healthy individuals, C. difficile spores pass through the stomach to the 
jejunum, rich in nutrients and primary bile acids, begin to germinate, and pass into the caecum 
where secondary bile salts inhibit the outgrowth of vegetative cells. Growth may also be limited 
by competition for nutrients and immune-modulation by the intact microbiota. Antibiotic 
treatment disrupts the microbiota reducing the capability of the flora to convert primary bile 
salts into secondary bile salts. This would lead to an increase in the concentration of primary bile 
salts, and decrease in secondary bile salts, in the caecum. This change in bile salt composition 
may facilitate the germination and outgrowth of C. difficile spores (Sorg and Sonenshein, 2008). 
The bile salt receptor has recently been identified as the protease CspC, although it is unclear 
how it activates downstream components of the germination pathway (Francis et al., 2013). 
Sensing of primary bile salts by CspC causes a proteolytic cascade which results in degradation 
of the spore’s peptidoglycan, rehydration of the spore, calcium dipicolinic acid (Ca-DPA) loss, 
and subsequent outgrowth of the bacterium. Glycine, through an unknown mechanism, is also 
able to act as a C. difficile co-germinant (Sorg and Sonenshein, 2008). 
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Fig.1.2: The structure of the C. difficile spore.  The innermost compartment of the spore, the core, 
contains the genome in a largely dehydrated cytosol. Ca-DPA constitutes approximately 25% of the dry 
weight of the core (Paredes-Sabja et al., 2014). The core is encased by a low-permeability inner membrane 
which protects the core from DNA damaging molecules.  Surrounding the inner membrane is the germ 
cell wall, which becomes the cell wall of the resulting vegetative cell. A thick modified-peptidoglycan layer, 
the cortex, surrounds the germ cell wall. Modifications to the cortex peptidoglycan allow specific 
recognition by cortex lytic enzymes required for germination, without hydrolysis of the germ cell wall. A 
mother cell derived outer membrane surrounds the cortex, on which a proteinaceous coat is assembled. 
The outer-most layer of the spore is the exosporium (Paredes-Sabja et al., 2014).  
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1.1.4 The C. difficile Toxins 
Once established in the gut, C. difficile proliferates and releases toxins. The two major 
toxins of C. difficile, encoded by tcdA and tcdB, are widely accepted as the major causes of CDI 
disease symptoms. In animal models, administration of purified TcdA (toxin A) and TcdB (toxin 
B) is sufficient to illicit all symptoms of CDI (Shen, 2012).  tcdA and tcdB are located within a 19.6 
kb pathogenicity locus (PaLoc) which also contains the toxin regulatory genes tcdR, tcdE, and 
tcdC (Hammond and Johnson, 1995). TcdR is an alternative sigma factor essential for toxin 
production, TcdC is predicted to be an anti-sigma factor that sequesters TcdR and negatively 
regulates toxin production, and TcdE is a predicted holin thought to be involved in toxin 
secretion (Dupuy et al., 2008; El Meouche et al., 2013; Tan et al., 2001). Interestingly, in 027 
strains, tcdC contains a nonsense mutation which has been suggested to contribute to the 
increased virulence of these strains (Curry et al., 2007), although this is disputed (Cartman et al., 
2012) (Bakker et al., 2012). 
The enterotoxin, toxin A, and the cytotoxin, toxin B, are two of the largest identified 
bacterial toxins, belonging to a family of large, glycosylating clostridial toxins. This family of 
toxins targets Rho and Ras GTPases, modifying them by mono-O-glucosylation (e.g. TcdA, TcdB) 
or by mono-O-N-acetylglucosaminylation (e.g. Clostridium novyi α-toxin) (Schirmer and Aktories, 
2004). These modifications result in the inhibition of the regulatory function of these targets. 
Toxin A and toxin B both target Rho GTPases which act as molecular switches controlling host 
signal pathways involved in many cellular processes, including cytoskeleton assembly (reviewed 
in (Hall, 2012)), disruption of which leads to loss of intercellular tight-junctions, cell rounding, 
fluid secretion, and eventual epithelium cell death (Shen, 2012). In addition, the toxins trigger 
the release of pro-inflammatory cytokines from immune cells and intestinal epithelial cells. This 
leads to an influx of neutrophils and further damage to the intestinal epithelia. Additionally, poor 
prognosis is associated with an influx of neutrophils into the peripheral blood, which may 
 Chapter I. Introduction 
 10 
 
suggest that over-stimulation of the immune system during infection may be responsible for 
much of the CDI pathology (Shen, 2012). 
The C. difficile toxins are composed of four functional domains, an N-terminal 
glucosyltransferase, an autoprotease domain, a hydrophobic pore-forming delivery domain, and 
a C-terminal combined repetitive oligopeptides (CROPs) domain (Chumbler et al., 2016). The 
CROPs are believed to be involved in receptor binding. The crystal structure of toxin A, lacking 
the CROPs domain, has now been resolved to 3.25 Å (Chumbler et al., 2016). This structure has 
been modelled into a previous EM structure revealing the overall organisation of the four 
domains of toxin A. The structure of toxin B is predicted to be similar (Chumbler et al., 2016; 
Pruitt et al., 2010). 
The exact contributions of the two major toxins to virulence has been a topic of great 
debate. Early experiments suggested that toxin A was the more potent, being sufficient to cause 
the symptoms of CDI in rodents, while toxin B required co-administration with a sub-lethal 
concentration of toxin A (Lyerly et al., 1985). However, toxin B was shown to be able to cause 
symptoms of CDI in humanised mice (Savidge et al., 2003). This may be due to poor expression 
of the toxin B receptors in standard rodent models.  More recent analysis, using isogenic toxin 
mutants, showed that toxin B is essential for virulence in the hamster model of infection (Lyras 
et al., 2009). TcdA+/TcdB-  mutants were found to avirulent (Lyras et al., 2009) although this is 
partially disputed (Kuehne et al., 2010). Although naturally occurring TcdA-/TcdB+ strains are 
frequently isolated, TcdA+/TcdB- strains have never been isolated from patients with CDI. 
Interestingly, for unknown reasons, TcdA-/TcdB+ strains may cause more severe disease than 
TcdA+/TcdB+ strains (Drudy et al., 2007). The exact contributions of toxin A and toxin B to 
virulence remains unclear.  
Several C. difficile strains also produce an additional toxin, the C. difficile binary toxin 
(CDT), which belongs to the ADP-ribosyltransferase toxin family. These toxins are composed of 
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two peptide subunits, an ADP-ribosyltransferase (encoded by cdtA) and a binding/translocation 
subunit (encoded by cdtB) (Aktories and Barth, 2004). The exact contribution of CDT to virulence 
is not currently understood and CDT alone is not sufficient to cause symptoms of CDI, although 
it has been associated with increased adherence to the host (Schwan et al., 2014) and can induce 
pathogenic inflammation via TLR2 (Cowardin et al., 2016). However, patients infected with C. 
difficile strains expressing CDT have 60% greater mortality rates than those infected with CDT 
deficient strains (Bacci et al., 2011) (Kuehne et al., 2014).  
1.1.5 Treatment of CDI 
Until recently, there has been little interest in the development of new treatments for 
CDI as severe infections were uncommon and the disease usually responded well to antibiotic 
treatment. Although recurrent infections were common, they were easily managed. However, 
due to the emergence of epidemic strains, and the increased incidence and severity of CDI, 
research into new treatments has increased over the past decade.  
1.1.5.1 Antibiotic Treatment of CDI 
Typically, metronidazole and vancomycin are used to treat CDI. Metronidazole is used 
to treat moderate cases of CDI, while vancomycin is reserved for severe, complicated, and 
recurrent infections (Debast et al., 2014). Metronidazole is less effective, with cure rates of 
approximately 70% compared to 80% for vancomycin (Johnson et al., 2014). Vancomycin use 
has been restricted in the past due to the fear of selecting for outgrowth of vancomycin-resistant 
Enterococcus, although evidence suggests that these restrictions are not warranted (Debast et 
al., 2014). As both these antibiotics are broad spectrum, their use results in further damage to 
the microbiota, leaving the patient susceptible to recurrent infection. 20-30% of CDI cases result 
in recurrent infection either through relapse or re-infection (Figueroa et al., 2012). As prolonged 
use of metronidazole can result in neurotoxicity, it is not recommended for use beyond first 
recurrence of CDI. Instead, tapered/pulsed doses of vancomycin are used to prevent C. difficile 
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growth and allow recovery of the microbiota (Debast et al., 2014). However, after 2-3 
recurrences, the chance of further recurrence increases to 40-60% (Johnson, 2009).  
In 2011, the macrocyclic antibiotic, fidaxomicin, was approved by the European 
medicines Agency and the US Food and Drug Administration Agency for treatment of CDI 
(Venugopal and Johnson, 2012). Fidaxomicin use has been shown to be as effective as 
vancomycin, with relatively minor effects on the microbiota and a significantly reduced risk of 
recurrence (Louie et al., 2012; Mullane et al., 2011). The use of fidaxomicin, however, may be 
limited due to the high cost of a full course of this antibiotic (Bartsch et al., 2013). 
1.1.5.2 Faecal Transplantation 
Faecal microbiota transplantation (FMT) involves the restoration of the natural 
microbiota using faecal matter donated from a healthy individual. FMT is not a new concept, 
with reports indicating that diarrhoea treatments using orally introduced faecal suspensions 
were used by fourth century Chinese physicians (Zhang et al., 2012). FMT was first used to treat 
pseudomembranous colitis in 1958 by the administration of faeces by enema (Eiseman et al., 
1958). However, it has only been in the last decade that FMT has gained popularity as a 
treatment for CDI. The use of FMT for recurrent CDI infections has been reported to have success 
rates of over 90% (Brandt et al., 2012; Oprita et al., 2016; van Nood et al., 2013).  
Although FMT shows great promise as a treatment for CDI, its use is limited for several 
reasons. Perhaps understandably, due to the unconventional nature of this treatment, there is 
reluctance amongst the general public to accept this treatment and for medics to perform it. In 
addition, there are obvious dangers that must be addressed in the clinical use of faecal matter. 
FMT involves introducing many bacteria and viruses into patients, necessitating the need for 
thorough screening of donor material to avoid secondary infection transmission (as reviewed in 
(Gupta et al., 2016)). Standardisation of FMT application must also be performed, including the 
time of sample collection and preparation, sample storage, donor selection, and route of 
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administration. This has led to the establishment of stool banks, such as the Netherlands Donor 
Faeces Bank, which has attempted to establish procedures for sample preparation and storage 
(as reviewed in (Terveer et al. 2017)). In addition, the contribution of the microbiota to human 
health is practically unknown, although there is a lot of evidence showing a role in human 
metabolism (as reviewed in (Clemente et al., 2012)). The long-term effects of manipulation of 
the microbiota may be drastic. Indeed, there are reports of patients exhibiting significant weight 
gain after FMT (Alang and Kelly, 2015).  
Research is now being undertaken to identify the constituents of the microbiota 
required for CDI resolution, to make this treatment more reproducible and palatable. 
Administration of six phylogenetically distinct, intestinal bacterial species is sufficient to clear 
CDI in the mouse model (Lawley et al., 2012). Complementing this observation, a recent study 
showed that administration of a preparation of thirty-three bacterial species was sufficient to 
cure two patients infected with ribotype 078 C. difficile. This treatment was comically referred 
to as rePOOPulating the gut (Petrof et al., 2013). However, the first treatment based on this 
observation, a pill containing stool derived bacterial spores, recently failed stage II clinical trials 
(Ratner, 2016).  
1.1.5.3 Diffocins and Avidocin-CDs 
Due to the high rates of recurrence, there is a need for C. difficile specific therapies that 
do not cause damage to the microbiota. One potential therapy is the use of Diffocins. These are 
high molecular weight bacteriocins that resemble the R-type Pyocins of Pseudomonas 
aeruginosa, naturally synthesised by C. difficile to kill competing strains (Gebhart et al., 2012; 
Nakayama et al., 2000).  
These structures resemble Myoviridae phage tails, consisting of a nanotube core and 
contractile sheath coupled to receptor binding proteins (RBPs) via a baseplate and tail fibres. 
Recognition of a cell surface receptor by the RBPs triggers contraction of the sheath, which in 
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turn pushes the needle-like core through the envelope of the bacterial cell. The core forms a 
small pore in the cell envelope causing leakage of ions from the cell, dissipation of the 
membrane potential, and eventually death (Scholl et al., 2009). A single Diffocin binding to the 
cell surface is therefore theoretically sufficient to result in killing. The genomes of C. difficile 
strains were mined, identifying a novel phage RBP (PtsM) which was used to modify the Diffocin 
structure. The modified Diffocin, termed Avidocin-CD, showed increased stability compared to 
naturally occurring Diffocins (Gebhart et al., 2015).  
Avidocin-CDs administered to mice via oral gavage remained active during transit in the 
mouse GI tract and were effective prophylactic agents. In addition, treatment with Avidocin-CDs 
did not result in a significant alteration to the microbiota of the mouse (Gebhart et al., 2015). 
These agents represent a promising alternative therapy for CDI. 
1.2 Bacterial S-layers 
Bacterial S-layers are proteinaceous, paracrystalline arrays that coat the outside of the 
cell. They are commonly found on Gram-positive and Gram-negative bacteria, and are 
ubiquitously in the Archaea. S-layers are composed of a single, or multiple, proteins. These S-
layer proteins (SLPs) are often glycosylated, and spontaneously self-assemble to form a 2D array 
containing regularly repeating units (Fagan and Fairweather, 2014). S-layers were first 
discovered in the 1950s (Houwink, 1953) and since then, structural data has been obtained for 
a small number of S-layers (see below). Despite their ubiquity, little is understood about the 
functions of these structures, partly due to the model organisms E. coli and B. subtilis lacking S-
layers. However, the S-layer shows potential as an antimicrobial target (as reviewed in (Kirk et 
al., 2017)).  
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1.2.1 S-layer Structure 
Since the discovery of S-layers their structures have been investigated with varying 
techniques. Some of the most interesting structural information was obtained using electron 
microscopy of cells which has shown that different S-layers form arrays with oblique (P1 & P2), 
square (P4), and hexagonal (P6) symmetries (Fagan and Fairweather, 2014).  Information on 
intact S-layer structure is limited however, largely due to the difficulties in obtaining 3D crystals 
of SLPs and the relatively low resolution obtained from electron microscopy experiments.  
Recently, the structure of the Caulobacter crescentus S-layer has been resolved (Bharat 
et al., 2017). Electron cryotomography was used to determine the native structure of the S-layer 
to 7.4 Å, and X-ray crystallography enabled the structure of residues 249-1026 of the major SLP 
of C. crescentus, RsaA, to be resolved to 2.7Å (Fig.1.3A).  The X-ray structure was fit into the 
electron cryotomography map, providing a near complete structure of the native S-layer to high 
resolution. The structure is arranged in a repeating hexameric lattice, with a central pore of 
approximately 20 Å and other gaps of no more than 27 Å. Within the structure there are bound 
Ca2+ ions, found at the lattice interfaces. Without addition of Ca2+ or Sr2+, no RsaA crystals were 
obtained and no sheets were observed in EM experiments, suggesting that Ca2+ is necessary for 
S-layer formation and stabilisation (Bharat et al., 2017).   
The S-layer of C. difficile is mainly composed of two proteins, the high molecular weight 
(HMW) and low molecular weight (LMW) SLPs, created through the cleavage of a pre-protein 
encoded by slpA.  The HMW and LMW SLPs form a heterodimer non-covalently anchored to the 
cell wall by three cell wall binding domains (CWB2) in the HMW SLP, with the LMW SLP exposed 
to the environment. Although the structure of the intact C. difficile S-layer has not been 
determined, the structure of the N-terminal of the LMW SLP is known (Fagan et al., 2009). In 
addition, the structure of the cell wall-binding domains of Cwp8 and Cwp6 which show high 
sequence similarity to the CWB2 domains of the HMW SLP, have been recently determined 
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(Usenik et al., 2017). Like the C. crescentus S-layer, the HMW and LMW SLPs are able to form 2D 
arrays in vitro in the presence of Ca2+ (Takumi et al., 1992). The LMW SLP contains three distinct 
domains. Domain 2 contains a novel protein fold, is exposed to the environment and shows the 
most sequence variability between C. difficile strains (see section 1.2.3). Domain 1 forms a two-
layer sandwich motif and the third, interaction domain, anchors the LMW SLP to the HMW SLP 
(Fig.1.3B) (Fagan et al., 2009). The HMW SLP contains three CWB2 domains, similar to Cwp8 and 
Cwp6. The CWB2 domains of Cwp8 and Cwp6 form pseudo-trimers, forming a rough triangular 
disk shape with a diameter of approximately 60 Å (Fig.1.3C). As this structure is thought to 
anchor the proteins to the cell wall, it is suggested that the pseudo-trimeric structure is an 
example of convergent evolution as the Surface Layer Homology (SLH) anchoring domains, that 
anchor the cell wall proteins of Bacillus to the cell wall (see section 1.2.4.1), also form pseudo-
trimers (Usenik et al., 2017).  
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Fig.1.3: SLP structures. (A) Structure of the native S-layer of C. crescentus. The C. crescentus S-layer is the 
most complete, native structure of an S-layer to date, forming a hexameric array with a 20 Å central pore. 
Interaction between each subunit is stabilised by Ca2+ atoms (grey) (Bharat et al., 2017). (B) Incomplete 
structure of the C. difficile LMW SLP. Shown are the surface exposed domain 2 (blue) and domain 1 
(green). The structure of the interaction domain has not yet been resolved (Fagan et al., 2009). (C) The 
CWB2 trimer of Cwp6. Each colour represents a single CWB2 domain (Usenik et al., 2017). Images were 
created using data obtained from the Protein Data Bank. PBD IDs 5N97, 3CVZ, and 5J72 respectively. 
Images were created using PyMOL molecular graphics system.  
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1.2.2 The Cell Wall Protein Family  
C. difficile encodes 28 proteins that belong to the Cell Wall Protein (CWP) family 
(Fig.1.4). These proteins are paralogues of SlpA and contain three CWB2 motifs (Fagan et al., 
2011). In addition to the cell wall binding domains, these proteins generally contain an additional 
domain, thought to provide extra function to the S-layer. Although only a few of these proteins 
have been characterised experimentally, many are predicted to provide functions typical of cell 
wall proteins, such as adhesion to the host (e.g. the adhesin Cwp66) (Waligora et al., 2001) and 
peptidoglycan modification (e.g. the L,D transpeptidase Cwp22) (Peltier et al., 2011). 
Cwp84 is a cysteine protease that is involved in S-layer biogenesis, cleaving SlpA into the 
two SLPs. However, purified Cwp84 also shows enzymatic activity against fibronectin, type IV 
collagen, and laminin (Janoir et al., 2007). This observation suggests that Cwp84 may play a role 
during infection. However, as a cwp84 mutant shows no loss of virulence in animal models of 
infection, this observation may not translate in vivo. Cwp13 is a homologue of Cwp84, sharing 
63% protein identity. However, this protein is only partially able to complement loss of Cwp84 
and recognises an additional site in the HMW SLP. It has therefore been suggested that Cwp13 
is involved in proteolysis of misfolded cell surface proteins (de la Riva et al., 2011).  
Cwp66 is an adhesin capable of mediating adherence to Vero cells (Waligora et al., 
2001), although animal studies using mutants lacking this protein have not been reported. Cwp2 
has also been suggested to function as an adhesin (Bradshaw et al., 2017). However, cwp2 
mutants showed no reduction in virulence and were not complemented.  
Finally, CwpV, the largest member of the CWP family, provides resistance to infection 
by bacteriophages and promotes bacterial aggregation (Reynolds et al., 2011; Sekulovic et al., 
2015). cwpV is under the control of a phase variable promoter, and as a result, only 5% of cells 
in a population express CwpV under normal lab growth conditions (Emerson et al., 2009). In 
addition to the cell wall anchoring domains at its N-terminal, CwpV also contains a region of 
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unknown function linked to a C-terminal region of 4-9 repeats of 79-120 residues (Reynolds et 
al., 2011). After secretion, CwpV undergoes auto-proteolysis forming a 42 kDa N-terminal 
fragment and a 90-120 kDa C-terminal fragment that, in a manner analogous to SlpA, form a 
heterodimeric complex on the cell surface (Dembek et al., 2012). The sequence of the C-terminal 
domain of this protein varies between strains and, to date, five distinct sequence types have 
been identified (Reynolds et al., 2011).  
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Fig.1.4: The Cell Wall Protein family. (A) SlpA and the 28 members of the Cell Wall protein Family. Each 
of these proteins contains an N-terminal secretion signal peptide (black boxes) and three CWB2 motifs 
(PF04122) (grey boxes). Shown are the predicated Pfam domains of each protein. LMWSLP_N (PF12211), 
SH3_3 (PF08239), PepSY (PF03413), CAP (PF00188), Glucosaminidase (PF01832), Big_3 (PF07523), YkuD 
(PF03734), CW_binding_1 (PF01473), Amidase_3 (PF01520), DUF187 (PF02638), Peptidase_C1 (PF00112) 
and β-lactamase (PF00144). Republished with permission of the Microbiology Society, (Fagan et al., 2011), 
permission conveyed through Copyright Clearance Center, Inc.  
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1.2.3 S-layer Variation  
In addition to the diversity shown by S-layers of different species, S-layers may also vary 
between strains of a single species. In the C. difficile genome slpA is located within an 
approximately 10 kb cassette, along with secA2, cwp2, and cwp66 (Dingle et al., 2013). This 
cassette shows considerable genetic diversity amongst C. difficile strains. To date, 12 divergent 
S-layer cassette types (SLCT) have been identified. One of these cassettes is considerably larger 
than the others due to the insertion of a 24 kb region containing genes predicated to be involved 
in S-layer glycosylation (see section 1.2.4.2).  
The S-layer cassette is hypothesised to undergo recombinational switching, enabling 
antigenic variation. The high degree of variation between slpAs from different SLCTs suggests 
that the S-layer is under selective pressure, potentially due to identification by the host immune 
system or by acting as the receptor for bacteriophages. This is reflected by the fact that most of 
the variation between different slpAs occurs within the LMW SLP encoding region and the LMW 
SLP is predicted to be exposed to the environment. It is therefore possible that the LMW SLP 
acts as the receptor for binding of host immune system effectors and bacteriophages (Dingle et 
al., 2013). A recent study suggested that the SLCT of a strain may influence its virulence, with 
the SLPs from ribotype 027 and 078 strains inducing a more potent immune system response 
(Lynch et al., 2017). This may contribute to the increased virulence observed with these strains. 
The diversity of SlpA between strains also highlights the challenges of developing antimicrobials 
that target this structure.  
1.2.4 Biosynthesis of the S-layer 
Many S-layer-containing bacteria possess a secretion pathway dedicated to the 
secretion of SLPs, perhaps unsurprising due to the large burden associated with secretion of 
such an abundant protein. For example, C. difficile is estimated to secrete 164 SlpA molecules 
per second, during exponential growth, to maintain overall S-layer structure (Kirk et al., 2017). 
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In Gram-negative bacteria, several mechanisms have evolved to overcome this problem. For 
example, specific type I secretion systems are required for SLP translocation in C. crescentus and 
C. fetus (Awram and Smit, 1998; Thompson et al., 1998), while Aeromonas species use a specific 
type II system (Noonan and Trust, 1995). The secretion of SLPs has been investigated in two 
Gram-positive bacteria, C. difficile and B. anthracis, both of which require the accessory Sec 
secretion system. 
After secretion, C. difficile SlpA is cleaved to form the HMW and LMW subunits by the 
cysteine protease Cwp84 (Kirby et al., 2009). Cwp84 cleavage is essential for S-layer formation, 
as mutants in the gene encoding this protein have a severe growth defect, abnormal S-layer, 
and shedding of surface proteins (Kirby et al., 2009). However, cwp84 mutants do not show any 
loss of virulence in vivo, likely due to host-proteases, such as trypsin, being able to functionally 
complement the loss of Cwp84. SLPs presumably spontaneously self-assemble, driven 
thermodynamically (Chung et al., 2010), and anchor to the cell wall. The formation of 2D crystals 
is mediated by crystallisation domains present in the some SLPs (Baranova et al., 2012), although 
such a domain has not been identified in either of the C. difficile SlpA subunits. Our 
understanding of S-layer biogenesis in C. difficile is summarised in Fig.1.5. 
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Fig.1.5: Model of C. difficile S-layer biogenesis. The C. difficile S-layer is largely composed of two proteins 
created through the cleavage of the preprotein SlpA. (1) SlpA is targeted to the Sec secretion channel 
(blue) by the accessory secretory protein, SecA2 (red). SecA2 is believed to use the canonical SecYEG 
complex for secretion as C. difficile does not express an accessory SecY homologue (SecY2) (Fagan and 
Fairweather, 2011). SlpA contains a signal peptide (Black) at its N-terminal. (2) After SlpA is translocated 
across the cytoplasmic membrane, its signal peptide is removed and SlpA is cleaved into the LMW SLP 
(orange) and the HMW SLP (green) by the cysteine protease Cwp84 (not shown) (Kirby et al., 2009). (3) 
The two subunits then spontaneously self-assemble to form a heterodimeric complex. This complex then 
becomes anchored to the cell wall (crosslinked grey) via the secondary cell wall polysaccharide, PS-II (not 
shown), via the three cell wall binding domains present in the HMW SLP (Willing et al., 2015). HMW-LMW 
complexes form a 2D array on the surface of the cell, with the LMW subunit exposed to the environment.   
 Chapter I. Introduction 
 24 
 
1.2.4.1 Anchoring the S-layer to the Cell Wall 
S-layers are non-covalently attached to the cell wall usually via interaction with 
lipopolysaccharide (LPS) in Gram-negative bacteria and secondary cell wall sugars in Gram-
positive bacteria (Fagan and Fairweather, 2014). The anchoring mechanism is poorly understood 
in Gram-negative bacteria. However, it is known that in C. crescentus, RsaA requires an intact O-
antigen on the LPS for interaction. Interaction between RsaA and the LPS is mediated by 
approximately 225 amino acids at its N-terminus (Awram and Smit, 2001; Ford et al., 2007).  The 
N-terminal is also responsible for LPS binding of the Campylobacter fetus SLP (Dworkin et al., 
1995).  
The anchoring mechanisms of Gram-positive S-layers are better characterised. There are 
two major anchoring modules in Gram-positive SLPs, the SLH and CWB2 domains, both of which 
act as functional pseudo-trimers. The SLH domains are the most wide-spread, present in the 
SLPs of Clostridium thermocellum, B. anthracis, and Deinococcus radiodurans among others. This 
best characterised of which are the major SLPs of B. anthracis, Sap and EA1 (Etienne-Toumelin 
et al., 1995; Mesnage et al., 1997). The three SLH domains present in these proteins act 
cooperatively to bind pyruvylated secondary cell wall polymers (SCWP) (Mesnage et al., 2000).  
The HMW SLP of C. difficile, and other members of the Cell Wall Protein family, contain 
three CWB2 domains. CWB2 domains were first identified in an autolysin, CwlB, from B. subtilis 
and are found within cell wall proteins of many members of the Firmicute family (Fagan and 
Fairweather, 2014). Recently, it was discovered that the anionic SCWP, PS-II, is responsible for 
anchoring the S-layer of C. difficile to the cell wall (Willing et al., 2015). Interestingly, 
immediately downstream of the genes encoding several of the major cell wall proteins are 
several genes essential for growth, thought to be responsible for sugar biosynthesis (Dembek et 
al., 2015). It is likely that these genes are responsible for PS-II synthesis (Willing et al., 2015).   
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1.2.4.2 Glycosylation of S-layer Proteins  
The S-layers of many bacterial species are glycosylated. The glycosylation patterns of 
these S-layers show high diversity and varying complexity between species (as reviewed in 
(Schaffer and Messner, 2017)). Although bacterial surface proteins and archaeal SLPs can be 
modified with either O-linked or N-linked glycans, bacterial SLPs have only been identified with 
O-linkages (Ristl et al., 2011).  
An S-layer glycan synthesis gene cluster (slg) was first identified in Geobacillus 
stearothermophilus, and has been identified in several organisms since. This gene cluster 
encodes a glycosyltransferase, glycan processing enzymes, and transport machinery required 
for protein glycosylation. This discovery led to the development of a model for S-layer 
glycosylation involving the transfer of galactose, from uridine diphosphate α-D-Galactose, to a 
lipid carrier (Ristl et al., 2011). A linker unit is then formed by the addition of glycans onto which 
the repetitive glycan chain is assembled. The repetitive glycan chain can be linear or branched 
and typically contains 15-50 repeat units each composed of 2-6 sugars (Ristl et al., 2011). The 
glycan chain is then translocated across the cytoplasmic membrane and ligated to the target SLP 
(Ristl et al., 2011). The overall structure of a typical glycan chain is similar to the LPS of Gram-
negative bacteria, which may suggest a common evolutionary origin for LPS and S-layer glycan 
synthesis pathways (Schaffer et al., 1996).  
The S-layer of C. difficile is usually not glycosylated (Qazi et al., 2009). However, one 
SLCT (SLCT-11) was shown to contain an insertion of approximately 24 kb, resembling the slg 
gene cluster (Dingle et al., 2013). The LMW subunit of SLCT-11 SlpA is much smaller than other 
SlpA types. Confirmation of S-layer glycosylation in these strains, and investigation of its 
contribution to virulence, are yet to be performed.  
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1.2.5 Functions of the S-layer 
As the S-layer is the major proteinaceous component of the cell surface, it is unsurprising 
that many different functions have been assigned to these structures. Despite this, no single 
function has been assigned to all the S-layers and its function is unknown in most bacterial 
species. This is especially true for C. difficile, partly due to the previous lack of genetic tools for 
C. difficile research, but also because the S-layer of C. difficile appears to be essential for growth 
in vitro (Dembek et al., 2015). There has been some research into its contribution to adherence 
to the host, but research into its function has been seriously hampered due to the lack of slpA 
mutants. However, due to the large metabolic sacrifice required to create and maintain these 
structures, coupled with the observation that it is essential for growth, the S-layer likely provides 
vital functions to the cell.  
1.2.5.1 S-layers as a Protective Coat 
As the S-layer form a contiguous array coating the cell, it is believed that it forms a 
molecular sieve, essentially acting as a size exclusion barrier (Sara and Sleytr, 1987). The atomic 
structure of the C. crescentus S-layer revealed pores no larger than 27Å (Bharat et al., 2017). 
This would theoretically prevent some harmful material such as phage and large globular 
enzymes such as lysozyme from reaching the cell wall. The S-layer may therefore provide 
resistance to environmental stresses. Reported pore sizes of S-layers vary significantly (Fagan 
and Fairweather, 2014). Further investigation into the atomic structure of these complexes may 
provide further insight into S-layer barrier function. The S-layer of C. crescentus has also recently 
been shown to provide resistance to antimicrobial peptides, including the human cathlicidin LL-
37 (de la Fuente-Nunez et al., 2012). These peptides kill bacteria by oligomerising and forming 
toroidal pores in the cytoplasmic membrane (Vandamme et al., 2012). Due to the small size of 
LL-37, it is likely that this peptide could pass through the pores of the S-layer.  However, as SLPs 
tend to have low isoelectric points (3.46 for RsaA of C. crescentus), this resistance may be 
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mediated through interaction of the cationic antimicrobial peptide with the negatively charged 
residues of the S-layers. This is thought to sequester the peptide at the S-layer, preventing them 
from reaching the cell membrane (de la Fuente-Nunez et al., 2012). 
The parasite Bdellovibrio bacterovirus is a bacterium that enters the periplasm of other 
bacteria where it replicates, digesting and eventually lysing its prey (Sockett, 2009). B. 
bacterovirus is not normally able to parasitise C. crescentus. However, S-layer mutants are 
susceptible to predation indicating that the S-layer provides protection from B. bacterovirus 
killing (Koval and Hynes, 1991). 
1.2.5.2 S-layers in Pathogenesis  
As the S-layer coats the cell surface, it is unsurprising that in many bacteria it has been 
associated with a role in pathogenesis. For example, C. fetus, the most common cause of 
abortion in cattle and also a cause of human systemic infection, expresses an S-layer essential 
for virulence (Blaser, 1993). Loss of its S-layer results in increased phagocytosis and sensitivity 
to killing by the complement system (Blaser, 1993). The S-layer of C. fetus is also antigenically 
variable, enabling evasion of the host immune system (Thompson, 2002). S-layers may also 
function as adhesins, facilitating binding of the bacterium to host tissue. The major SLP of 
Lactobacillus crispatus, present in the avian and human gut microbiota, can bind to type I and 
IV collagen (Sillanpaa et al., 2000).  
Although the exact contribution of the C. difficile S-layer to virulence remains elusive, 
aspects of its role in pathogenicity have been investigated. Purified C. difficile SLPs can induce 
the release of pro-inflammatory cytokines from human monocytes, maturation of monocyte 
derived dendritic cells, and enhance allogenic T-cell proliferation (Ausiello et al., 2006). More 
recent studies using the mouse model of infection have shown that the SLPs induce maturation 
of bone marrow derived dendritic cells, important for the induction of helper T-cells, and 
cytokine production (Ryan et al., 2011). Toll like receptor 4 (TLR4) was responsible for dendric 
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cell maturation and TLR4 knock-out mice show increased sensitivity to C. difficile infection 
presenting more severe symptoms (Ryan et al., 2011). Activation of dendritic cells required both 
the HMW and LMW SLPs, suggesting that TLR4 recognises the intact complex. Based on these 
observations, it appears that TLR4 is important for the clearance of C. difficile infections, 
mediated by recognition of the S-layer complex (Ryan et al., 2011). Recently it has been 
suggested that the S-layers of different SLCTs may elicit different immune responses (Lynch et 
al., 2017). More potent macrophage responses were observed using the SLPs of ribotype 027 
and 078 relative to 001 and 014 (Lynch et al., 2017).  In addition, the S-layer may function as an 
adhesin. Although the lack of a knock-out mutant makes the study of this function difficult, SlpA 
has been shown to bind to fixed gut enterocytes (Calabi et al., 2002). This was complemented 
by the observation that isolated SLPs can inhibit binding of C. difficile to Caco-2 cells (Merrigan 
et al., 2013). 
1.2.5.3 Additional Roles of the S-layer 
S-layers have, due to their great diversity, been associated with many additional 
functions. The structure of the C. crescentus S-layer revealed similarities to antifreeze proteins 
and a surface lined with threonine residues, which suggests a role in surface hydration and ice 
crystal avoidance (Bharat et al., 2017). The B. anthracis SLPs Sap and EA1 have peptidoglycan 
hydrolase activity despite lacking obvious functional domains (Ahn et al., 2006). Indeed, sap 
mutants display an increased cell chain length. This phenotype can be complemented through 
exogenous addition of purified BslO, a protein involved in cell division, to cell culture medium. 
BslO also contains three SLH domains, and is a member of the B. anthracis S-layer associated 
protein (BSL) family, along with 23 other proteins including EA1 and Sap (Kern et al., 2012). Sap 
localises on the lateral cell wall, while BslO localises to the septum. This suggests that the Sap S-
layer may exclude other SLH containing proteins, enabling localisation of other functional 
proteins to areas not occupied by Sap, such as the septum (Kern et al., 2012). It has also been 
speculated that while S-layers could not determine bacterial shape, they may have a role in its 
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maintenance (Engelhardt, 2007). Although the underlying mechanism remains unknown, two 
SLPs from marine cyanobacterium, Synechococcus, are essential for swimming motility. These 
proteins are SwmA, a 130 kDa glycosylated SLP, and SwmB, a 1.12 MDa SLP. (Brahamsha, 1996; 
McCarren and Brahamsha, 2007). Additional genes required for motility encode 
glycosyltransferases and an ABC transporter (McCarren and Brahamsha, 2009).  
1.3 The Sec Secretion and Accessory Pathways  
Over 30% of bacterial proteins are exported to extra-cytoplasmic locations where they 
perform their functions (Tsirigotaki et al., 2017). These proteins, which constitute the 
secretome, are embedded in the membrane, bind to the cell wall, or localise in the periplasmic 
space or the extracellular environment.  Several bacterial pathways have evolved to translocate 
proteins across the cytoplasmic membrane including the Tat system and the type I-VI systems 
(as reviewed in (Green and Mecsas, 2016)). However, most members of the secretome are 
translocated via the Sec system, a secretion pathway found in all domains of life.  
1.3.1 Targeting Proteins to the Sec Pathway 
The Sec secretion system translocates proteins via two distinct pathways. Membrane proteins 
generally utilise the co-translational pathway, in which nascent proteins emerging from a 
ribosome are targeted to the SecYEG channel and translocated whilst still being synthesised (Xie 
and Dalbey, 2008). Other proteins are translocated post-translationally, where they are 
maintained in an unfolded state by a chaperone, and targeted to the SecYEG channel by their N-
terminal signal peptide.  
Integral membrane proteins secreted co-translationally are recognised by the signal recognition 
particle (SRP) by their hydrophobic transmembrane domains. The ribosome and the nascent 
peptide chain are directed to the SecYEG complex by the SRP through interaction with its 
membrane associated receptor, FtsY (Parlitz et al., 2007; Valent et al., 1997). Once inserted into 
 Chapter I. Introduction 
 30 
 
the SecY channel, a lateral gate within the pore opens allowing the insertion of transmembrane 
helices into the membrane (Egea and Stroud, 2010). 
Peptides secreted post-translationally are synthesised as pre-proteins, and are distinguished 
from the other members of the proteome by the presence of a N-terminal signal peptide. The 
signal peptide is largely conserved, containing a short positively charged N-terminus, a 
hydrophobic core, and a polar C-terminus (von Heijne, 1990). The C-terminus contains a signal 
peptidase cleavage site to allow removal of the signal peptide post-secretion (Dalbey and 
Wickner, 1985). As proteins must be unfolded to allow Sec-mediated secretion, post-
translationally secreted proteins must be maintained in an unfolded conformation. This can be 
achieved by the binding of cytoplasmic chaperones such as trigger factor, SecA, housekeeping 
chaperones, or specialised Sec chaperones such as SecB in Gram-negative bacteria. SecA then 
targets the protein to SecYEG (Tsirigotaki et al., 2017).  
1.3.2 Secretion Through the Sec System  
The secretory machinery is composed of two major elements, the channel complex 
SecYEG, through which proteins are translocated, and the motor protein SecA, which provides 
energy for translocation. SecY contains ten transmembrane helices which form the channel pore 
in the cytoplasmic membrane (Van den Berg et al., 2004). In its resting conformation, 
hydrophobic residues in the middle of the pore restrict its diameter to 5 Å, and the pore is 
capped by a helical plug. These two elements may act as channel gates (Park and Rapoport, 
2011). SecE is bound to the cytoplasmic protrusions of SecY, stabilising its structure. Both SecE 
and SecY are essential for protein translocation. The non-essential SecG forms hydrophobic 
interactions with two of the transmembrane helices of SecY, with its cytoplasmic loop sealing 
the cytoplasmic side of the SecY pore (Tanaka et al., 2015).  
Several SecA structures have now been resolved to high resolution, the first being that 
of B. subtilis (Hunt et al., 2002). SecA is composed of several domains. The DEAD motor box 
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domain, composed of Nucleotide binding domain 1 and 2 (NBD1 and NBD2), catalyses the 
hydrolysis of ATP, providing the energy for proteins translocation (Hunt et al., 2002). Stemming 
off of NBD1 is the peptide crossing linking domain (PPXD) which is involved in binding to protein 
substrates (Papanikou et al., 2005). The helical scaffold domain (HSD) forms a long alpha helix 
that binds all SecA domains and connects the motor domains with the specificity domain. The 
helical wing domain (HWD) connects the intra-molecular regulator of ATP hydrolysis 1 (IRA1), 
believed to function in inserting the protein substrate into the SecY channel (Erlandson et al., 
2008). Finally, the C-terminal domain (CTD) is believed to interact with the SecB chaperone in 
Gram-negative bacteria and phospholipids (Breukink et al., 1995).  
Although the exact mechanism by which proteins are translocated through the SecYEG 
channel remains elusive, decades of research have illuminated some of the key features of Sec 
secretion (as reviewed in (Tsirigotaki et al., 2017)). During post-translational export, SecA 
recognises the signal peptide on the pre-protein substrate and targets the complex to the 
SecYEG channel through interactions with SecY and membrane lipids (Breukink et al., 1995; van 
der Sluis et al., 2006). The signal peptide is then inserted into the SecY channel and SecA 
undergoes cycles of ATP binding and hydrolysis. ATP hydrolysis is associated with large changes 
in the conformation of SecA, which facilitates the translocation of the pre-protein (Economou 
and Wickner, 1994; Robson et al., 2009). The IRA1 domain of SecA is thought to insert into the 
SecY channel during these cycles to facilitate translocation (Zimmer et al., 2008). Once the 
protein has been translocated, the peptide signal is removed by specific signal proteases and 
the mature protein folds into its functional conformation (Dalbey and Wickner, 1985).  
1.3.3 The Accessory Sec Secretion Pathway 
Recently it has come to light that many bacterial species contain an accessory Sec 
secretion pathway (as reviewed in (Feltcher and Braunstein, 2012)). This is characterised by the 
presence of an additional SecY and/or SecA, termed SecY2 and SecA2. The accessory system 
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secretes a small subset of proteins while the canonical Sec machinery acts as the housekeeping 
pathway, secreting the majority of proteins.  
SecA2-SecY2 systems are well conserved in Streptococcus and Staphylococcus species. 
secA2 and secY2 are located on a genetic locus along with a gene encoding a large serine rich 
protein secreted by the accessory system, genes encoding glycosylation machinery responsible 
for the glycosylation of this substrate, and genes encoding export machinery of unknown 
function (Feltcher and Braunstein, 2012). It appears that the SecA2-SecY2 systems have evolved 
to secrete these large serine rich proteins, which contain an abnormally large N-terminal peptide 
sequence and are involved in adhesion to the host (Siboo et al., 2005). Interestingly, one such 
protein, GspB, is heavily glycosylated, and this modification occurs in the cytoplasm (Bensing et 
al., 2004). B. anthracis also contains a SecA2-SecY2 system, although it is phylogenetically 
distinct from the Staphylococcus and Streptococcus systems, and secY2 is not found in the same 
locus as secA2 (Rigel and Braunstein, 2008). SecA2 in B. anthracis is required for the efficient 
secretion of the S-layer proteins Sap and EA1 (Nguyen-Mau et al., 2012). 
C. difficile contains a SecA2-only system, lacking a SecY2 homologue. SecA2 of C. difficile 
is the only identified SecA2 that is essential for growth in vitro. SecA1 and SecA2 function 
independently in C. difficile. Knock-down experiments showed that depletion of SecA1 did not 
affect the export of SecA2 substrates (Fagan and Fairweather, 2011). Due to the lack of a SecY2 
homologue, it is believed that SecA2 secretion utilises the canonical SecY channel complex. In 
support of this model, experiments were performed using dominant negative variants of SecA, 
SecA1K106R and SecA2K106R. These variants are unable to hydrolyse ATP and are therefore 
predicted to be unable to dissociate from the SecYEG complex, effectively blocking them. 
Expression of SecA1K106R resulted in diminished secretion of SecA2 substrates, providing 
evidence that SecA1 and SecA2 share the canonical SecYEG channel (Fagan and Fairweather, 
2011). The only identified substrates of SecA2 in C. difficile to date are SlpA and CwpV although 
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it has been suggested that SecA2 dependent secretion may be a characteristic of more, if not 
all, of the members of the CWP family (Fagan and Fairweather, 2011). However, the exact 
mechanism for the specificity of SecA2 for its substrates remains elusive, as SlpA and CwpV 
contain what appear to be normal signal peptide sequences. In addition, the only shared motif 
of SlpA and CwpV are their CWB2 domains. However, the CWB2 domains of SlpA are located on 
the C-terminus, whereas they are N-terminal in CwpV and are therefore unlikely recognition 
sites for SecA2 binding. One of the best characterised SecA2-only system is that of 
Mycobacterium tuberculosis. M. tuberculosis SecA2 (MtbSecA2) is responsible for the secretion 
of several virulence factors, and is not essential for growth in vitro; mutants show diminished 
growth in models of infection (Braunstein et al., 2003). The crystal structure of MtbSecA2, the 
only SecA2 structure solved to date, revealed that it is smaller than SecA1 due to truncations in 
the HWD and CTD (Swanson et al., 2015) which may have effects on substrate specificity. 
1.4 Project Aims 
The S-layer of C. difficile is likely to provide vital functions to the cell, owing to the 
metabolic cost associated with its synthesis, and the fact that it is essential for growth in vitro. 
The lack of an SlpA-deficient mutant has severely hindered research into the function of this 
array. However, challenging growing cultures of C. difficile with the recently created Avidocin-
CDs has resulted in the isolation of spontaneous mutants resistant to these antimicrobials that 
lack a functional S-layer, allowing analysis of S-layer function for the first time.  
During this project, we aimed to identify the major functions of the S-layer, and its 
contribution to virulence, through characterisation of the S-layer deficient mutant. In addition, 
we also investigated the properties of this mutant that allow its growth without an S-layer, to 
gain insight into why the S-layer of C. difficile is usually essential for growth. In addition, as little 
is known about the biogenesis of the S-layer, crystallographic analysis of the SecA2 structure 
and microscopic analysis of its intracellular localisation was performed. This was done in the 
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hope of identifying features of SecA2 allowing its substrate specificity and to determine where 
the S-layer is assembled. 
 “New Class of Precision Antimicrobials Redefines Role of Clostridium difficile S-layer in 
Virulence and Viability”, a manuscript we have recently had accepted for publication in Science 
Translational Medicine, has been included as chapter III of this thesis. This paper describes the 
characterisation of the recently isolated S-layer mutant, FM2.5, and led to many of the 
observations described in chapter IV of this thesis. The version of the manuscript included is the 
one accepted for publication posted with permission from the AAAS.  
Our published paper “Heat shock increases conjugation efficiency in Clostridium 
difficile” is also included in the Appendices. Work presented in this paper describes the 
optimisation of a conjugation protocol essential for the mutagenesis described in chapters IV 
and V.
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Chapter II 
Materials and Methods 
2.1 Handling of Bacterial Strains 
2.1.1 Bacterial Strains and Growth Conditions 
Bacterial strains used are described in table A1. C. difficile strains were routinely 
cultured on pre-reduced brain heart infusion (BHI) agar (Sigma), BHIS (BHI supplemented with 
0.5% w/v yeast extract and 0.1% w/v cysteine) agar, TY (Dupuy and Sonenshein, 1998) (3% 
tryptose, 2% yeast extract (Bacto)) agar or Clostridium difficile Minimal Medium (CDMM) (table 
2.1)(Karlsson et al., 1999). Liquid cultures of C. difficile were grown using pre-reduced TY broth, 
TYG broth (TY broth containing 0.5% glucose), or BHIS broth. Cultures were supplemented with 
anhydrotetracycline (Atc) (4-700 ng/ml), thiamphenicol (15 μg/ml), cycloserine (250 μg/ml) or 
lincomycin (5 μg/ml) when appropriate. C. difficile was grown in an anaerobic work station (Don 
Whitley Scientific) containing an environment composed of 80% N2, 10% CO2 and 10 % H2 at 
37°C.  
E. coli strains were routinely grown on LB agar (Sigma) or in LB broth (Fisher Chemicals). 
Cultures were supplemented with chloramphenicol (15 μg/ml), kanamycin (50 μg/ml) and/or 
carbenicillin (50 μg/ml) when appropriate. E. coli strain CA434 was used as a conjugation donor 
for transferring plasmids into C. difficile. E. coli stains Neb5α (New England Biolabs) and Top10 
were used routinely for cloning and plasmid propagation. Expression for protein purification was 
carried out using E. coli strain Rosetta (Novagen). Cultures were grown with agitation (225 rpm) 
at 37°C.   
Bacterial strains were stored in 20% glycerol at -80°C. 
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Table 2.1: C. difficile minimal medium composition 
 Stock concentration (mg/ml) Final concentration (mg/ml) 
Amino acids (5X)   
Casamino acids 50 10 
L-Tryptophan 2.5 0.5 
L-cysteine 2.5 0.5 
   
Salts (10X)   
Na2HPO4 50 5.0 
NaHCO3 50 5.0 
KH2PO4 9.0 0.9 
NaCl 9.0 0.9 
   
Trace salts (50X)   
(NH4)2SO4 2.0 0.04 
CaCl2 · 2H2O 1.3 0.026 
MgCl2 · 6H2O 1.0 0.02 
MnCl2 · 4H2O 0.5 0.01 
CoCl2 · 6H2O 0.05 0.001 
   
Glucose (20X)   
D-glucose  200 10 
   
Iron (100X)   
FeSO4 · 7H2O 0.4 0.004 
   
Vitamins (1000X)   
D-biotin 1.0 0.001 
Calcium-D-panthothenate  1.0 0.001 
Pyridoxine 1.0 0.001 
   
5-fluorocytosine  10 0.05 
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2.1.2 Clostridium difficile Spore Isolation 
15 ml TGY broth (3% tryptic soy broth (Bacto), 1% yeast extract, 2% glucose, 0.1% L-
cysteine) was inoculated with a single colony of C. difficile and incubated O/N. The cultures were 
then sub-cultured 1:10 in 15 ml of SMC broth (9% Bacto peptone (Bacto), 0.5% proteose peptone 
(Sigma), 0.1% ammonium sulphate, 0.15% tris base) and allowed to grow to OD600nm 0.4-0.7. 100 
µl of the SMC culture was then spread on SMC agar plates (6 for R20291 or FM2.5RW, or 30 for 
FM2.5). The plates were anaerobically incubated for a further 7 days before growth was 
harvested in 3 ml of sterile water. The harvested material was then washed by resuspending the 
pellet in 0.5 ml of ice-cold sterile water. Samples were the centrifuged (5,000 x g, 1 min). The 
wash step was repeated a further 4 times. Before the final wash, growth from 3-4 plates was 
pooled. Pellets were then resuspended in 0.5 ml of 20% (w/v) HistoDenz (Sigma). This was then 
layered on top of 1 ml of 50% (w/v) HistoDenz and centrifuged (15 min at 15,000 x g). Using this 
method, the spores form a pellet, while vegetative cells and debris remain suspended in the 
HistoDenz density gradient.  The HistoDenz was then removed and the spores washed an 
additional five times with ice-cold sterile water as before. Purified spores were resuspended in 
sterile water and were quantified by both absorbance at OD600nm and by counting CFU on BHIS 
supplemented with 0.1 % sodium taurocholate. Purity of each preparation was checked by 
phase contrast microscopy. Purified spores were stored at -80°C. 
2.2 DNA Manipulation 
2.2.1 Genomic DNA Isolation  
High quality C. difficile  genomic DNA (gDNA) was isolated using a modified version of 
the phenol-chloroform method previously described (Wren and Tabaqchali, 1987). 1.5 ml of O/N 
culture was harvested via centrifugation (2 min, 12,000 x g) and resuspended in 200 μl PBS 
supplemented with 10 μl of the purified bacteriophage endolysin CD27L catalytic domain (Mayer 
et al., 2008), followed by incubation at 37°C for 1 h. 10 µl pronase (final concentration 1 mg/ml) 
 Chapter II. Materials and Methods 
 38 
 
was added to the sample and incubated at 55°C for 1 h. 80 µl of N- lauroylsarcosine (final 
concentration 2%) was then added to the sample and incubated at 37°C for 1 h. Finally, 200 µl 
of an RNase solution (final concentration 0.2 mg/ml) was added to the sample and incubated at 
37°C for 1 h. 500 µl of Phenol:chloroform:isoamyl alcohol (25:24:1) was added to the sample 
and gently mixed. The sample was centrifuged in a phase lock gel tube (13,000 x g, 2 min) to 
allow separation of the organic phase and DNA containing aqueous phase. The aqueous phase 
was recovered and treated with Phenol:chloroform:isoamyl alcohol as before. Excess phenol 
was removed from the recovered aqueous phase by treatment with 500 µl chloroform:isoamyl 
alcohol (24:1) and centrifugation in a gel lock tube as before. The resulting aqueous phase was 
then added to an equal volume of ice-cold isopropanol and incubated at -20°C O/N to precipitate 
the gDNA. gDNA was harvested by centrifugation (4,000 x g, 15 min) and washed once in 70% 
ethanol. The gDNA was then harvested again (4,000 x g, 10 min) and air dried to remove residual 
ethanol. gDNA was resuspended in 50 μl nuclease free water and quantified using a Nanodrop 
spectrometer. Purity was determined through analysis of A260/A280 and A260/A230 ratios.  
Low-quality gDNA preparations for use in PCR were also prepared using Chelex 100 resin 
(Sigma). A single colony of C. difficile was resuspended in 100 µl of nuclease free water 
containing a small amount of Chelex resin, before being boiled for 10 min and briefly 
centrifuged. The supernatant was used as a template for PCR. These preparations were made 
fresh before each PCR reaction.  
2.2.2 Polymerase Chain Reaction 
2x Phusion polymerase high fidelity master mix (Thermo) was used routinely as per the 
manufacturer’s instructions, for reactions that required high fidelity polymerisation as well as 
for most PCRs using C. difficile chelex preparations. 20 µl reactions contained either 2 µl of a C. 
difficile chelex prep, 200 ng of purified gDNA or 1 ng of plasmid DNA, as the template. 5% (v/v) 
DMSO was also added to the reaction when required, i.e. when using primers with long over-
lapping regions or A/T rich stretches. Initial denaturation was carried out at 98°C for 30 sec 
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followed by 32 cycles of denaturation at 98°C for 30 sec, annealing at 2°C below the annealing 
temperature of the primers for 30 sec, and extension at 72°C for 20 sec per kb for DNA fragments 
up to 3 kb in length or 30 sec for DNA fragments longer than 3 kb. A final extension was 
performed at 72°C for 5 min. 
Taq polymerase was used for PCRs where high fidelity was not required, including 
colony PCRs.  A 2x master mix, prepared in house, was routinely used. The 2x master mix 
contained 0.01% cresol red, 0.5 M sucrose, 400 µM of each dNTP, purified Taq polymerase 
(estimated to be 0.1 U/µl), 20 mM tris-HCl pH9, 100 mM KCl, 0.02% gelatin, 0.02% tween 20, 4 
mM MgCl2. Initial denaturation was carried out at 95°C for 3 min followed by 35 cycles of 
denaturation at 95°C for 30 sec, annealing at 2°C below the annealing temperature of the 
primers for 30 sec, and extension at 72°C for 1 min per kb. A final extension was performed at 
72°C for 5 min. 
PCR reactions were performed using a T100 Thermo Cycler (BIORAD). Primers were 
synthesised by Eurofins and are listed in table A2. 
2.2.3 Agarose Gel Electrophoresis 
0.8-2% (w/v) agarose (VWR) was melted in TAE buffer (40 mM tris-acetate pH8, 1 mM 
EDTA). The percentage of agarose used was dependent on the size of the DNA fragments to be 
resolved, as higher percentage gels are better able to resolve small DNA fragments, while lower 
percentage gels are better able to resolve large fragments. The agarose was cooled to 
approximately 55°C and cast in a horizontal Perspex tray with the addition of SybrSafe DNA stain 
(1/10,000 final volume) (Invitrogen). When the gel had set, trays were submerged in TAE buffer 
in an electrophoresis gel tank. DNA loading buffer was added to the DNA samples, either 
standard DNA loading buffer (New England Biolabs) or UView (Bio-rad) for gel extraction, and 
samples were loaded into the gel wells. Electrophoresis was performed at 130 V for 15-30 min. 
DNA bands were visualised using a BioRad ChemiDoc MP imaging system (Bio-Rad). 
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2.2.4 Purification of PCR Products  
Purification of PCR products was accomplished using either a GeneJET PCR Purification 
kit (Thermo) per the manufactures guidelines, or via gel extraction (see below). DNA was eluted 
in 20 µl nuclease free water and quantified via A260 spectrometry. 
2.2.5 Gel Extraction of DNA 
DNA samples were resolved on agarose gels (see above). DNA was visualised using a UV 
transilluminator and bands were cut out using a scalpel. DNA was extracted from the gel using 
the GeneJET Gel Extraction kit (Thermo), as per the manufacturer’s instructions. DNA was eluted 
in nuclease free water and quantified via A260 spectrometry. 
2.2.6 Restriction Endonuclease Digestion of DNA 
Endonuclease restriction of DNA was performed using restriction enzymes as per the 
manufacturer’s guidelines (New England Biolabs). Restriction endonuclease and its appropriate 
buffer was added to solutions containing purified DNA and incubated at 37°C for 1 h. For removal 
of template plasmid DNA from completed Phusion PCR reactions, 2 µl of DpnI was added to the 
Phusion PCR reaction mix, without prior DNA purification, and incubated at 37°C for 2 h. 
Digested DNA was purified as described above. 
2.2.7 Asymmetric Endonuclease Digestion Assay 
Amplification of fragments used in asymmetric digest analysis was performed using 2x 
Taq PCR master mix (Thermo), as per the manufacturer’s instructions, from purified gDNA. 10 
µl of each PCR reaction was combined with equal volumes of solutions containing 1x 
concentrations of the endonuclease and its appropriate buffer. Digestion of DNA was then 
performed at 37°C for 1-2 h using a T100 thermocycler (Bio-Rad). DNA loading buffer was added 
to a final concentration of 1x before the DNA was resolved using 2% agarose gel electrophoresis. 
DNA was visualised using a BioRad ChemiDoc MP imaging system. Image Lab software (Bio-Rad) 
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was used to perform densitometric analysis on the resulting image to quantify the relative 
amounts of DNA in each band.  
2.2.8 Ligation of DNA  
DNA fragments were ligated using T4 DNA ligase (New England Biolabs) as per the 
manufacturer’s instructions. Briefly, enzyme reactions contained 1x T4 ligase buffer, 25 ng 
vector DNA, insert DNA at a molar ratio of 1:3 vector to insert, 0.5 μl T4 ligase, and nuclease free 
water to make a 10 µl final volume. Reactions were incubated at RT for 1 h before being used in 
E. coli transformations (see below). Linearised vectors created by inverse PCR were first 
phosphorylated using T4 polynucleotide kinase (New England biolabs) (37°C, 30 min), as per the 
manufacturer’s guidelines, and PCR purified prior to ligation.  
2.2.9 Splicing by Overlap Extension 
To combine two PCRs fragments, splicing by overlap extension (SOEing) was performed 
(Horton et al., 1989). Briefly, PCR fragments to be spliced were amplified using primers 
containing 30 bp overlapping regions, at the ends to be joined. The resulting fragments were 
PCR purified and 10-20 ng of each fragment were used as DNA templates in a 20 µl Phusion PCR 
reaction. The forward primer of the 5’ fragment and the reverse primer of the 3’ fragment were 
included in the reaction at a final concentration of 0.5 µM. 5% (v/v) DMSO was added when 
required. The reaction was then treated as a standard Phusion PCR reaction and the combined 
fragment was purified by gel extraction (see above). 
2.2.10 Gibson Assembly of DNA Fragments 
Multiple fragments of DNA were ligated in one step through the use of Gibson assembly 
(Gibson et al., 2009). This was achieved using the NEBuilder HiFi DNA Assembly Cloning Kit (New 
England Biolabs). Vector DNA was linearised using Phusion PCR. Insert fragments were amplified 
using primers so that the resulting fragments contained 30 bp of overlapping sequence with the 
adjacent DNA fragment. PCR fragments gel extracted as previously described. Reactions were 
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performed in a final volume of 10 μl, containing either 25 ng vector and a two-fold molar excess 
of insert (for fewer than three fragments), or approximately 200 ng of vector DNA and equimolar 
insert (more than three fragments). HiFi assembly master mix was added to a final concentration 
of 1x and the reactions were made to volume using nuclease free water. Reactions were then 
incubated at 50°C for 0.5 -1 h before being used in E. coli transformations. 
2.1.11 Production of Chemically Competent E. coli 
O/N cultures of E. coli were sub-cultured 1:100 and grown to log-phase (OD600nm 0.4-06) 
before being harvested by centrifugation (10 min, 4,000 x g at 4°C). Pellets were resuspended in 
5 ml ice cold 100 mM CaCl2 and incubated on ice for 15 min. Cells were harvested as before and 
resuspended in 1 ml 100 mM CaCl2 with 15% (V/V) glycerol before being incubated on ice for 2 
h. The cell suspension was then aliquoted in 50 µl samples and stored at -80°C. 
2.2.12 Transformation of E. coli 
2 μl of ligation or HiFi assembly reaction, or approximately 0.25 μl of a plasmid miniprep, 
was added to approximately 25 μl of chemically competent E. coli and incubated on ice for 30 
min. Cells were then heat-shocked at 42°C for 30 sec and incubated on ice for a further 5 min. 
475 μl of SOC medium was then and the mixture was incubated at 37°C for 1 h before being 
spread on LB agar containing the appropriate antibiotic(s). 
2.2.13 Isolation of Plasmid DNA  
5 ml of O/N E. coli culture was harvested by centrifugation (4,000 x g, 10 min) and 
plasmid DNA was extracted using the GeneJET Plasmid Miniprep kit (Thermo) as per the 
manufacturer’s instructions. DNA was eluted in 60 μl nuclease free water. Plasmids used in this 
project are outline in table A3. 
2.2.14 Sequencing of DNA  
Routine sequencing of plasmid and PCR-amplified DNA was carried out using the GATC 
Biotech (Konstanz, Germany) SUPREMERUN or LIGHTRUN Sanger sequencing services. Geneious 
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sequence analysis software (Biomatters) was used for the analysis of sequencing data. Illumina 
sequencing of bacterial genomes was performed by MicrobesNG (Birmingham, UK) or by the 
Welcome Trust Sanger Institute (Hinxton, UK). Genome assembly and analysis was performed 
by Dr Roy Chaudhuri (University of Sheffield, UK). PacBio sequencing of bacterial genomes was 
performed by Genome Québec (Quebec, Canada). Data analysis and genome assembly was 
performed by Nadia Fernandes (University of Sheffield). 
2.2.15 Conjugative Transfer of Plasmid DNA to C. difficile  
The protocol for conjugative plasmid transfer into C. difficile was optimised as part of 
this PhD studentship and the results published in the journal Anaerobe (appendix IV) (Kirk and 
Fagan, 2016). Briefly, 200 μl of C. difficile O/N culture was heat-treated (50-52°C, 5-15 min) and 
used to resuspend a pellet of plasmid bearing E. coli strain CA434 obtained by centrifugation 
(4,000 x g, 2 min) of 1 ml O/N culture. The resulting cell suspension was spotted onto BHI agar 
and incubated for 8-24 h at which point the growth was harvested using approximately 900 μl 
TY broth and a spreader. The harvested growth was then spread on BHI containing cycloserine, 
to prevent E. coli growth, and thiamphenicol for plasmid selection. To prevent E. coli outgrowth, 
transconjugants were restreaked onto selective BHI containing cycloserine twice before further 
use.  
2.2.16 ClosTron Mutagenesis 
Due to the availability of more precise tools for the manipulation of the C. difficile 
genome, ClosTron insertional mutagenesis (Heap et al., 2007) was only used to inactivate a 
single gene in R20291, FM2.5 and FM2.5RW to replicate the published method of recV 
inactivation described in (Reynolds et al., 2011). pASF075, carrying group II intron targeted to 
recV, was transferred into C. difficile via conjugation as previously described. Transconjugants 
were restreaked on BHI containing lincomycin (5 µg/ml) to select for successful insertion based 
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on the activity of the retrotransposition-activated marker, ermB. Successful mutants were 
confirmed through PCR using primers flanking the intron insertion site. 
2.2.16 C. difficile Allele Exchange Mutagenesis 
Precise manipulation of the C. difficile genome was achieved through allele exchange 
using the codA heterologous counterselection system described previously (Cartman et al., 
2012). 600-1200 bp fragments, upstream and downstream of the sequence to be altered, were 
amplified by PCR and purified. PCR products were ligated into pMTLSC7215 or pMTLSC7315 
using either restriction/ligation or a combination of SOEing PCR and Gibson assembly. The 
resulting plasmids were transferred into C. difficile strains R20291 or 630, respectively, via 
conjugation (see above). pMTLSC7215 and pMTLSC7315 contain sub-optimal origins of 
replication and thus, under antibiotic selection, the growth rate of plasmid bearing C. difficile is 
limited by the rate at which these pseudosuicide vectors can be replicated. The first 
recombination event was identified by the appearance of large colonies on selective agar, as the 
growth rate of single-crossover integrant is no longer limited by the rate of plasmid replication. 
Single recombination was confirmed by PCR and colonies restreaked on non-selective BHI agar 
and incubated for 72 h to facilitate the second recombination event and plasmid loss. The 
bacterial growth was then harvested from the BHI plates using 1 ml of sterile, pre-reduced PBS. 
The resulting cell suspension was then serially diluted in PBS and plated on CDMM containing 
the counter-selection agent, 5-fluorocytosine. Colonies that arose after 48-72 h were screened 
by PCR using primers flanking the altered site. The resulting fragment was then sequenced. 
2.3 Protein Purification 
2.3.1 Recombinant Protein Expression 
C. difficile strain 630 bearing the appropriate plasmid was grown O/N and used to 
inoculate 10 l TYG to OD600nm 0.1. The culture was grown to OD600nm 0.5 and induced with 700 
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ng/ml of Atc. Cultures were then incubated for approximately 5 h and harvested via 
centrifugation (4,000 x g, 10 min) and cell pellets stored at -20°C.  
2.3.2 Purification of Recombinant Proteins  
Proteins purified during this project were all designed to contain a strep-tag at the N-
terminus to facilitate a one-step purification process (Schmidt and Skerra, 2007). Pelleted cells 
were resuspended in 25 ml of 2x binding buffer (200 mM tris-HCl pH8, 300 mM NaCl, 2 mM 
EDTA) containing approximately 1 ml of purified the bacteriophage endolysin CD27L catalytic 
domain and cOmplete protease inhibitor cocktail (Roche). The resulting mixture was incubated 
at 37°C for 30 min followed by centrifugation at 20,000 x g for 3 min to remove cell debris. The 
cell lysate was then filtered through a 0.44 µm filter, diluted to 50 ml using 1x binding buffer and 
loaded onto 2x strep-tactin columns (GE healthcare) using an ÄKTAprime (GE healthcare). The 
columns were then washed using 10 column volumes of 1x binding buffer and proteins eluted 
by addition of an elution buffer (binding buffer containing 2.5 mM desthiobiotin) gradient. 
Protein content of fractions was analysed by SDS-PAGE (section 2.5.2) and the fractions 
containing the desired protein were pooled.  
2.3.3 Dialysis and Concentration of Purified Proteins  
Purified proteins were dialysed using 10 MWCO Slide-A-Lyzer dialysis cassettes 
(Thermo). Cassettes were submerged in dialysis buffer (25 mM tris-HCl pH8, 50 mM NaCl) for 2 
min to wet the membrane. 3 ml of protein solution was then injected in between the 
membranes of the cassette. The cassettes were then submerged in 1 l of dialysis buffer and 
incubated at 4°C with gentle stirring, initially for 2 h, then for 3-4 hours and finally O/N. In-
between incubations the buffer was exchanged for fresh dialysis buffer. The following morning 
the protein was removed from the cassette and concentrated using a 10 MWCO Amicon ultra-4 
centrifugal filter. Protein concentrations were quantified using A280 spectrometry.  
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2.3.4 Crude S-layer Extraction 
S-layer extracts were prepared using the low pH glycine method as described previously 
(Calabi et al., 2001). 5-20 ml of C. difficile cultures were harvested via centrifugation (4,000 x g, 
10 min). Pelleted cells were resuspended to an approximate OD600nm of 50 in 0.2 M glycine-HCl 
pH 2.2 and incubated with rotation at RT for 15 min. The suspensions were centrifuged (20,000 
x g, 2 min) and the supernatants containing the S-layer proteins were recovered and neutralised 
using 2 M tris.  
2.5 Protein Characterisation  
2.5.1 Protein Crystallisation and 3D Modelling   
Solutions of purified SecA2 were concentrated to approximately 1 mg/ml. Crystal 
screening was initially carried out using PACT, Cryo, Screen 1, and Morpheus suites 
(Qiagen) using the sitting drop vapour diffusion method with a 200 nl drop size (1:1 
protein/precipitant ratio). After 7 days, the plates were screened for crystal growth. 
Optimisation of crystal growth was performed by Dr Paula Salgado (University of Newcastle) 
using a range of concentrations of MgCl2 (100-250 mM) and PEG6K (15-30%) buffered with either 
100 mM MES pH 6.0-6.5 or 100 mM HEPES pH 7.0-7.5 using a hanging drop vapour 
diffusion method. Diffraction data was obtained from crystals using the I24 microfocus 
X-ray source (Diamond light source, Oxford). Data was processed and analysed entirely 
by Dr Paula Salgado. 
2.5.2 SDS-PAGE 
Electrophoretic analysis of proteins was carried out using denaturing polyacrylamide 
gels (Laemmli, 1970). 30% acrylamide:bisacrylamide (37:5:1) gels were prepared according to 
standard protocols. The final acrylamide concentration used was dependent on the size of the 
proteins to be resolved, i.e. lower percentages were used for larger proteins. Samples were 
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combined with an equal volume of 2x Laemmli loading buffer (150 mM Tris-HCl, pH 6.8, 30% 
(v/v) glycerol, 1.5% (w/v) SDS, 15% (v/v) β-mercaptoethanol, 2 μg/ml bromophenol blue) and 
electrophoresis was performed using Mini-Protean tetra cell apparatus (Bio-rad). 
Electrophoresis was performed using a constant voltage (190 V), until the dye front approached 
the bottom of the gel. When required, gels were stained O/N in 45% (v/v) methanol, 10% (v/v) 
acetic acid, 0.25% (w/v) brilliant blue R-250 and destained using 45% (v/v) methanol, 10% (v/v) 
acetic acid.  
2.5.3 In-gel Fluorescence  
C. difficile strains expressing SNAP protein fusions were grown in liquid broth and SNAP-
TMR star added to a final concentration of 250 nM. Bacteria were then harvested via 
centrifugation (20,000 x g, 2 min) and pellets were resuspended and lysed. Lysates were 
combined 1:1 with 2x Laemmli loading buffer and conventional SDS-PAGE performed. Proteins 
bands were visualised using a BioRad ChemiDoc MP imaging system. 
2.5.4 Transfer to PVDF Membrane  
Following SDS-PAGE, proteins were transferred to PVDF membrane in one of two ways. 
For relatively small proteins (<100 kDa) the semi-dry transfer method was employed. Gels were 
equilibrated in Cation buffer (40 mM glycine, 25 mM tris-HCl, 10% (v/v) methanol, ph 9.4) for 10 
min. During this time, PVDF membranes were briefly soaked in methanol, submerged in water 
for 2 min and equilibrated in Anode buffer II (25 mM tris-HCl, 10% (v/v) methanol, pH 9.4) for 8 
min. Transfer stacks were then assembled, anode to cathode, as follows. Two pieces of 3 MM 
Whatman filter paper soaked in Anode buffer I (300 mM tris-HCl, 10% (v/v) methanol, pH 10.4), 
one piece of filter paper soaked in Anode buffer II, the Anode II buffer equilibrated membrane, 
the Cathode buffer equilibrated gel, and finally three pieces of filter paper soaked in Cathode 
buffer. Transfer was carried out using a TransBlot Turbo transfer system (Bio-Rad), at a constant 
voltage (15 V) for 15 min.  
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When analysing large proteins (>100 kDa) the wet transfer method was employed. PVDF 
membranes were soaked briefly in methanol, submerged in water for 2 min and equilibrated in 
transfer buffer (25 mM tris, 192mM glycine, 10% (v/v) methanol). Gels were also equilibrated in 
transfer buffer. The membrane and gel were sandwiched between three transfer buffer soaked 
pieces of filter paper on each side. Transfer stacks were then incorporated into Mini Trans-Blot 
Modules (Bio-rad) and submerged in ice-cold transfer buffer in a Mini-Protean Tetra Cell (Bio-
Rad). Transfer was carried out at a constant voltage (100 V) for two hours. 
To determine the quality of protein transfer, membranes were covered with Ponceau 
red stain (0.1% (w/v) Ponceau S, in 5% acetic acid) and washed using distilled water until protein 
bands could be easily visualised. Membranes were then dried by submerging in methanol 
followed by incubation at room temperature for a minimum of 30 min. 
2.5.5 Western Blot Analysis 
Dried membranes were incubated with primary antibody in a 3% skimmed milk PBS 
solution, either O/N at 4°C or at RT for 1 h, with gentle rocking. Membranes were washed three 
times with PBS and incubated with horseradish peroxidase (HRP) conjugated secondary 
antibodies in 3% skimmed milk at RT for 1 h. Membranes were washed an additional four times 
with PBS and developed using Clarity Western ECL Blotting Substrate (Bio-Rad). Blots were 
imaged using the BioRad ChemiDoc MP imaging system.  
2.5.6 Preparation of Samples for Peptide Mass Fingerprinting 
Protein samples were first reduced, alkylated and trypsinized as follows. 5 µl of protein 
solution were added to 35 µl digestion buffer (final concentration 100 mM NH4HCO3). Samples 
were reduced through the addition of 2 µl DTT (final concentration 10 mM) and incubation for 
1 h at 56°C. Samples were cooled to RT and alkylated by adding 2 µl iodoacetamide (final 
concentration 10 mM). Samples were vortexed and incubated in the dark at RT for 30 min. 1 µl 
of 500 mM DTT was then added to quench the alkylation reaction. Trypsin was then added to a 
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final ratio of 25:1 protein to protease, and digestion carried out at 37°C O/N. The following 
morning samples were desalted using C18 spin columns (Thermo), eluted in 40 µl of 70% 
acetonitrile and dried in a vacuum evaporator. 
2.5.7 Peptide Mass Fingerprinting 
Peptide mass fingerprinting was carried out by Dr Richard Beniston at the Biological 
Mass Spectrometry Service (Department of Chemistry, University of Sheffield). Peptide mass 
was determined via LC-MS/MS using a Thermo Orbitrap Elite. Mass spectrometry experiments 
were performed using biological duplicates. Proteins were analysed using two different 
concentrations and once without prior reduction/alkylation.  
2.6 Microscopy 
2.6.1 Fixing Cells With Paraformaldehyde   
1 ml of sample was harvested (20,000 x g, 2 min) and washed three times with PBS. Cells 
were then resuspended in 3.2% paraformaldehyde in PBS and incubated on a rotary shaker for 
15 min at RT. Samples were then washed twice in PBS. The cross-linker was then quenched by 
the addition of 0.5 ml 20 mM NH4Cl and incubated for 15 min at RT. Samples were washed a 
further two times in PBS and stored as pellets at 4°C. 
2.6.2 Phase Contrast and Epifluorescence Microscopy 
For phase contrast microscopy, fixed cells were resuspended in sterile water to an 
appropriate cell density and dried onto glass slides. Slides were rinsed using distilled water and 
dried. Cover slips were mounted in 80% glycerol. 
Samples for use in SNAP-tag fluorescence microscopy were stained with SNAP TMR-Star 
(New England Biolabs) prior to being fixed. SNAP TMR-Star (final concentration 250 nM) was 
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added to 1 ml samples of growing C. difficile cultures and incubated at 37°C anaerobically for 30 
min, washed twice using 0.5 ml sterile PBS, and fixed and mounted as described above.  
For HADA labelling of the cell wall, O/N cultures of C. difficile were used to inoculate 
fresh broth to OD600nm 0.05. 1.5 h post-inoculation, HADA (final concentration 0.6 mM) was 
added to the growing culture. When the cultures reached OD600nm 0.6, 1 ml samples were 
harvested by centrifugation (2,000 x g) and washed 3x with sterile, pre-reduced TY broth. 
Bacterial pellets were then resuspended in TY broth and incubated anaerobically for a further 
30 min. Samples were then processed as above. 
For immunofluorescence, samples were fixed and dried onto glass slides as above. Slides 
were blocked O/N in 3% BSA in PBS at 4°C. Slides were then drained and rinsed in PBS. 15 µl of 
primary antibody in 3% BSA in PBS was spotted onto the dried cells and incubated for 1 h at RT. 
Slides were rinsed in PBS before 15 µl secondary antibody in 3% BSA in PBS was spotted onto 
the slide. Slides were incubated for a further 1 h at RT. Slides were thoroughly rinsed in PBS and 
sterile water, dried and mounted using 5 µl SlowFade gold (Thermo). All samples were visualised 
using a Nikon Ti Eclipse inverted microscope.  
2.6.3 Electron Microscopy 
TEM analysis was performed by Christopher Hill at the electron microscopy unit of the 
University of Sheffield. After fixation with paraformaldehyde, cells were further fixed with 3% 
glutaraldehyde in 0.1 M cacodylate buffer followed by 1% osmium tetroxide. Samples were 
dehydrated in ethanol, embedded in araldite resin and sectioned at 85 nm on a Leica UC6 
ultramicrotome. Sections were then transferred onto copper coated grids and stained with 
uranyl acetate and lead citrate. Samples were visualised using a FEI Technai BioTWIN TEM at 80 
kV fitted with a Gatan MS600CW camera.  
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2.7 Phenotypic Assays 
2.7.1 Sporulation Efficiency Determination   
Sporulation assays were performed as previously described (Dembek et al., 2015). Single 
colonies of C. difficile were used to inoculate pre-reduced BHIS media. The following morning, 5 
ml of fresh BHIS media was inoculated to OD600nm 0.01 and incubated for 8 h. This culture was 
then used to inoculate 10 ml of fresh BHIS media to OD600nm 0.0001. This was performed to 
ensure minimal carry over of spores from the original culture. For total CFU counts, the following 
morning (T0) samples were serially diluted in PBS and 10 µl of the dilutions were spotted in 
triplicate on BHIS plates containing 0.1% (w/v) sodium taurocholate. For total spore counts, 0.5 
ml samples of the culture were heated to 65°C for 30 min. This treatment kills all vegetative cells 
in the sample. Heated samples were serially diluted and plated on sodium taurocholate 
containing BHIS plates. CFU enumeration was performed the following day. This process was 
repeated every day for a further 5 days (T1-T5). Samples were also taken, fixed, mounted, and 
visualised using phase contrast and electron microscopy. 
2.7.2 Spore Thermal Resistance  
Sporulation assays were prepared as above. At T5 total counts and spore counts were 
performed as above. In addition, 0.5 ml samples were also heated to 75°C for 30 min. CFU 
enumeration was performed as above.  
2.7.3 Germination Efficiency  
Germination assays were performed as previously described (Dembek et al., 2015). 
Purified spores were resuspended in BHIS containing 0.5% sodium taurocholate to OD600nm 1.0. 
Ca2+-DPA release and core-rehydration was then monitored over time by measuring the A600nm.  
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2.7.4 C. difficile Growth Analysis 
O/N cultures of C. difficile grown in TY broth were used to inoculate fresh, pre-reduced 
TY to OD600nm 0.05. Growth was then measured by recording the OD600nm every hour. In addition, 
200 µl samples were serially diluted and spotted in triplicate on BHI agar. CFU enumeration was 
performed after O/N incubation.  
2.7.5 Lysozyme and LL37 resistance 
Cultures for lysozyme and LL-37 challenge experiments were prepared as described 
above (section 2.7.4). Lysozyme (500 µg/ml) and LL-37 (5 µg/ml) were added 2.5 h post 
inoculation and the OD600nm was recorded hourly. 
2.7.6 Avidocin-CD Killing  
Broth based Avidocin-CD killing assays were performed as above (section 2.7.5) in TY 
supplemented with 1 mM CaCl2. Avidocin-CDs were added 2.5 h post inoculation and the OD600nm 
was then measured hourly. Avidocin-CDs were added in excess to ensure complete killing.  
2.7.7 Comparative Toxin Production and Toxin Release Assays 
For comparative analysis of toxin production, O/N cultures of C. difficile were used to 
inoculate fresh, pre-reduced TY to an OD600nm of 0.01. Cultures were incubated for 8 h and sub-
cultured in TY broth to OD600nm 0.0001. After O/N incubation, the culture was subcultured to 
OD600nm 0.05. 1 ml samples were harvested (20,000 x g, 2 min) after 5, 24, 48 and 72 h. Pelleted 
cells were washed once in 0.5 ml PBS and stored at -20°C until required. Supernatants were 
passed through a 0.44 µm filter and stored at -20°C. Before analysis, supernatants were thawed 
and concentrated to a relative OD600nm of 20. Pelleted cells were resuspended to OD600nm 20 in 
PBS containing the CD27L bacteriophage endolysin, followed by incubation at 37°C for 30 min.   
To determine if Avidocin-CD killing causes the release of intracellular toxin, Av-CD291.2 
challenge experiments were performed. This was done using cultures incubated for 24 h, as this 
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was determined to the time-point where cells contain the highest concentration of intracellular 
toxin. After 24 h incubation, 1 ml samples were centrifuged in the anaerobic work station (2,000 
x g, 3 min) and washed once with 0.5 ml pre-reduced TY media. Pelleted bacteria were then 
resuspended to OD600nm 20 in TY supplemented with 10 mM CaCl2. Av-CD291.2 was added in 
equal volumes to samples at different ratios of bacterial cells: Avidocin-CD. Av-CD684.1 was 
added (1:500 cells to Avidocin-CD) to one sample and one sample was left untreated to act as 
negative controls. Samples were incubated anaerobically at 37°C for 1 h. Serial dilutions of 
samples were then spotted in triplicate on BHI agar containing taurocholate. A sample of the 
culture was also heated to 65°C and spore counts calculated as previously described. CFU was 
enumerated after 24 h to enable an accurate amount of killing by the Avidocin-CD. Treated 
samples were harvested by centrifugation (13,000 x g, 3 min). Supernatants were recovered and 
centrifuged again (16,000 x g, 3 min) to prevent contamination by bacterial cells.  
The cell lysates and supernatant samples were combined 1:1 with 2x Laemmli loading 
buffer and loaded on 6% SDS-PAGE gels ready for western blot analysis using an anti-toxin B 
antibody (Thermo Fisher). 
2.8.8 β- Glucuronidase Quantification 
These assays were performed as previously described (Dupuy and Sonenshein, 1998). C. 
difficile cultures were grown to exponential phase (approximately OD600nm 0.7). 5 ml samples 
were harvested (4,000 x g, 10 min) and pelleted cells were stored at -20°C. Each 5 ml sample 
was resuspended in 100 µl Z-buffer (60 mM Na2HPO4, 60 mM NaH2PO4, 10 mM KCl, 1 mM 
MgSO4, 50 mM 2-mercaptoethanol, pH 7.0) containing CD27L bacteriophage endolysin. Samples 
were incubated at 37°C for 30 min and centrifuged at 20,000 x g for 10 minutes. 700 µl Z-buffer 
was added to each sample and incubated at 37°C for 5 min. Enzyme reactions were initiated by 
the addition of 160 µl of 6 mM p-nitrophenyl--D-glucuronide. The start time of each reaction 
was recorded. After the development of a yellow colour to the solutions, reactions were stopped 
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by the addition 0.4 ml 1 M Na2CO3. Samples were then centrifuged (20,000 x g, 10 min) to 
remove cell debris and the OD405nm recorded. Enzyme activity was calculated using the formula 
(OD405nm x 1000)/(OD600nm x reaction time (min) x 1.25 x vol of culture (ml)). 
2.8.9 Bacterial Two-Hybrid  
BACTH reporter E. coli strains DHM1 and BTH101 were co-transformed with plasmids 
expressing bait and prey proteins fused to the T25 and T18 fragments of the catalytic domain of 
adenylate cyclase (CyaA). Transformants were grown O/N in LB broth supplemented with the 
appropriate antibiotics. 10 µl of O/N culture was spotted onto LB agar containing 0.5 mM IPTG 
and 40 µg/ml X-gal. Plates were incubated for up to 48 h at either 37°C or 30°C, and monitored 
for the development of a blue colour to the E. coli growth. 
2.8 Bioinformatics 
Geneious sequence analysis software 10.0.9 (Biomatters) was used routinely for analysis 
of protein and nucleotide sequences, including sequence alignment, in silico cloning, and 
experimental design. Bacterial promoter prediction was performed using SoftBerry BPROM 
(www.softberry.com). Primers to amplify fragments used in either SOEing or Gibson assembly 
were designed using NEBuilder (http://nebuilder.neb.com/). Calculation of protein parameters 
including the estimated extinction coefficient was performed using the ExPASy protParam tool 
(Wilkins et al., 1999). Analysis of the inverted repeat sequences conservation was performed by 
aligning the left and right inverted repeat of each genetic switch. A 21 bp region of high 
consensus identified and used to create a logo-plot. Logo plots were created using the WebLogo 
online application (Crooks et al., 2004).  
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2.9 Statistical Analysis 
Statistical analysis of data was performed using a combination of one way ANOVA, two 
tailed t-tests using Welch’s correction, and Mann-Whitney U tests. Statistical tests were 
performed using GraphPad Prism 7 (GraphPad Software Inc). 
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10.1126/scitranslmed.aah6813. 
New Class of Precision Antimicrobials Redefines Role of 
Clostridium difficile S-layer in Virulence and Viability 
 
Joseph A. Kirk1, Dana Gebhart2, Anthony M. Buckley3, Stephen Lok2, Dean Scholl2, Gillian R. 
Douce3, Gregory R. Govoni2*, Robert P. Fagan1*  
1: Krebs Institute, Department of Molecular Biology and Biotechnology University of Sheffield, 
Sheffield S10 2TN, UK.  
2: AvidBiotics Corp. South San Francisco, California, USA.  
3: Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary & Life 
Sciences, University of Glasgow, Glasgow G12 8TA, UK.  
*To whom correspondence should be addressed:  Gregory R. Govoni: ggovons@gmail.com;  
Robert P. Fagan: r.fagan@sheffield.ac.uk   
Abstract:  
Avidocin-CDs are a new class of precision bactericidal agents that do not damage resident gut 
microbiota and are unlikely to promote the spread of antibiotic resistance. The precision killing 
properties result from the fusion of bacteriophage receptor binding proteins (RBPs) to a lethal 
contractile scaffold from an R-type bacteriocin. We recently described the prototypic 
AvidocinCD, Av-CD291.2, that specifically kills C. difficile ribotype 027 strains and prevents 
colonization of mice. We have since selected two rare Av-CD291.2 resistant mutants of strain  
R20291 (RT027; S-layer cassette type-4, SCLT-4). These mutants have distinct point mutations in 
the slpA gene that result in an S-layer null phenotype. Reversion of the mutations to wild-type 
restored normal SLCT-4 S-layer formation and Av-CD291.2 sensitivity; however, 
complementation with other SCLT alleles did not restore Av-CD291.2 sensitivity despite 
restoring S-layer formation. Using newly identified phage RBPs, we constructed a panel of new 
Avidocin-CDs that kill C. difficile isolates in an SLCT-dependent manner, confirming the Slayer as 
the receptor in every case. In addition to bacteriophage adsorption, characterization of the S-
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layer null mutant also uncovered important roles for SlpA in sporulation, resistance to lysozyme 
and LL-37, and toxin production. Surprisingly, the S-layer-null mutant was found to persist in the 
hamster gut despite its completely attenuated virulence. Avidocin-CDs have significant 
therapeutic potential for the treatment and prevention of C. difficile Infection (CDI) given their 
exquisite specificity for the pathogen. Furthermore, the emergence of resistance forces mutants 
to trade virulence for continued viability and, therefore, greatly reduce their potential clinical 
impact.  
3.1 Introduction  
New antibacterial agents are needed to counteract the impending loss of effective treatment 
options for multi-drug resistant bacteria. Furthering this need is the realization that dysbiosis 
caused by broad-spectrum antibiotic use contributes to the prevalence of diseases/disorders 
such as inflammatory bowel disease, obesity and gastrointestinal infections (1). Strategies to 
overcome these threats include use of narrow spectrum or precision agents and the design of 
drugs that target virulence instead of in vitro viability (2, 3). One pathogen for which alternative 
treatment approaches are needed is C. difficile. This spore-forming, obligate anaerobe is the 
leading cause of nosocomial infections worldwide. Approximately 450,000 cases and 29,000 
deaths each year are attributed to this pathogen in the US alone (4). As a result, the Centers for  
Disease Control and Prevention has identified C. difficile as an urgent threat to human health 
(5). This opportunistic pathogen exploits a reduction in gut microbiota diversity that often 
follows broad spectrum antibiotic use to proliferate, release toxins, and cause life-threatening 
colitis (6). Although the toxins have been studied in great detail, other aspects of C. difficile 
virulence, including colonization of the gut, are not well understood (6). The C. difficile cell 
surface is covered by a paracrystalline surface layer (S-layer) largely comprised of SlpA and 
sparsely interspersed by 28 related cell wall proteins (7). The S-layer precursor SlpA is 
proteolytically processed on the cell surface to generate the Low and High Molecular Weight S-
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layer Proteins (LMW and HMW SLPs). The SLPs interact with high-affinity to form a heterodimer, 
the basic unit of the mature S-layer (8). The slpA gene is located within a highly variable S-layer 
cassette consisting of 5 genes; 13 distinct S-layer cassette types (SLCTs) have been described to 
date (9). The variation that defines individual cassette types is largely confined to the LMW 
SLPencoding region of slpA (4). The HMW SLP region is highly conserved and includes the cell 
wall binding motifs that anchor the S-layer to the cell wall (10). The S-layer and several 
associated cell wall proteins have been implicated in colonization of host tissues (7) and in 
stimulation of the host immune response via TLR4 signaling (11).   
Whereas C. difficile is not significantly resistant to the frontline antibiotics used to treat CDIs 
(vancomycin, metronidazole and fidaxomicin), the use of these antibiotics causes further 
disruption of the resident microbiota leading to frequent CDI relapse (6). To be safe and 
effective, new agents to treat and prevent CDIs must not harm the diverse gut microbiota and 
the colonization resistance it provides. Avidocin-CDs represent one such potential agent (12). 
These bactericidal proteins are genetically modified versions of natural R-type bacteriocins 
(a.k.a. diffocins) produced by C. difficile to kill competing C. difficile strains (13). Diffocins 
resemble myoviridae phage tails and consist of a contractile sheath, nanotube core, baseplate 
and tail fiber structures. However, instead of delivering DNA across the bacterial membrane as 
does a bacteriophage, R-type bacteriocins function as killing machines by injecting a nanotube 
core through the bacterial cell envelope and creating a small pore that dissipates the cell’s 
membrane potential (14). Killing specificity is determined by the receptor binding proteins 
(RBPs) located at the tail fiber tips that trigger sheath contraction upon binding with a cognate 
receptor on the bacterial cell surface. Genetic replacement or fusion of the RBP gene with 
homologues from other strains or RBP sources (i.e. C. difficile bacteriophages and prophage 
insertions) make it possible to retarget killing (12, 15-17). These modified bacteriocins are 
known as Avidocin-CDs. An Avidocin-CD prototype, Av-CD291.2, constructed with a 
bacteriophage RBP identified within a prophage insertion was found to be more stable than the 
 Chapter III. Avidocins and the Funciton of the S-layer 
 60 
 
natural parent diffocin. AvCD291.2 had a modified killing spectrum that included all 
hypervirulent RT027 C. difficile strains tested, blocked C. difficile colonization in a mouse model 
of spore transmission and did not disrupt the resident gut microbiota (12). These properties 
encourage the further development of Avidocin-CDs as oral human therapeutics.   
Here we further characterize the Av-CD291.2 mechanism of action and describe an expanded 
panel of Avidocin-CDs that cover all clinically relevant C. difficile strain types using newly 
identified bacteriophage RBPs. Rare resistant mutants were isolated in vitro under Av-CD291.2 
selection. Analysis of these mutants enabled the identification of SlpA as the cell surface 
receptor for all tested Avidocin-CDs and, by extension, the corresponding bacteriophage and 
prophage RBP-sources. We also identified previously unsuspected roles for SlpA in sporulation, 
resistance to lysozyme and the natural anti-microbial peptide LL-37, toxin production and 
virulence. Surprisingly, despite their complete attenuation of virulence, resistant mutants could 
colonize and persist in the hamster gut for the duration of a 14-day study. These findings imply 
that antimicrobial agents that force pathogens to trade virulence for continued viability would  
have clear clinical advantages should resistance emerge during treatment. 
3.2 Results   
3.2.1 Av-CD291.2-resistant mutants lack an S-layer  
Resistance to any antimicrobial agent can occur and be exploited to understand its mode 
of action. We isolated two spontaneous mutants of C. difficile strain R20291 (ribotype 027) that 
were resistant to killing by Av-CD291.2. These mutants appeared at a frequency of < 1 x 10-9 and 
were found to encode independent point mutations in the slpA gene (Fig.3.1A). Both mutations 
were predicted to truncate SlpA at a site N-terminal to the post-translational cleavage site and, 
thereby, prevent formation of an S-layer. Both FM2.5 and FM2.6 lacked detectable cell surface 
S-layer protein subunits as predicted but still expressed minor cell wall proteins including Cwp2 
and Cwp6 (Fig.3.1B). These mutations did not affect the growth rate of the bacteria in vitro 
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(Fig.S4B); however, FM2.5 displayed a slight, but statistically significant earlier entry into 
stationary phase (maximum OD600nm: FM2.5 = 2.2; R20291 = 3.2, p =  
0.000012). We attempted to complement the FM2.5 and FM2.6 mutations with a plasmid-borne 
wild-type R20291 slpA; however, unexpected homologous recombination restored the wild type 
slpA gene to the chromosome (Fig.3S1). Accordingly, we created genetically identifiable 
recombinants “watermarked” with synonymous substitutions in the R20291 slpA allele 
(Fig.3.1A). The resulting strains, FM2.5RW and FM2.6RW, were found to have LMW and HMW 
SLPs on their surface (Fig.3.1B) and regained sensitivity to Av-CD291.2 (Fig.3.1C and D). These 
results confirmed that an intact S-layer is required for Av-CD291.2 killing but did not determine 
whether SlpA itself or a protein dependent on the S-layer for surface localization was the 
receptor for Av-CD291.2. To address this question, slpA alleles from the most common 
nonR20291 SLCTs were individually cloned into an inducible expression plasmid and transferred 
into the S-layer deficient FM2.5 (Fig.3.1E). Each resulting strain expressed the expected LMW 
and HMW SLPs on the cell surface, indicative of S-layer formation (9), but did not regain 
sensitivity to Av-CD291.2, thus, ruling out the possibility that the simple formation of an S-layer 
was responsible for sensitivity to Av-CD291.2. To address whether Av-CD291.2 directly interacts 
with SLCT-4 SlpA, plasmids encoding SlpA from 8 different SLCTs were introduced into the non-
isogenic laboratory strain 630 (SLCT-7; ribotype 012), which is insensitive to AvCD291.2 (Table 
3S1). In this fully S-layer competent SLCT-7 wild type strain, only induction of SLCT-4 SlpA was 
sufficient to confer sensitivity to Av-CD291.2 (Fig.3S3). Moreover, the degree of sensitivity was 
dependent on the level of induction with only 10 ng/mL of inducer required  
(Fig. S3A). Taken together these observations clearly demonstrate that the SLCT-4 variant of  
SlpA is the cell surface target of Av-CD291.2.  
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Fig.3.1: Mutations in slpA confer Av-CD291.2 resistance. (A) Alignment of the slpA sequence (nucleotides 
268-294) from R20291, FM2.5, FM2.6, FM2.5RW and FM2.6RW. A nucleotide insertion at position 283 of 
FM2.5 slpA results in a frameshift and premature stop codon (in blue). A nucleotide substitution at 
position 280 of FM2.6 slpA results in a nonsense mutation (in red). To allow differentiation from the wild 
type sequence, two synonymous mutations were introduced into slpA in FM2.5RW and FM2.6RW (in 
green) (B) SDS-PAGE analysis of S-layer extracts from R20291, FM2.5, FM2.6, FM2.5RW and FM2.6RW. 
The positions of the LMW and HMW SLPs and minor cell wall proteins Cwp2 and Cwp6 are indicated. (C 
and D) The impact of Av-CD291.2 on exponentially growing R20291, FM2.5, FM2.5RW and FM2.6RW was 
monitored by measuring the optical density at 600 nm. Av-D291.2 addition is indicated with an arrow. 
Experiments were carried out in triplicate on biological duplicates. Means and standard deviations are 
shown. (E) SDS-PAGE analysis and Av-CD291.2 sensitivity of FM2.5 complemented with slpA alleles from 
multiple SLCTs following induction with anhydrotetracycline (20 ng/ml). R20291 and FM2.5RW are 
included as controls. A zone of clearance in the agar lawn indicates killing.   
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3.2.2 Sensitivity to all Avidocin-CDs is slpA allele-specific  
These observations suggested that each variant of SlpA may serve as a specific receptor 
for additional C. difficile bacteriophage RBPs. In an attempt to expand Avidocin-CD coverage 
beyond SLCT-4, we constructed ten new Avidocin-CDs using predicted bacteriophage RBPs 
mined from the genome sequences of C. difficile clinical isolates or newly isolated 
bacteriophages (Table 3S1). Source strains for RBP sequences were chosen based on their SLCT 
since strain typing information for the RBP source often correlates with sensitivity to the 
corresponding Avidocin (e.g. ribotype 027 and sensitivity to Av-CD291.2; SLCT-1 of phi-147 
propagating strain and sensitivity to Av-CD147.1) (12, 15, 16). Preparations of Diffocin-4 
(scaffold for all Avidocin-CDs), Av-CD291.2, and each of the new Avidocin-CDs were tested for 
killing activity on a panel of 62 C. difficile isolates containing all 13 known SLCTs and a newly 
identified 14th SLCT (Fig.3S2). Only two strains, representing SLCTs 3 and 5, were not killed by a 
single Avidocin-CD (Fig.3S2); otherwise, every isolate from all 12 other SLCTs was killed by at 
least one Avidocin-CD. A near perfect correlation was observed between a strain’s SLCT and its 
sensitivity to each of the Avidocin-CDs. The only exceptions were SLCT-2 isolates with Av-
CD027.2 and Av-CD685.1. A strong correlation was also observed between ribotype and 
sensitivity to a particular Avidocin-CD since all ribotypes in the panel, except 012, 014 and 015, 
were found to associate exclusively with a single SLCT. Similar correlations with strain sensitivity 
and SLCT or ribotype were not observed for killing with Diffocin-4, suggesting this natural R-type 
bacteriocin binds to C. difficile via another receptor.  
Having made these observations, we wanted to determine if sensitivity to specific  
Avidocin-CDs was directly dependent upon the variant of SlpA present. The panel of isogenic 
FM2.5 strains complemented with slpA alleles from the 10 most common SLCTs was tested for 
sensitivity to a panel of the most potent Avidocin-CDs (Fig.3.2). The corresponding parental 
strains from which the slpA alleles were obtained were used as controls. Each complemented 
strain became sensitive to the same Avidocin-CDs as the parental strain. To confirm that this 
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engineered sensitivity did not result from altered cell surface architecture, an analogous 
experiment was performed in a second panel of isogenic strains created when plasmids 
encoding SlpAs from 8 SLCTs were introduced into the S-layer competent strain 630 (Fig.S3B and 
C). As before, the spectrum of killing was identical to that of the parental strains from which the 
slpA alleles were obtained. These data conclusively demonstrate that the polymorphic SlpA acts 
as the binding receptor for each of the Avidocin-CDs tested and, therefore, the corresponding 
bacteriophage RBPs.  
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Fig.3.2: Avidocin-CD sensitivity correlates with SLCT. (A) SDS-PAGE analysis of SLPs extracted from a 
panel of strains representing the 11 most commonly isolated SLCTs. (B) Spot bioassays with 8 Avidocin-
CDs on the C. difficile strains used in panel A, as well as FM2.5 alone (-) and FM2.5 complemented with 
slpA alleles from 10 SLCTs following induction with anhydrotetracycline (20 ng/ml). The zone of clearance 
caused by each Avidocin-CD is shown along with SLCT (H = Hybrid 2/6).  
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3.2.3 S-layer null mutants are abnormally sensitive to innate immune 
effectors  
Bacterial S-layers serve many critical cellular functions (7). Given its location on the cell 
surface, the S-layer has been proposed to act as a molecular sieve to selectively limit exposure 
of the underlying cell envelope to large biomolecules such as the innate immune effector 
lysozyme (18). Until now, analysis of C. difficile S-layer function has been hampered by an 
inability to isolate slpA-deficient mutants (19). While C. difficile is highly resistant to killing by 
this enzyme, resistance has been attributed to extensive peptidoglycan deacetylation (20). To 
determine if the S-layer also plays a role in lysozyme resistance, we treated exponentially 
growing bacteria with a high concentration of lysozyme (500 µg/ml) and monitored the effects 
on growth (Fig.3.3A). Upon addition of lysozyme an immediate decrease in optical density 
consistent with cell lysis, followed by slower growth, was observed for the S-layer mutant FM2.5. 
In contrast, R20291 and FM2.5RW displayed only a transient decrease in growth rate, consistent 
with natural resistance. Having confirmed a role for the S-layer in lysozyme resistance, we then 
tested for resistance to the human cathelicidin antimicrobial peptide LL-37 to determine if S-
layer-mediated resistance extended to other innate immune effectors (Fig.3.3B). LL-37 is found 
at mucosal surfaces at concentrations of up to 5 µg/ml in normal conditions with further 
expression induced in response to infection (21). Treatment with 5 µg/ml of LL-37 completely 
killed exponentially growing cultures of the S-layer mutant FM2.5; whereas, the same treatment 
caused only a slight reduction in growth rates for R20291 and FM2.5RW. Taken together, these 
data demonstrate a role for the S-layer in resistance to both lysozyme and LL-37.   
3.2.4 S-layer null mutants display severe sporulation defects  
It was noted that the S-layer mutant strains survived poorly in the standard charcoal 
medium used to transport C. difficile strains. The ability of C. difficile to survive in the 
environment and be transmitted to new hosts is reliant on the bacterium’s ability to produce a 
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heat and chemical-resistant spore (22). We analyzed sporulation efficiency by measuring the 
numbers of heat-resistant spores as a percentage of total viable CFUs over 5 days (Fig.3S4A).  
Spore production by wild type R20291 and FM2.5RW cultures was reproducible and equivalent 
and represented 73 and 85% of total viable counts on day 5, respectively (Fig.3.3C). In contrast, 
spore production by FM2.5 was significantly lower (p = <0.00001). Spores only represented  
4.3% of total viable counts on day 5, which is a 17-20-fold reduction compared to R20291 and 
FM2.5RW. These observed differences in FM2.5 spore formation were not due to an inability to 
germinate efficiently (Fig.3.3D). When the bile salt germinant taurocholate was added to 
purified spore preparations, the speed and efficiency of germination initiation for FM2.5 spores 
was indistinguishable from that of R20291 and FM2.5RW. Analysis of bacterial cultures by phase 
contrast microscopy also pointed to a reduction in sporulation efficiency (Fig.3S4C and D), as  
5.2-fold fewer phase bright spores were observed in cultures of FM2.5 (FM2.5, 8.7% vs R20291, 
44.9%; FM2.5RW, 45.4%). Interestingly, we noted a discrepancy between the magnitudes of the 
sporulation defect determined microscopically (5.2-fold less than R20291) compared with direct 
counting of viable spore CFUs (20-fold less than R20291). This suggests that many of the 
microscopically counted spores were nonviable following the 65°C heat treatment required to 
differentiate spores from vegetative cell CFUs. To test the FM2.5 spores for possible stress 
resistance defects, we exposed the cultures to a harsher heat treatment (75°C for 30 min). The  
75°C heat treatment further reduced FM2.5 spore viability 33-fold compared with the standard 
65°C (Fig.3.3C). The same treatment only reduced spore viability by 1.5-fold for R20291 and 
2fold for FM2.5RW. Collectively, these data indicate that the production and quality of the 
infectious spores are severely impaired by the loss of the S-layer.   
Transmission electron microscopy was employed to identify potential morphological 
changes associated with these defects (Fig.3S5). In FM2.5 cultures we observed spores with 
disorganized material loosely attached to the electron-dense core that lacked discernible, 
wellorganized protein coat layers (23) (Fig.3S5A). To determine if these unusual spore 
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morphologies were responsible for the observed thermal sensitivity, we repeated these 
analyses with spores purified on a Histodenz gradient. Following purification, spores of FM2.5 
were morphologically indistinguishable from those of R20291 and FM2.5RW (Fig.3S5C). 
Surprisingly, purified FM2.5 spores still displayed increased thermal sensitivity. A 75°C heat 
treatment reduced FM2.5 spore viability 37.1-fold compared to 10- and 18.1-fold for R20291 
and FM2.5RW respectively (Fig.3S5B). Several distinct biochemical and structural features of the 
spore, including the concentric cortex peptidoglycan and protein layers and core dehydration, 
have been independently linked to heat resistance (24-26). Minor defects in any of these 
features could explain the observed thermal sensitivity of FM2.5 spores.  
  
 Chapter III. Avidocins and the Funciton of the S-layer 
 69 
 
 
Fig.3.3: Phenotypic characterization of FM2.5. (A and B) Cultures of R20291, FM2.5 and FM2.5RW were 
challenged with lysozyme (500 µg/ml; A) or LL-37 (5 µg/ml; B) in exponential phase after 2.5 h (indicated 
with arrows). Untreated control cultures were grown in parallel. Experiments were carried out in triplicate 
on biological duplicates. Means and standard deviations are shown. (C) Sporulation of R20291, FM2.5, 
and FM2.5RW after 5 days. Spore CFUs were determined following a standard 65°C heat treatment for 30 
minutes or a harsher 75°C heat treatment for 30 minutes. Heat-resistant spore CFUs are expressed as a 
percentage of total viable CFUs (spores and vegetative cells). Experiments were carried out in duplicate 
on biological duplicates. Mean and standard deviation are shown. * = P<0.01, determined using two-tailed 
t-tests with Welch's correction. (D) Germination of R20291, FM2.5, and FM2.5RW spores. Synchronous 
germination of purified spores was induced with the bile salt taurocholate. Germination initiation was 
monitored by measuring the resulting decrease in optical density at OD600nm.  
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3.2.5 S-layer null mutants are completely avirulent despite persistent gut 
colonization  
We tested the ability of the S-layer mutant FM2.5 to cause disease in the Golden Syrian 
hamster model of acute CDI. As expected, all animals inoculated with FM2.5RW behaved 
similarly to animals inoculated with the wild type R20291 strain and succumbed to C. difficile 
infection within 102 h of infection, with mean times to cull for R20291 and FM2.5RW of 67 h 36 
min and 57 h 19 min, respectively (p = 0.52, Fig.3.4A). Both groups of hamsters showed typical 
signs of disease including wet tail and drop in body temperature at experimental endpoint. In 
contrast, all animals inoculated with FM2.5 displayed no signs of disease and survived for the 
duration of the 14-day study (p = 0.0018; FM2.5 vs R20291, Fig.3.4A). Very few described 
mutations located outside of the PaLoc locus have resulted in complete avirulence in this model 
(27). Surprisingly, the lack of virulence was not due to a colonization defect. FM2.5 was capable 
of persistent colonization; CFUs in the caecum and colon at the end of study (14 days) were not 
statistically different to those observed for R20291 and FM2.5RW in the same tissues taken at 
experimental endpoint some 10 days earlier (Fig.3.4B). Toxin measurements from gut contents 
14 days after inoculation with FM2.5 showed dramatic reductions in both toxin A or  
B activity compared to samples taken from hamsters that succumbed to infection with either 
the R20291 or FM2.5RW strains (Fig.3.4C and D).  
3.2.6 S-layer null mutants lack toxin production in vitro  
Given the avirulence and low toxin activity observed in animals, we assayed the FM2.5 
and control strains for toxin production in vitro (Fig.3.4E). Toxin B was used as an indicator for 
both toxins since they are coordinately expressed and released (6). As expected, both R20291 
and FM2.5RW produced toxin upon entry into stationary phase. A small amount of Toxin B was 
detected intracellularly at 24 hours; thereafter, Toxin B was exclusively detected in the culture 
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supernatant. Cultures of FM2.5 produced less Toxin B at all time-points, consistent with in vivo 
observations. 
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Fig.3.4: In vivo analysis of slpA mutant in the Syrian Golden hamster. (A) Times to experimental endpoint 
of animals infected with R20291 (black line), FM2.5 (dark blue line) and FM2.5RW (light blue line) 
respectively. Each line represents 6 animals. (B) Total CFUs and spore CFUs (following heat treatment at 
56°C for 20 min) were determined for Lumen- (LA) and tissue associated (TA) bacteria recovered from 
caecum (CAE) and colon (COL) of infected animals and quantified at experimental endpoint (R20291 and 
FM2.5RW) or at 14 days post-infection (FM2.5). Shown are the mean and standard error. The horizontal 
dotted line indicates the limit of detection. None of the observed differences, including those for the TA-
spore CFUs from the colon, are statistically significant. (C and D) Relative toxin activity of filtered gut 
samples on HT-29 (toxin A) and Vero cells (toxin B) respectively. Values represent the reciprocal of the 
first dilution in which cell morphology was indistinguishable from untreated wells. Samples were taken at 
experimental endpoint (R20291 and FM2.5RW) or at 14 days post-infection (FM2.5). (* = P <0.05, ** = P 
<0.01, NS = not significant, determined using a two-tailed nonparametric Mann-Whitney test. (E) In vitro 
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cell lysate and culture supernatant samples from R20291, FM2.5 and FM2.5RW were normalized to an 
equivalent optical density and separated on 6% SDS polyacrylamide gels. Toxin B was detected by Western 
immunoblot using an anti-toxin B monoclonal antibody. Samples were taken at the indicated time points. 
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3.3 Discussion   
The bactericidal properties of Avidocin-CDs bode well for the clinical application of this 
new class of antimicrobial agents for combating CDI. Previous studies demonstrated that killing 
by the prototypic Avidocin-CD, Av-CD291.2, was highly specific for BI/NAP1/027-type strains and 
did not detectably alter the resident gut microbiota in mice (12). For production purposes 
fermentation of genetically modified B. subtilis expressing these agents is similar to many 
established industrial processes and scalable to thousands of liters. We selected, isolated and 
characterized rare C. difficile mutants resistant to Av-CD291.2 to better understand its 
mechanism of action. In the process, we discovered the Avidocin-CD binding receptor, the C. 
difficile S-layer protein SlpA. Indeed, our 10 new Avidocin-CDs were all found to target variants 
of SlpA associated with different SLCTs. Given that the great majority of the sequence variation 
in SlpA is found within the surface exposed LMW subunit (9), this relationship between SLCT and 
Avidocin-CD sensitivity strongly suggests that the LMW SLP is the binding site for all the studied 
Avidocin-CDs. Further, it indirectly identifies this portion of the SlpA as the binding receptor for 
many C. difficile Myophages since each Avidocin-CDs is constructed with a different 
bacteriophage-derived RBP. These findings help explain the limited host ranges observed for 
many C. difficile Myophages (28, 29). It also suggests that antigenic variation observed between 
SLCTs may not be due to immune escape as previously proposed (9) but rather due to a 
molecular arms race between bacteria and bacteriophages. C. difficile is under selective pressure 
to change the bacteriophage receptor, which in turn puts selective pressure on the 
bacteriophages to evolve new RBPs.   
 Interestingly, patterns of strain sensitivity to each Avidocin-CD indicate killing was much 
broader than the parental bacteriophage’s host range (Fig.3S2 and 3S7). A possible explanation 
for this observation is that a typical bacteriophage infection cycle is a 7-step process: 
attachment, genome injection, replication, transcription, translation, assembly and lysis. 
Bacteria can become resistant to a bacteriophage by blocking any stage of the infection cycle. 
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For example, CRISPR-Cas or restriction-modification systems that prevent phage DNA from 
replicating (30). In contrast, Avidocin-CD killing is a 2-step process: attachment to the target 
bacterium followed by killing via creation of a small pore that dissipates the target bacterium’s 
membrane potential, importantly, without lysis or release of macromolecules such as exotoxin 
from the cytoplasm (Fig.3S6). As observed with other Avidocins and R-type bacteriocins (16, 31), 
selected Avidocin-CD resistant mutants survived due to mutations that caused the loss or 
modification of the SlpA binding receptor and not due to mutations that directly disrupted the 
killing mechanism, such as improper pore formation, or caused proteolytic cleavage of the 
agent. The bias towards receptor mutations suggests the Avidocin-CD killing mechanism is 
simple and robust.   
Modification of the binding receptor to avoid Avidocin-CD killing either through 
missense mutations or S-layer switching, as evidenced by the random association between 
clades and SLCTs (9), could also theoretically lead to resistance. While sequence variations 
between slpA alleles within each SLCT indicate missense mutations do occur (9), our findings 
suggest resistance due to this type of modification is unlikely since the bacteriophage RBPs used 
to construct the Avidocin-CDs have already evolved to counter this mode of potential escape. 
For instance, both Av-CD684.1 and Av-CD685.1 kill every SLCT-7 strain tested despite sequence 
identities between SLCT-7 SlpAs as low as 81% (Fig.3S8). As for the emergence of resistance via 
horizontal transfer of the S-layer cassette, the administration of a cocktail of Avidocin-CDs that 
kill all the common SLCTs would make successful resistance via S-layer switching extremely 
unlikely. It appears that the only likely means of resistance to all the Avidocin-CDs is through 
complete loss of SlpA, as observed for resistance to Av-CD291.2. As a consequence the observed 
phenotypes for FM2.5 are germane to all likely Avidocin-CD-resistant mutants.  
For a precision medicine agent to be successful, knowing the molecular target, in this 
case the binding receptor, is vital in designing accurate diagnostics to guide treatment decisions. 
If Avidocin-CDs were to be administered individually, a diagnostic determining SLCT of infecting 
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C. difficile would be highly accurate for informing Avidocin-CD treatment decisions. However, an 
increase in the prevalence of hybrid cassettes, as found in ribotype 078 strains (9), would 
decrease the accuracy for this typing method. Strain ribotyping could also be employed to avoid 
development of new diagnostics, but predicting sensitivity to a particular Avidocin-CD may be 
challenging as ribotypes are not consistently linked to a single SLCT (i.e. 012, 014, and 015, as 
noted above). SlpA-typing would provide the most accurate diagnostic as well as prove more 
illuminating than ribotyping since SlpA is directly related to the physiology of C. difficile, 
whereas, ribotyping detects physiologically inconsequential ribosomal RNA gene 
polymorphisms. It may also be possible to administer a cocktail of 5-6 Avidocin-CDs that target 
12 of the 14 C. difficile SLCTs. If such a cocktail of Avidocin-CDs were to be administered, a point 
of care diagnostic would only need to detect the presence of C. difficile to guide treatment 
decisions.  
The strong selective pressure afforded by Av-CD291.2 allowed isolation of the first 
spontaneous C. difficile S-layer null mutants. In addition to enabling identification of the 
Avidocin-CD cell surface receptor, these mutants also provide an unprecedented opportunity to 
study S-layer function (Fig.3.5). Given the ubiquity of S-layers in both Bacteria and Archaea, 
including many pathogenic species, surprisingly little is known about their function. It has been 
suggested that the S-layer could act as a molecular sieve to exclude certain large biomolecules 
from the cell envelope (18); however, this has not been confirmed in live cells. We have 
demonstrated that an intact S-layer is required for resistance to two components of the innate 
immunity system, lysozyme and the antimicrobial peptide LL-37. Assembled S-layers are highly 
symmetrical with regular repeating pores. The size of the pores in the C. difficile S-layer is not 
yet known but in other species pore sizes of between 2 and 6 nm have been reported. A pore 
size of 2 nm could conceivably exclude the16 kDa globular protein lysozyme but a small peptide 
such as LL-37 would experience no such steric hindrance. It is possible that charged surfaces on 
the assembled S-layer serve to sequester the cationic peptide away from the cell envelope in a 
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manner analogous to capsular polysaccharides (32). Our data has identified other pleiotropic 
functions for the C. difficile S-layer. It is clear that the S-layer is the cell surface receptor for all 
of the Avidocin-CDs described here and, by extension, the receptor for the bacteriophages from 
which the RBP-encoding genes were cloned. Although a Bacillus bacteriophage has been found 
to bind S-layer protein Sap (33), this is the first time a receptor for a C. difficile bacteriophage 
has been identified. Furthermore, our data imply that S-layer recognition is a common feature 
of bacteriophages that infect this species.  
Surprisingly, the S-layer mutant also displayed severe sporulation defects, with fewer 
and morphologically defective spores produced. Despite a number of well-studied spore-
forming organisms producing S-layers, including B. anthracis (33), S-layer biogenesis has not 
been reported previously to affect sporulation. There is currently no evidence to suggest that 
the SLPs are a structural part of the mature spore and the mechanisms by which the S-layer can 
influence sporulation are currently unknown. However, this observation has serious 
ramifications for the ability of an Avidocin-CD-resistant, S-layer defective mutant to survive and 
be transmitted to other hosts. The spore is an absolute requirement for C. difficile survival in the 
aerobic environment and is critical for transmission (22). In addition to sporulation defects, the 
S-layer mutant was also found to produce less toxin in vitro. Interestingly, there have been 
previous suggestions of feedback between sporulation and the complex regulatory network 
controlling toxin production (22). Although the mechanism by which these processes are 
affected in SlpA null mutants is far from clear, it is possible that the S-layer feeds into a point of 
crosstalk between regulation of virulence and transmission. Given the poor toxin production and 
other diverse phenotypes identified for the S-layer mutant, it is probably not surprising that the 
mutant was entirely avirulent in the hamster model of acute infection. What did come as a 
surprise, however, was the ability of the S-layer mutant to stably colonize and persist in the 
hamster gut for the 14-day duration of the experiment. Previous reports have pointed to a role 
for the S-layer in epithelial cell adhesion; however, these earlier studies were performed without 
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access to an slpA-defective strain (34). The S-layer defective mutants and isogenic controls 
expressing the SLCT-specific slpA alleles provide the ideal controls to test these conflicting 
findings and better define the effect SlpA type has on these functions.  
There are several study limitations that should be considered when evaluating the data 
presented. The activity of each new Avidocin-CD was observed in vitro and needs to be 
confirmed in an animal treatment model, as done for Av-CD291.2. Similarly, the exquisite 
specificity of each agent for distinct C. difficile SLCTs also needs be tested in vivo to confirm that 
treatment with these agents will not alter the diversity of the gut microbiota. The avirulent 
phenotype and long-term persistence of the Avidocin-CD-resistant slpA mutants in the hamster 
model should also be confirmed in other animal species. Finally, the implications of the mutants’ 
observed sporulation defects on transmission and the spread of resistance remain to be tested 
in vivo. In all cases, we do not anticipate different outcomes from those described here.  
After accounting for these limitations, analysis of the data clearly demonstrates that 
acquisition of Avidocin-CD resistance results in loss of toxin production and complete loss of 
virulence. Virulence factors make attractive targets for new antimicrobials as they tend to be 
species-specific, and emergence of resistance is likely to reduce virulence. The ability of the S-
layer mutant to stably colonize the gut in the absence of clinical disease reveals that the in vivo 
lifestyle of the organism is independent of toxin production and virulence. The prevalence of 
non-toxigenic, avirulent C. difficile strains in the general population (35) supports this 
hypothesis. As a result, we predict that there will be no competing selective pressure to restore 
virulence in the context of Avidocin-CD resistance.  
 In summary, we have developed and characterized multiple new Avidocin-CDs, 
providing crucial insights into their potential advantages in the clinic. The precise killing activity 
of Avidocin-CDs makes them attractive agents for both treatment and prevention since they can 
be administered to patients without altering the diversity of the complex gut microbiota. In 
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addition, when resistance does emerge, Avidocin-CDs force the pathogen to sacrifice virulence 
for viability - making the potential clinical impact of resistance inconsequential.  
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Fig.3.5: Schematic diagram depicting the phenotypes of Wild Type (A) and S-layer null mutant (B) cells 
in C. difficile biology and pathophysiology. Processes labelled in black indicate new functions discerned 
in this manuscript. Processes labelled in grey indicate previously identified functions. Dotted lines indicate 
relationships that need to be studied further. Question marks indicate previously described connections 
incompatible with observations made with the S-layer null mutant and warranting further investigation. 
(C) Schematic of Avidocin-CD structure and function. Binding to C. difficile by the Avidocin-CD receptor 
binding proteins (RBPs) triggers the sheath to contract and force the hollow nanotube core across the cell 
envelope. The resulting pore allows small metabolites, such as protons, ATP and cations, to escape from 
the cell cytoplasm, which, in turn, disrupts the cell’s membrane potential and kills the cell.  
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3.4 Materials and Methods  
3.4.1 Study design  
The objective of this study was to characterize a panel of Avidocin-CDs, anti-bacterial protein 
complexes constructed to specifically target and kill C. difficile. During these experiments, the 
isolation of Avidocin-CD resistant slpA mutants allowed detailed analysis of S-layer function for 
the first time. Starting from the prototypic Av-CD291.2 (12) we constructed a panel of new 
Avidocin-CDs using bacteriophage RBPs we identified. Each new Avidocin-CD displayed a unique 
spectrum of killing activity with a strong correlation to SLCT. Sensitization of two insensitive C. 
difficile strains by heterologous expression of a cognate SLCT SlpA alone allowed identification 
of the S-layer as the receptor for all described Avidocin-CDs. Analysis of the slpA mutant 
identified previously unsuspected in vitro roles for the S-layer in resistance to the immune 
effectors lysozyme and LL-37, and in the production of mature heat-resistant spores. Finally, use 
of the Golden Syrian hamster model of acute infection demonstrated that the slpA mutant was 
entirely avirulent despite persistent infection. Greatly reduced toxin activity was detected in 
intestinal contents from animals colonized with the slpA mutant and this observation was 
supported by identification of a toxin production defect in vitro..  
3.4.2 Strains, bacteriophage and culture conditions.  
Bacterial strains used in this study are described in Figure 3S2. DNA oligonucleotides are 
described in Table 3S2. E. coli strains were routinely grown in LB broth and on LB agar (VWR).  
C. difficile strains were routinely grown under anaerobic conditions on BHI or BHI-S agar and in  
TY broth (36) except where otherwise stated. Cultures were supplemented with 
chloramphenicol (15 µg/ml), thiamphenicol (15 µg/ml) or anhydrotetracycline (20 ng/ml) as 
required. C. difficile SLCTs were determined by analyzing the nucleotide sequence of the slpA 
gene. When necessary, the slpA gene was sequenced using oligonucleotide primers previously 
described (37, 38) or primers 023-F and 023_010-R or 014+++-F and 014_002+-R (nucleotide 
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sequences – Table 3S2). The variable region of strain 19142 (ribotype 046) slpA gene did not 
display high sequence identity with other slpA alleles, and has been designated SLCT-13. A partial 
strain 19142 slpA sequence was deposited in Genbank (accession: KX610658).  
3.4.4 Cloning of slpA alleles and construction of revertants.  
The slpA genes from a panel of C. difficile strains with distinct SLCTs were amplified using the 
primers listed in Table 3S2 and cloned between BamHI and SacI sites in the inducible expression 
plasmid pRPF185 (40). Plasmids were transferred into C. difficile strain FM2.5 by conjugation 
from the E. coli donor CA434. For construction of slpA revertants, a watermark consisting of two 
adjacent synonymous mutations, was introduced into the SLCT-4 slpA using primers RF135 and 
RF136. Single crossover recombinant colonies were identified by an enhanced growth 
phenotype, and recombination was confirmed by PCR using primers RF33 and NF1323. Stable 
double crossover revertants were isolated following growth without selection for approximately 
20 generations and confirmed by screening for plasmid loss, sequencing of the slpA gene, and 
confirmation of SLP expression by SDS-PAGE analysis (described below).  
3.4.5 Construction and expression of Avidocin-CDs.  
New Avidocin-CDs were constructed with bacteriophage RBPs identified from newly isolated 
bacteriophages and prophage insertions. The RBP genes along with the adjacent 3’end of the 
Baseplate attachment region (Bpar) and chaperone genes were cloned and inserted into an 
integration vector containing the Diffocin-4 gene cluster via a combination of restriction enzyme 
digests and Gibson assembly. The fusion sites used to replace the bacteriocin genes and 
integrate the bacteriophage derived genes are shown (Fig.3S9). Avidocin constructs using the 
downstream fusion site 1 are denoted with a “.1” suffix (i.e. Av-CD681.1), while constructs using 
the downstream fusion site 2 are denoted with a “.2” (i.e. Av-CD027.2). The resulting integration 
vectors were sequence verified and transformed into the B. subtilis production strain as 
previously described (12). The nucleotide sequences for the Bpar fusion, RBP and downstream 
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chaperones have been deposited in Genbank along with source information. Accession numbers 
are provided in Table 3S3. Expression of each Avidocin-CD was induced with IPTG as previously 
described (12). Preparation of each Avidocin-CD and Diffocin-4 relied on a combination of 
Polyethlene-glycol-8000 precipitations and ultracentrifugation as described previously (12). 
3.4.6 Isolation of Av-CD291.2-resistant clones.  
A greater than 100-fold excess of active Av-CD291.2 was added to exponentially growing C. 
difficile strain R20291. After 75 min bacteria were harvested, resuspended in phosphate 
buffered saline (PBS), and spread on non-selective Brucella agar plates maintained under 
anaerobic conditions at 37°C overnight. CFU counts before and after addition of Av-CD291.2 
were compared to determine resistance frequency. Resistant colonies were streaked on C. 
difficile selective agar and Av-CD291.2-resistance was confirmed. Av-CD291.2-resistant strains 
FM2.5 and FM2.6 was sequenced by Illumina Miseq and identified slpA mutations were 
confirmed by Sanger sequencing.  
3.4.7 Bioassays to determine Avidocin-CD killing activity.  
Avidocin-CD bactericidal activity was assayed by a semi-quantitative spot method as previously 
described (12, 13). For broth-based killing assays, C. difficile strains were grown overnight in  
TY broth and then sub-cultured to an OD600nm of 0.05 in 1 ml fresh TY supplemented with 1mM 
CaCl2. Av-CD291.2 (50 µl) was added to each culture after 2.5 h. Growth was monitored by 
measuring the OD600nm hourly.  
3.4.8 Extraction of S-layer and associated proteins.  
S-layer proteins were extracted using low pH glycine as previously described (8) and analyzed by 
SDS-PAGE using standard methods.  
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3.4.9 Quantitative analysis of sporulation and germination.  
Overnight bacterial cultures were diluted to 0.01 OD600nm in BHI-S broth, incubated for 8 hours, 
diluted again to 0.0001 OD600nm and grown overnight. The resulting stationary phase cultures 
(T=0) were then incubated for 5 days. The relative proportion of spores and vegetative cells was 
determined at 24 h intervals by counting total and heat-resistant (65°C for 30 min) CFUs on BHI-
S agar supplemented with 0.1 % taurocholate. Assays were repeated in triplicate with biological 
triplicates. In order to test a range of different stress conditions, additional samples were taken 
on day 5 and treated at either 75°C for 30 min, 50% ethanol for 30 min or incubated aerobically 
for 18 h before enumerating viable spores as before. For the germination studies, spores were 
purified as previously described (19) and Ca2+-DPA release and core rehydration was monitored 
by measuring changes in OD600nm upon addition of 0.5% taurocholate.  
For microscopic examination, bacterial samples were washed with PBS and fixed in 3.2% 
paraformaldehyde. For phase contrast microscopy, samples were mounted in 80% glycerol and 
visualised using a Nikon Ti Eclipse inverted microscope. For TEM, samples were additionally fixed 
in 3% glutaraldehyde in 0.1 M cacodylate buffer followed by 1% OsO4, then dehydrated in 
ethanol and embedded in araldite resin. Embedded samples were sectioned at 85 nm on a Leica 
UC6 ultramicrotome, transferred onto coated copper grids, stained with uranyl acetate and lead 
citrate and visualized using a FEI Tecnai BioTWIN TEM at 80 kV fitted with a Gatan MS600CW 
camera.  
3.4.10 Analysis of resistance to lysozyme and LL-37.  
Broth based killing assays were carried out as described above but with lysozyme (500 µg/ml) or 
LL-37 (5 µg/ml) added after 2.5 h growth. Cell density was monitored by measuring the OD600nm 
hourly. Assays were carried out in triplicate on biological duplicates.   
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3.4.11 Animal experiments.  
The Golden Syrian hamster model was performed as previously described (39). All procedures 
were performed in strict accordance with the Animals (Scientific Procedures) Act 1986 with 
specific approval granted by the Home Office, U.K. (PPL60/4218). 
Briefly, 3 weeks before bacterial challenge, telemetry chips were surgically inserted by 
laparotomy into the peritoneal cavity of female Golden Syrian hamsters. Animals were allowed 
to recover from surgery before being placed in cages above transponder receiver plates that 
allow direct monitoring of body temperature. All animals were orally dosed with clindamycin 
phosphate (30 mg/kg) five days prior to challenge with 104 spores of either C. difficile R20291, 
FM2.5 or FM2.5RW as previously described (39). Six animals per group were inoculated and 
animals monitored carefully for onset of symptoms. Animals were culled when core body 
temperature dropped below 35°C.  
To quantify colonization at experimental endpoint, the caecum (CAE) and colon (COL) of each 
animal were removed, opened longitudinally and washed thoroughly in PBS to remove unbound 
bacteria; these organisms were designated luminal associated organisms (LA). The washed 
tissue was then homogenized and subsequently recovered material contained more intimately 
associated organisms; designated tissue associated (TA). Total viable counts were determined 
by plating serial dilutions on ChromID (Biomeuriex). Spores were enumerated following heat 
treatment at 56°C for 20 min. Colonies from all plates were subjected to PCR amplification of 
both the slpA gene specifically, using primers RF110 and RF111, and seven repeat regions to 
confirm strain identity by MVLA analysis 2 to confirm strain identity.  
3.4.12 Quantification of toxin expression.  
Quantification of toxin activity was performed using a Vero cell based cytotoxicity assay. 
Dilutions of filtered (0.45 µm) post-challenge gut contents were added to confluent monolayers 
for 24h and the end-point titer was defined as the first dilution at which Vero cell morphology 
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was indistinguishable from untreated wells. Each experiment was performed in duplicate on two 
separate occasions. For measurements of toxin production in vitro, whole cell lysates or culture 
supernatants were separated by SDS-PAGE, transferred to PVDF membrane and toxin B 
detected by Western immunoblot using a specific mouse monoclonal antibody (MA1-7413, 
Thermo Fisher). 
3.4.13 Statistical analyses.  
Data were analyzed using GraphPad Prism software (GraphPad Software Inc.). Toxin production 
was compared using a two-tailed nonparametric Mann-Whitney test, and animal survival curves 
were analyzed using a Log-rank (Mantel-Cox) test. All other statistical analyses were performed 
using two-tailed t-tests with Welch's correction.   
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3.10 supplemental tables and figures  
Fig.3S1: Restoration of wild type slpA to the chromosome of FM2.5 and FM2.6. Plasmid pRPF233, 
carrying a wild type copy of the R20291 slpA gene under the control of a tetracycline-inducible promoter, 
was introduced into FM2.5 and FM2.6 by conjugation from an E. coli donor strain CA434. (A) When grown 
on solid media, supplemented with thiamphenicol to select for the plasmid, both FM2.5/pRPF233 and 
FM2.6/pRPF233 produced two distinct colony morphologies; small colonies that were indistinguishable 
from those typical of FM2.5 and FM2.6 and larger colonies that appeared to grow significantly faster than 
the slpA mutants. (B) When the S-layer profile of the larger colonies was analyzed by SDS-PAGE 
constitutive SlpA expression, independent of anhydrotetracycline (ATc) induction, was observed. 
However, when the slpA gene from strain 630 (SLCT-7), which shares 69.4% nucleotide identity with 
slpAR20291 (SLCT-4), was introduced expression of SlpA remained inducible. (C) Analysis of these large 
colonies by PCR using one chromosome-specific primer (RF33, annealing 1,250 bp downstream of slpA in 
the secA2 gene) and one plasmid-specific primer (NF1323, annealing in the Ptet promoter 122 bp 
upstream of slpA on pRPF233) confirmed that pRPF233 had integrated into the chromosome at the slpA 
locus by a single crossover recombination event. Stable slpA revertants, FM2.5RW and FM2.6RW, were 
later generated from these single crossover mutants by culturing the bacteria without selection and then 
screening for plasmid loss and retention of the fast growth colony phenotype.   
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Fig.3S2: C. difficile strain sensitivity patterns to Avidocin-CDs and Diffocin-4. Preparations of each 
Avidocin-CD and Diffocin-4 were serially diluted and spotted on bacterial lawns for each strain. If a zone 
of clearance correlating with killing was detected, the strain was deemed sensitive to the agent tested 
and is demarked by a “+” in the figure. If no zone of clearance was observed, the strain was deemed 
insensitive and is demarked with “-“ in the figure. Faint zones of clearance are demarked with a “w”. Not 
all strains were tested against each Avidocin-CD preparation. The number of strains killed per the total 
number of strains assayed is listed for each SLCT. Totals in red indicate less than 100% sensitivity. Boxes 
highlighted in red indicate testing on RBP strain source.  The strain designation, source, ribotype and SLCT 
are listed.  Source designations: Dingle = Kate Dingle, University of Oxford; Riley = Tom Riley, University 
of Western Australia; Lawley = Trevor Lawley, Wellcome Trust Sanger Institute; Tenover = Fred Tenover, 
Cepheid; Young = Vincent Young, University of Michigan; R.M.A.R.  
= R.M. Alden Research Laboratory.  
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Fig.3S3: Avidocin-CD sensitivity correlates with SLCT. (A) Av-CD291.2 killing efficiency is dependent on 
the level of SLCT-4 SlpA induction. Strain 630 (SLCT-7) or 630 carrying a plasmid-borne inducible copy of 
SLCT-7 SlpA or SLCT-4 SlpA were subcultured to an OD600nm of 0.05, grown for two hours, induced with the 
indicated concentration of ATc and then challenged with Av-CD291.2 following two hours of induction. 
Identical untreated cultures were included as controls. Shown are means and standard deviations of 
biological duplicates assayed in triplicate. p =<0.01, determined using two-tailed t-tests with Welch's 
correction. (B) SDS-PAGE analysis of S-layer extracts from 630 (SLCT-7) and a panel of eight 630 derivative 
strains expressing SLCT-1, 2, 4, 6, 7, 8, 10 and 12 under the control of a tetracycline-inducible promoter 
(40). Heterologous SlpA expression was induced with 20 ng/ml anhydrotetracycline. The positions of the 
LMW and HMW SLPs, the minor cell wall proteins CwpV and Cwp2, and the flagellar subunit FliC are 
indicated. (C) Spot bioassays with 5 Avidocin-CDs on the C. difficile strains used in panel B following 
induction with anhydrotetracycline (20 ng/ml). The zone of clearance caused by each Avidocin-CD is 
shown along with the SLCT.  
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Fig.3S4: Characterization of growth and sporulation. (A) Sporulation of R20291, FM2.5, and FM2.5RW 
over 5 days. Total CFUs and heat-resistant spore CFUs (65°C for 30 min) were determined at 24 h intervals. 
Experiments were carried out in duplicate on biological duplicates. Mean and standard deviation are 
shown. The dotted line indicates the limit of detection. (B) Overnight cultures of strains R20291, FM2.5, 
and FM2.5RW were subcultured to an OD600nm of 0.05 and growth was monitored hourly for 9 hours by 
measuring the OD600nm and direct counting of CFUs. Shown are the means and standard deviations of 
biological duplicates with technical triplicates. Growth of all 3 strains is identical until an OD600nm of 1.25. 
FM2.5 prematurely enters stationary phase, reaching a maximum OD600nm of 2.2 compared with 3.2 for 
R20291. (C) Sporulation of R20291, FM2.5, and FM2.5RW was monitored by direct counting vegetative 
cells and phase bright spores by phase contrast microscopy at T=0, 48 and 120 of a standard 5 day 
sporulation assay. 20 microscope fields were counted for each strain at each timepoint. The number of 
spores is expressed as a percentage of total with the mean and standard deviations shown. * = p<0.01, 
determined using using two-tailed t-tests with Welch's correction. (D) Example microscope fields 
representative of those counted for panel C. For clarity only 40% of each field is shown. In the bottom 
right image representative spores are marked with red arrow heads, a representative vegetative cell with 
a blue arrow head and representative cell debris with green arrow heads.  
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Fig.3S5: Spore morphology and thermal sensitivity. (A) Electron micrographs of cultures on day 5 of the 
sporulation assay shown in Figure 3S4A. Spore-containing representative fields are shown. Example 
spores (red arrows) and vegetative cells (blue arrows) are indicated. Higher magnification views of 
individual spores are shown below (boxed in top panels). The core, cortex and coat layers are indicated. 
(B) Spores were purified on a 20-50% Histodenz gradient and CFUs were quantified prior to (Untreated) 
and following heat stress at 65°C or 75°C for 30 min. Shown are the mean and standard errors of biological 
triplicates assayed in triplicate. * = p<0.01, determined using using two-tailed t-tests with Welch's 
correction. (C) Electron micrographs of spores used in panel B. The scale bar on each image indicates 2 
µm.  
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Fig.3S6: Bactericidal activity by Avidocin-CD does not result in intracellular toxin release. For toxin 
producing pathogens, antibiotics that lyse bacteria or increase toxin production can exacerbate disease 
severity and lessen the effectiveness of the treatment by inadvertently releasing toxins (41). We examined 
culture supernatants following treatment with Avidocin-CDs for the presence of extracellular Toxin B to 
determine if killing by an Avidocin-CD could result in unwanted toxin release. R20291 (RT027) bacteria 
were incubated for an hour with either Av-CD291.2 at the indicated ratio of agent to cells, Av-CD684.1 
(which does not kill strain R20291) at a 500:1 ratio, or left untreated. After incubation, surviving bacteria 
(CFU/mL) were enumerated. The percentage of CFU following each treatment relative to untreated 
control is shown. The number of spores present in the untreated sample was determined following heat 
treatment at 65 °C for 30 min to kill vegetative cells (lane HK). Av-CD291.2 killing occurred in a dose-
dependent manner, while Av-CD684.1 treated cells behaved like untreated controls. Following Avidocin-
CD treatment released toxin B in culture supernatants (ExC) was detected by Western immunoblot using 
a specific monoclonal antibody. As a positive control for toxin release, R20291 was treated with a 
bacteriophage (CD27L) endolysin, which effectively lyses C. difficile (42). Following Avidocin-CD treatment, 
the amount of remaining intracellular toxin B was determined by lysing cells with CD27L endolysin and 
detection by Western immunoblot as before (IntC). A fresh sample of untreated R20291 was lysed with 
CD27L endolysin to show normal intracellular toxin quantities (lane EL). Despite effective killing, 
intracellular Toxin B remained constant with no detectable release observed in the culture supernatants 
(ExC) at any concentration, including samples that exhibited total killing of all vegetative bacterial cells 
due to a large excess (500:1) of Avidocin-CD to bacteria. These results confirm that Avidocin-CDs are 
bactericidal but neither lyse the target cell nor release harmful intracellular stores of toxin B. As a result, 
the use of Avidocin-CD to treat or prevent CDI is unlikely to exacerbate disease symptoms. 
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Fig.3S7: Comparison of C. difficile bacteriophage host range vs. Avidocin-CD sensitivity. Preparations of 
each bacteriophage and corresponding Avidocin-CD were serially diluted and spotted on bacterial lawns 
corresponding to the bacteriophage propagating strains, bacteriophage host strains and strains with same 
SLCT as propagating strain. Bacteriophage plaques are small and numerous. Avidocin-CD killing results in 
a large zone of clearance. Only one host strain, denoted in red, had a different SLCT than propagating 
strain. At high bacteriophage titers, bacteriophage are observed to cause “lysis from without” and is 
denoted by small white arrows.  
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Fig.3S8: Clustal Omega alignment of SlpA sequences from strains 630 and M68. Identical residues are 
demarked with an asterisk. Residues with strongly similar properties are demarked with colon. Residues 
with weakly similar properties are demarked with a period. An 81.7% sequence identity was found 
between the two SLCT-7 SlpA variants.  
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Fig.3S9: Schematic describing Avidocin-CD construction. (A) The fusion sites used to integrate the 
bacteriophage and prophage genes into the Diffocin-4 gene cluster are shown. There is a Bpar fusion site 
in rtbL as well as alternative downstream fusion sites before or after the predicted Diffocin-4 chaperones.  
The nucleotide sequences for the fusion region created in each Avidocin-CD construct fusion have been 
deposited in Genbank and given the following accession numbers (Table 3S3). (B) Schematic depicting R-
type Bacteriocin and Bacteriophage regions for fused BPAR protein.  
  
 Chapter III. Avidocins and the Funciton of the S-layer 
 105 
 
Table 3S1: Newly identified C. difficile phages 
Phage  Source  Propagating Strain  PtsM-like RBP  
Phi-027b  panel of 027 strains  20315 (SLCT-4)  Yes  
Phi-123  19123 (SLCT-6)  TL176 (SLCT-10)  No  
Phi-147  19147 (SLCT-1)  19108 (SLCT-1)  Yes  
Phi-242.c1  CD242 (SLCT-12)  CD62 (SLCT-12)  Yes  
Phi-68.4  M68 (SLCT-7)  CF-5 (SLCT-7)  Yes  
 
Table 3S2: Primers used in this chapter 
Primer 
name  
Primer sequence  Use  
023-F  ATGAAAAAAAGAAATTTAGCA  Amplification of slpA variable 
region  
023_010-R  CTATAGCTGTTTSTATTCTGTC  Amplification of slpA variable 
region  
014+++-F  ATGAATAAGAAAARTTTRGCA  Amplification of slpA variable 
region  
014_002+-R  CTATWGCAGTCTCTATTCTATC  Amplification of slpA variable 
region  
RF1  GATCGGATCCTTACATACTTAATAAATC 
TTTTAATTTATTTATAACTG  
Cloning of SLCT-4 slpA from 
strain R20291 with RF2  
RF2  GATCGAGCTCTATAATGTTGGGAGGAAT 
TTAAGAAATG  
Cloning of SLCT-4 slpA from 
strain R20291 with RF1  
RF6  GATCGGATCCTTACATATCTAATAAATC 
TTTTATTTTACTTACAAC  
Cloning of SLCT-H2/6 slpA from 
strain Ox575 with RF2  
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RF7  GATCGGATCCCTACATATCTAATAAGTC 
TTTTATCTTAGTG  
Cloning of SLCT-10 slpA from 
strain Ox1533 with RF2  
RF8  GATCGGATCCTTACATATCTAATAAATC 
TTTTAATTTGCTAACAAC  
Cloning of SLCT-1 slpA from 
strain Ox1424 with RF2  
RF33  GGCTTCTATAGCTTGGTGAA  Confirmation of slpA 
recombination with NF1323. 
Chromosome-specific  
RF99  GATCGGATCCTTACATATCTAATAAATC 
TTTTATTTTATTTATTACTG  
Cloning of SLCT-6 slpA from 
strain Ox1896 with RF2  
RF101  GATCGGATCCTTATAATTCTAATAAATC 
TTTTATTCTCTTAATAAC  
Cloning of SLCT-9 slpA from 
strain Ox1192c with RF134  
RF110  GACATAACTGCAGCACTACTTG  Amplification of SLCT-4 slpA 
region containing point 
mutations and watermark  
RF111  CAGGATTAACAGTATTAGCTTCTGC  Amplification of SLCT-4 slpA 
region containing point 
mutations and watermark 
RF132  GATCGGATCCTTACATATTTAATAAATC 
TTTAAGCTTAGTTAC  
Cloning of SLCT-8 slpA from 
strain Ox1396 with RF2  
RF133  GATCGGATCCTTACATTCCTAATAAATC 
TTTTAATTTATTAATAAC  
Cloning of SLCT-12 slpA from 
strain Ox1342 with RF134  
RF134  GATCGAGCTCTATAATGTTGGGAGGAAT 
TTAAGGAATG  
Cloning of SLCT-9 and 12 slpA 
with RF101 and RF133 
respectively  
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RF135  CAGGTTGATAATAAATTAGACAATTTAG 
GTGATGG  
Introduction of slpA watermark 
with RF136  
RF136  TGTAAACAATAATTTACTTGCATCTTCT 
G  
Introduction of slpA watermark 
with RF135  
RF231  GATCGGATCCTTACATATCTAATAAATC 
TTTCATTTTGCTTATTAC  
Cloning of SLCT-2 slpA from 
strain Ox858 with RF2  
NF1323  CTGGACTTCATGAAAAACTAAAAAAAA TATTG  Confirmation of slpA 
recombination with RF33. 
Plasmid-specific  
NF1414  GATCGAGCTCTATAATGTTGGGAGGAAT 
TTAAGAAATG  
Cloning of SLCT-7 slpA from 
strain 630 with NF1415  
NF1415  GATCGGATCCTTACATATCTAATAAATC 
TTTCATTTTG  
Cloning of SLCT-7 slpA from 
strain 630 with NF1414  
 
Table 3S3: Genbank accession identifiers 
Construct  Source  Accession Id:  
Diffocin-4  CD4  KX557294  
Av-CD291.2  R20291 genome  KX592438  
Av-CD027.2  Phi-027b  KX592434  
Av-CD681.1  M68 genome  KX592441  
Av-CD682.1  M68 genome  KX592442  
Av-CD684.1  M68 genome/phi-M68.4  KX592443  
Av-CD685.1  M68 genome  KX592444  
Av-CD305.1  CD305 genome  KX592439  
Av-CD123.2  Phi-123  KX592435  
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Av-CD242.2  Phi-242.c1  KX592437  
Av-CD147.1  Phi-147  KX592436  
Av-CD630.1  630 genome  KX592440  
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Chapter IV 
Characterisation of FM2.5 and the Roles of the S-layer 
4.1 Introduction 
The work described in the previous chapter (Kirk and Fagan, 2016) focused on 
phenotypic characterisation of C. difficile mutants that have lost slpA function, specifically to 
investigate the clinical threat of these Avidocin-CD resistant mutants. Further characterisation 
of these mutants, was required to understand the functions of the S-layer and the requirements 
for C. difficile growth when lacking this structure.  
The largest member of the Cell Wall Protein family, CwpV, was overexpressed in the slpA 
deficient mutants. Approximately 5% of cells within a population of C. difficile express CwpV, 
when grown under standard laboratory conditions (Emerson et al., 2009). CwpV expression is 
under control of a phase variable promoter, with expression being either ON or OFF, depending 
on the orientation of a genetic switch upstream of the ORF. The 195 bp genetic switch, flanked 
by 21 bp inverted repeats, is inverted through site-specific recombination, mediated by the 
recombinase RecV. When this switch region is in the OFF orientation, a rho-independent 
terminator is predicted to form, resulting in premature termination of transcription (Emerson et 
al., 2009). CwpV is an auto-aggregation protein, and its expression is associated with a change 
in colony morphology, bacterial aggregation in liquid broth, and phage resistance (Reynolds et 
al., 2011; Sekulovic et al., 2015). CwpV has also been identified as a SecA2 substrate (Fagan and 
Fairweather, 2011) and undergoes auto-proteolysis post-secretion (Dembek et al., 2012).  
Phase variation is a common mechanism for regulation of extracellular structures, 
including but not limited to, pili, cellular capsules, and flagella. This can aid in the evasion of the 
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host immune system and regulation of adhesion to the host (as reviewed in (van der Woude and 
Baumler, 2004)). Phase variable expression is not limited to extracellular proteins however. For 
example, the flgB operon of C. difficile is under the control of a RecV-dependent phase variable 
promoter. This operon contains the gene encoding the regulatory protein SigD which, in turn, 
controls the expression of flagella proteins, the toxins, other regulatory proteins, and proteins 
involved in metabolism (El Meouche et al., 2013). When the flgB switch is in the OFF orientation, 
cells are attenuated for toxin production (Anjuwon-Foster and Tamayo, 2017). Phase variation 
of regulatory proteins results in coordinated phase variable expression of genes under control 
of these proteins. Phase variation therefore has the potential to have polar effects on genes in 
multiple genetic pathways. To date, four phase variable regions have been described in the C. 
difficile strain R20291 genome, upstream of cwpV, flgB, CDR20291_1514, and, CDR20291_0685 
(Anjuwon-Foster and Tamayo, 2017; Stabler et al., 2010). Excluding CDR20291_0685, these 
phase variable regions are flanked by inverted repeats, a characteristic property of site-specific 
recombination-dependent phase variable regions. 
Work presented in this chapter focuses on characterisation of the effects of 
overexpression of CwpV in FM2.5. In addition, genomic and epigenetic difference between 
FM2.5 and R20291 were investigated, leading to the identification of an addition phase variable 
promoter and potential suppressor mutations in FM2.5. Characterisation and modification of 
the native slpA locus is necessary for more in depth analysis of S-layer function. Attempts to 
modify this locus and identify the slpA promoter are also described. 
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4.2 Results 
4.2.1 CwpV Expression in FM2.5 
Although CwpV is normally only expressed in approximately 5% of wild-type cells in a 
population (Emerson et al., 2009), CwpV is more frequently found in S-layer extracts from FM2.5 
(Fig.4.1A). This was also observed for the independent mutant FM2.6 (data not shown). Due to 
this observation, the effects of loss of slpA function on CwpV expression, and of CwpV expression 
in FM2.5 were investigated. 
4.2.1.1 CwpV is Expressed More Frequently in FM2.5 
As CwpV expression is phase variable, it was hypothesised that increased CwpV 
expression in FM2.5 may be due to an increased frequency of cells in a population containing 
the cwpV switch in the ON orientation. To examine the frequency of CwpV expression in FM2.5 
and to confirm if this was caused by loss of slpA function, quantification of CwpV expression in 
FM2.5 and FM2.5RW was necessary.  
gDNA was purified from O/N cultures of eight biological replicates of R20291, FM2.5, 
and FM2.5RW. The orientation of the cwpV switch was determined by asymmetric restriction 
digest analysis of PCR amplified DNA fragments (Fig.4.1C and D). There was no statistically 
significant difference between the recorded frequencies of promoter orientation between 
R20291 and FM2.5RW (median of 0% ON). However, there was a significant difference between 
R20291 and FM2.5 (median of 92% ON, P < 0.005). These data confirm the previous observation 
that cwpV expression is upregulated in FM2.5, and this upregulation is dependent on loss of slpA 
function. 
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Fig.4.1: Analysis of CwpV expression in FM2.5. (A) Representative 12% SDS-PAGE showing S-layer 
extracts from R20291, FM2.5 and FM2.5RW. CwpV is cleaved post-secretion and the N-terminal and C-
terminal subunits are labelled. CwpV is present in S-layer extracts isolated from FM2.5 more frequently 
than those from R20291 or FM2.5RW. (B) Schematic representation of the promoter region of cwpV in 
the ON and OFF orientations. Expression of CwpV is phase variable due to the presence of inverted repeats 
(LIR and RIR) flanking an invertable region downstream of the promoter. A Rho-independent terminator 
is predicted to form when the promoter region is in the OFF orientation leading to premature 
transcriptional termination (Emerson et al., 2009).   Primers NF863 and NF823 flank the invertable region, 
which contains an AseI restriction site. AseI digestion of DNA amplified using these primers results in DNA 
fragments of different sizes depending on the orientation of the switch region. (C) 2% agarose gels 
showing representative AseI RFLP analysis of DNA fragments amplified from gDNA isolated from R20291, 
FM2.5, and FM2.5RW. This results in 84 bp and 389 bp fragments when in the “ON” orientation, and 187 
bp and 286 bp fragments when in the “OFF” orientation. (D) Quantitative analysis of the percentage of 
bacteria containing the cwpV switch in the ON orientation from populations of R20291, FM2.5 and 
FM2.5RW. This was calculated via densitometric analysis of relevant bands from agarose gels containing 
AseI digested DNA. Asymmetric digest analysis was performed using eight biological replicates. Each circle 
on the graph represents one biological repeat and the medians are shown.  ** P < 0.005 determined using 
non-parametric, two tailed Mann-Whitney U tests.  
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4.2.1.2 Generation of cwpV Locked ON and OFF Strains 
To test the effects of CwpV expression in FM2.5, it was first necessary to lock the cwpV 
switch in both the ON and OFF orientations. This was achieved through inactivation of the gene 
encoding the recombinase responsible for inversion of the cwpV switch, recV (Emerson et al., 
2009). recV mutants, created in FM2.5 and FM2.5RW using ClosTron mutagenesis, were 
designated FM2.5 recV::erm and FM2.5RW recV::erm (Fig.4.2A).  
To lock the cwpV switch in either the ON and OFF orientation, recV inactivated strains 
were restreaked on BHI and the orientation of the switch was determined via PCR (Fig.4.2B). 
This was repeated until strains where the switch region was locked in one orientation were 
isolated. FM2.5 recV::erm was exclusively isolated with the genetic switch in the ON orientation 
and FM2.5RW recV::erm was isolated with the switch in the OFF orientation. These strains were 
denoted as FM2.5 recV::erm cwpV ON (FM2.5 cwpV ON) and FM2.5RW recV::erm cwpV OFF 
(FM2.5RW cwpV OFF). Isolation of recV inactivated mutants with the cwpV switch in the 
opposite orientations was first attempted using the previously described method (Reynolds et 
al., 2011). RecV was transiently expressed in the mutant strains to complement the phase 
switching defect. However, we failed to isolate mutants with the switch in the opposite 
orientations. pMTLSC7215 vectors were then created in which the cwpV switch, flanked by 
sequences of homology to the chromosome, were in the OFF and ON orientations. These 
plasmids were used to performed allele exchange mutagenesis in the recV inactivated strains 
(Fig.5.2C). This method resulted in the isolation of FM2.5 recV::erm cwpV OFF (FM2.5 cwpV OFF) 
and FM2.5RW recV::erm cwpV ON (FM2.5RW cwpV ON).  
R20291 recV::erm mutants (R20291 cwpV ON and R20291 cwpV OFF) were provided by 
Neil Fairweather (Imperial College London). All six strains displayed the expected pattern of 
CwpV expression (Fig.4.2D).   
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Fig.4.2: Creation of cwpV ON and OFF strains. (A) recV was inactivated in FM2.5 via ClosTron mutagenesis. 
pASF075 was conjugated into FM2.5 and FM2.5RW and transconjugants were restreaked onto BHI agar 
containing 5 µg/ml lincomycin to select for group II intron insertion. Potential mutants were then screened 
via PCR using primers NF1215 and RF438, which flank the intron insertion site. An increase of 
approximately 2.8 kb relative to FM2.5 confirms intron insertion. (B) The orientation of the cwpV switch 
was determined via PCR using primer pairs NF825/NF823 and NF826/NF823. FM2.5 recV::erm cwpV 
ON and FM2.5RW recV::erm cwpV OFF were isolated. To create mutants with the switch in the opposite 
orientations allele exchange mutagenesis was performed. Primer pair RF798/RF799 were used to PCR 
amplify a 2.4 kb fragment from FM2.5RW cwpV OFF and FM2.5 cwpV ON gDNA. These PCR fragments 
contained the cwpV switch, in the OFF and ON orientation respectively, and 1.2 kb upstream and 
downstream of the switch. These fragments were ligated into pMTLSC7215 via the PmeI restriction site, 
creating pJAK073 and pJAK074 respectively. pJAK073 was conjugated into FM2.5 cwpV ON and pJAK074 
was conjugated into FM2.5RW cwpV OFF. Mutagenesis was performed as previously described (Cartman 
et al., 2012). (C) FM2.5 recV::erm cwpV OFF (FM2.5 cwpV OFF) and FM2.5RW cwpV ON (FM2.5RW ON) 
were selected via PCR screening using NF823/NF825 (Lanes ‘1’) and NF823/NF826 (lanes ‘2’).  (D) S-layer 
extracts were isolated from overnight cultures of cwpV ON and OFF strains and analysed by SDS-PAGE. 
The two subunits of CwpV are labelled.  
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4.2.1.3 cwpV Expression Has No Effect on Growth of FM2.5 
As CwpV is a paralogue of SlpA, we hypothesised that CwpV overexpression in FM2.5 
may complement the growth defect of this mutant (Kirk and Fagan, 2016). This would allow 
CwpV expressing cells within a population of FM2.5 to grow quicker than the surrounding cells, 
leading to disproportionate numbers of cwpV ON cells within a population, consistent with our 
previous observation.  
4.2.1.3.1 Growth of FM2.5 cwpV ON and OFF Strains in Liquid Media 
To test this hypothesis, growth assays were performed by monitoring the optical density 
of growing cultures of FM2.5 cwpV ON and OFF (Fig.4.3A). No significant difference in growth 
was observed between the ON and OFF strains. Although the growth rate of these two strains 
was slower than the wild type, surprisingly, both the cwpV ON and OFF strains reached a final 
cell density comparable to R20291. O/N cultures of FM2.5 ON and FM2.5 OFF were also analysed 
via TEM of thin sections, and no discernible morphological difference was observed between 
the two strains (Fig.4.3B). 
4.2.1.3.2 Colony Morphology of cwpV ON and OFF Strains 
Previous studies have shown colonies of cwpV ON strains have smaller, smoother edged 
morphologies than OFF strains (Reynolds et al., 2011). Similar colony morphologies were 
observed in flgB ON and OFF strains, although not linked to the orientation of the flgB switch 
(Anjuwon-Foster and Tamayo, 2017). After 48 h growth on BHI agar, the same difference was 
observed between R20291 cwpV ON and R20291 cwpV OFF. No difference was observed 
between FM2.5 cwpV ON and FM2.5 cwpV OFF or FM2.5RW cwpV ON and FM2.5RW cwpV OFF 
(Fig.4.3C). The FM2.5 and FM2.5RW ON and OFF strains all formed small, smooth edged 
colonies. FM2.5 produced smaller colonies after 48 h growth than any of the R20291 or 
FM2.5RW strains.  
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Fig.4.3: Growth of cwpV locked ON and OFF strains: (A) Growth assays were performed by monitoring 
OD600nm of growing cultures of FM2.5 cwpV ON and OFF. Both strains showed similar growth rates and 
reached the same final cell density which, interestingly, was comparable to the final cell density of growing 
cultures of R20291.These assays were performed in technical triplicates using biological duplicates. Shown 
are the means and standard deviations. (B) TEM analysis of O/N cultures of FM2.5 cwpV ON and FM2.5 
cwpV OFF revealed no morphological difference between these two strains. (C) Colony morphologies of 
cwpV ON and OFF strains after 48 h growth on BHI agar. Smaller, smooth edged colonies of R20291 cwpV 
ON were observed, compared to R20291 cwpV OFF as previously reported (Reynolds et al., 2011).  No 
morphological difference was observed between colonies of FM2.5RW cwpV ON and FM2.5RW cwpV OFF. 
This was also observed for colonies of FM2.5 cwpV ON and FM2.5 cwpV OFF, although these colonies 
were much smaller than colonies of R20291 and FM2.5 strains.  
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4.2.2 Genomic Analysis of FM2.5 
4.2.2.1 SMRT Sequencing of the FM2.5 Genome 
As slpA is essential for C. difficile growth, the genome of FM2.5 was sequenced to detect 
any suppressor mutations. This was initially done with Illumia sequencing. Analysis of the data 
only revealed a single SNP within the FM2.5 genome within slpA, as previously reported (Kirk 
and Fagan, 2016). However, Illumina sequencing results in short read lengths meaning that large 
insertions, deletions and, inversions in the genome are often overlooked. In addition, due to the 
relatively poor coverage of the sequencing data, other SNPs in the genome may have been 
missed. The genome of FM2.5 was therefore sequenced using a method resulting in longer read 
lengths; PacBio’s single molecule real-time (SMRT) sequencing (Rhoads and Au, 2015). Sequence 
analysis and genome assembly was performed by Nadia Fernandes (the University of Sheffield, 
personal communication). Due to the large read lengths, a single contig, covering the entire 
genome, was assembled from the data.  
The newly assembled genome was aligned to the published R20291 genome using the 
progressiveMauve alignment plugin for Geneious R10. Many SNPs were identified within the 
FM2.5 genome. Most of these were contained within stretches of adenines and thymine and 
were assumed to be an error with the published genome sequence, as sequencing errors occur 
commonly in AT rich regions using Illumina sequencing. Several other SNPs were identified in 
non-coding regions within the genome. However, in addition to the previously identified SNP 
within slpA, SNPs were identified within the ORF of three genes. These result in the substitution 
of tyrosine 146 to asparagine in CodY, isoleucine 58 to methionine in CDR20291_2781, and 
glutamine 138 to lysine in CDR20291_1323. 
In addition, multiple insertions in the FM2.5 genome were identified. A 149 bp insertion 
was identified within CD0667, resulting in a 34 aa truncation of CDR20291_0667 and alteration 
of the C-terminal primary sequence of the truncated protein. Within the putative transcription 
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regulator, CD1R20291_542, an insertion of approximately 15 kb was identified, predicted to 
contain multiple ORFs including genes involved in iron uptake. Two insertions, of approximately 
6 kb and 1.5 kb, were identified in rRNA coding regions. The significance of these mutations is 
yet to be explored.  
It was unsurprising that the cwpV switch was identified in the ON orientation in the 
FM2.5 genome. However, two other short sequences were found in inverse orientations relative 
to the published genome. These regions were upstream of CDR20291_1514 and 
CDR20291_3128. The inverse orientation of the CDR20291_1514 region has been identified 
previously (Stabler et al., 2010), however the CDR20291_3128 switch has not been previously 
described. BPROM analysis of the sequences upstream of CDR20291_3128 and 
CDR20291_1514, predicted the promoters of these genes are contained within the invertable 
regions, which would result in gene expression being turned ON or OFF depending on switch 
orientation (Fig.4.4A). BPROM analysis also predicted a promoter immediately downstream of 
CDR20291_1514, suggesting the CDR20291_1514 switch only controls the expression of 
CDR20291_1514, a putative c-phosphodiesterase (Bordeleau et al., 2011). CDR20291_3128 is 
the first gene in an operon, along with CDR20291_3127 and CDR20291_3126. CDR20291_3127 
is a predicted two-component sensor histidine kinase, CDR20291_3128 and CDR20291_3126 are 
predicted two-component response regulators.  
4.2.2.2 Characterisation of CDR20291_1514 and CDR20291_3128 Switch Inversion 
As the CDR20291_1514 and CDR20291_3128 switches have never been characterised, 
it was first necessary to confirm these regions are indeed phase variable and to identify the 
recombinase(s) responsible for switching. Firstly, switching was confirmed via PCR using multiple 
primer pairs in which one primer annealed within and the other primer annealed outside of the 
invertable region (Fig.4.4A). It was observed that the CDR20291_1514 and CDR20291_3128 
switches exist in both orientations in populations of R20291 (Fig.4.4B).  
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To determine if RecV is responsible for switching at the CDR20291_1514 and 
CDR20291_3128 loci, the orientation of these switches was examined in our recV mutants. 
Although the CDR20291_1514 and CDR20291_3128 switches were found in both orientations in 
populations of R20291, these switches were locked in the recV mutants (Fig.4.4B), confirming 
that RecV is responsible for inversion of the CDR20291_1514 and CDR20291_3128 switches.  
Including the CDR20291_1514 and CDR20291_3128 switches, four phase variable 
regions have now been shown to be dependent on RecV for switching.  All four phase variable 
switches are flanked by inverted repeats. The repeats flanking these switches differ in sequence. 
The flgB switch is flanked by the imperfect repeats 5’-AAGTT(A/G)CTAT(A/T)TTACAAAAAA-3’ 
(Anjuwon-Foster and Tamayo, 2017), the cwpV switch is flanked by the imperfect repeats 5’- 
AAGTA(T/G)CCTTTAGAATTA(G/A)AA -3’ (Emerson et al., 2009), the CDR20291_3128 switch is 
flanked by the imperfect repeats 5’-
TCC(C/A)TT(T/C)TCCAACAA(A/T)(T/C)GG(C/A)(T/G)ACTTTAA-3’, and the CDR20291_1514 switch 
is flanked by the perfect inverted repeat 5’-AAACTATCCATTTTACAAGAAATG-3’. These inverted 
repeats all contain a poorly conserved 21 bp sequence (Fig.4.4C) 
 
  
 Chapter IV. Characterisation of FM2.5 and the Roles of the S-layer 
 120 
 
Fig.4.4: Identification of two novel phase-variable switches in the R20291 genome. (A) Schematic 
representation of the CDR20291_1514 and CDR20291_3128 promoter regions. BPROM analysis predicted 
that the promoter regions upstream of these genes are contained within the invertable region. The ON 
and OFF orientations of these switches were therefore modelled using the predicted promoter regions, 
as only one orientation would allow transcription. If these switches are in the ON orientation, PCR using 
RF994/RF995 (CDR20291_1514) or RF990/RF992 (CDR20291_3128) would result in products of 429 and 
420 bp respectively. When in the OFF orientation, PCR using RF997/RF995 (CDR20291_1514) or 
RF991/RF992 (CDR20291_3128) would result in products of 217 and 211 bp respectively. (B) PCR analysis 
of R20291, R20291 cwpV ON, and R20291 cwpV OFF to determine CDR20291_3128 and CDR20291_1514 
switch orientation. PCR analysis shows the CDR20291_1514 and CDR20291_3128 switches exist in both 
orientations in R20291 populations, confirming these regions as being phase variable. However, PCR 
products were only observed for one orientation in the recV inactivated strains suggesting that RecV is 
responsible for phase switching at these regions. (C) A logo-plot showing a 21 bp conserved sequence 
found within the inverted repeats that flank four phase variable switches.  
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4.2.3 Orientation of the Phase Variable Switches 
4.2.3.1 Phase ON Frequencies of the flgB, CDR20291_1514 and CDR20291_3128 
switches 
As the CDR20291_1514 and CDR20291_3128 switches were identified in the inverse 
orientations in the FM2.5 genome, it was necessary to quantify the orientation frequency of all 
four phase variable switches. PCR analysis confirmed phase switching at the flgB, 
CDR20291_1514, and CDR20291_3128 loci in FM2.5 and FM2.5RW (Fig.4.5A), as both 
orientations of the switches were observed in populations of these strains (data not shown). 
Orientation frequency was quantified using asymmetric digests of PCR fragments (Fig.4.5A and 
B). There was no significant difference in the orientation frequency of either the 
CDR20291_1514 or CDR20291_3128 between populations of R20291, FM2.5 and FM2.5RW. 
CDR20291_1514 was shown to be ON in the minority of cells within a population (mean of 8.6% 
in R20291), while CDR20291_3128 was shown to be ON in the majority of cells within a 
population (mean of 76.8% in R20291).  There was, however, a significant difference in the 
observed frequencies of flgB ON cells within population of R02921 (median 0%) and FM2.5 
(median 100% P<0.0005). However, no significant difference was observed in the frequency of 
flgB ON variants between populations of FM2.5 and FM2.5RW. 
4.2.3.2 Orientation of the switch regions in the recV Inactivated Mutants 
As R20291 cwpV ON and FM2.5RW cwpV ON display different colony morphologies 
(Fig.4.3C), the change in colony morphology previously reported to be due to CwpV expression, 
must in fact be CwpV-independent. The orientations of the other phase variable switches were 
determined in the recV inactivated mutants to confirm phenotypes associated with CwpV 
expression were not actually due to the other phase variable regions.  As expected, the three 
other switch regions were in the same orientation in FM2.5 cwpV ON and FM2.5 cwpV OFF (all 
OFF), and FM2.5RW cwpV ON and FM2.5RW cwpV OFF, where only the CDR20291_1514 switch 
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was in the OFF orientation. However, while the three other switches were in the OFF orientation 
in R20291 cwpV OFF, in R20291 cwpV ON the CDR20291_3128 switch is locked in the ON 
orientation (Fig 4.5C). CDR20291_3128 expression may, therefore, be responsible for altered 
colony morphology.   
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Fig.4.5: Orientation of the flgB, CDR20291_3128 and CDR20291_1514 genetic switches. (A) Schematic 
representation of the flgB, CDR20291_1514, and CDR20291_3128 promoter regions. PCR amplification 
using primer pairs RF966/RF963, RF994/RF997, or RF991/RF990, respectively, results in a small DNA 
fragment containing an asymmetrically located restriction site. Digestion of these fragments using either 
SwaI (flgB), HphI (CDR20291_1514), or XbaI (CDR20291_3128) results in differently sized fragments 
depending on the orientation of the switch. (B) Digested PCR fragments were run on 2% agarose gels and 
densitometric analysis performed, enabling the calculation of the proportion of each these switches in 
the ON orientation. This analysis was performed using eight biological repeats. (C) Analysis of the 
orientation of all four switches in the recV insertional mutants. Primer pairs RF964/RF963, RF995/RF994, 
RF992/RF990, NF825/NF823 (ON) and RF964/RF966, RF995/RF997, RF991/RF992, NF823/NF826 (OFF) 
were used to determine the orientation of the flgB, CDR20291_1514, CDR20291_3128 and cwpV switches 
respectively. 
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4.2.4 Manipulation of the Native slpA Locus 
The native slpA locus is notoriously difficult to manipulate. However, the isolation of S-layer 
deficient mutants provides a unique opportunity to genetically modify this locus. We have 
already replaced the native slpA with a watermarked variant (Kirk and Fagan, 2016). This paved 
the way for substitution of the native slpA with a mutant variant, encoding SlpA lacking the 
variable domain (domain 2) of the LMW subunit. This mutant (FM2.5RΔD2) has been used to 
provide further insight into S-layer structure (Banerji, 2017). As there are thirteen published 
SLCTs, it would be interesting to express the different slpA variants in FM2.5. This would allow 
investigation of the contributions of the different SLCTs to virulence using an isogenic expression 
system.  
4.2.4.1 Substitution of Native SLCT-4 slpA with SLCT-7 slpA 
Allele exchange mutagenesis using pMTLSC7215 was initially chosen to substitute the 
native SLCT-4 slpA with SLCT-7 slpA. This method would allow the exchange of the native slpA in 
not only FM2.5, but also in R20291. 1 kb fragments immediately upstream and downstream of 
slpA  were cloned into pMTLSC7215, flanking slpA from 630. The resulting plasmid was denoted 
as pJAK072. 
Conjugation of pJAK072 into both R20291 and FM2.5 was attempted using varying heat 
shock treatments (Kirk and Fagan, 2016). However, transconjugants were only obtained for 
R20291. As pJAK072 contains 1.2 kb upstream of slpA, it was assumed that this plasmid contains 
the complete slpA promoter. Expression of SLCT-7 SlpA was therefore investigated in R20291/ 
pJAK072. S-layer extraction was performed using O/N cultures of this strain and analysed via 
SDS-PAGE and western blotting using SLCT-4 and SLCT-7 specific antibodies. Only bands 
representing SLCT-4 HMW and LMW SLPs were observed in the SDS-PAGE and confirmed by 
western blot. These results suggest that plasmid borne slpA is not expressed in R20291/pJAK072.  
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Allele exchange mutagenesis was attempted as standard using this strain. The first 
recombination event, resulting in integration of the plasmid into the chromosome, was 
confirmed via PCR (Fig.4.6A and B). During the second recombination selection step, Avidocin-
CD291.2 was added to the harvested cells. Avidocin-CD 291.2 kills SLCT-4, but not SLCT-7 
expressing C. difficile, allowing selection of cells which have lost the SLCT-7 slpA. Eight colonies 
were isolated after selection for the second recombination event. S-layer extracts from these 
colonies were analysed by SDS-PAGE and western blotting. (Fig.4.6C and D). Of the eight 
colonies, one did not grow in TY broth and four still expressed SLCT-4 SlpA. One of the isolates 
seemed to contain an S-layer different to either SLCT-7 or SLCT-4 and showed extremely poor 
growth in TY broth, although it is possible that this was a contaminant. The two remaining 
isolates did not seem to express SlpA and were denoted JK1 and JK2. Primers RF110/RF111 were 
used to amplify the 5’ region of slpA, shown to contain mutations in FM2.5 and FM2.6, from JK1 
and JK2. Sequencing of these fragments revealed the same mutation, an insertion of a single 
adenine at position 283, as FM2.5. Interestingly, CwpV was observed in the S-layer extracts of 
both JK1 and JK2 (Fig.4.6C). 
As pMTLSC7215 is notoriously difficult to conjugate into R20291, and as FM2.5RW and 
FM2.5RΔD2 were made using pMTL960 based vectors, the pJAK072 insert region was amplified 
using RF835/RF836 and ligated into pRPF185 via the KpnI and SacI sites. The resulting plasmid, 
pJAK076 was successfully conjugated into FM2.5. However, large colonies of FM2.5/pJAK076, 
indicative of slpA function complementation, were not observed. Due to the possibility that slpA 
under control of its native promoter may cause toxic effects when introduced on a multi-copy 
plasmid, the slpA promoter was removed from pJAK076. This was achieved through inverse PCR 
of pJAK076 using RF901/RF902, and ligation of the resulting fragment. The resulting plasmid, 
pJAK086, therefore contained a 115 bp upstream of slpA. However, when conjugated into 
FM2.5, again, large colonies were not observed.   
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Fig.4.6: Manipulation of the native slpA locus. (A) 1 kb downstream of slpA was amplified from R20291 
gDNA using RF659/RF660. slpA was amplified from 630 gDNA using RF750/RF658. These fragments were 
assembled into pMTLSC7215, linearised by PCR using primers RF311/312, by Gibson assembly. The 
resulting plasmid was linearised using RF779/RF780 and was used in a second Gibson assembly reaction 
with 1 kb upstream of slpA, which was amplified from R20291 gDNA using RF655/RF656. The resulting 
plasmid was denoted pJAK072 and was transformed into the conjugation donor CA434.  Schematic 
representation of pJAK072 and the result of the first recombination event leading to insertion of the 
plasmid into the C. difficile genome. Recombination can happen at either the right homology arm or left 
homology arm (blue boxes), resulting in either sequence R or sequence L. (B) PCR analysis of potential 
single recombinants selected by an increase in colony size (Cartman et al., 2012). PCR was performed 
using combinations of primers flanking the plasmid insertion site, RF33 and RF826, and primers specific 
for the plasmid, RF21 and RF22. R20291 was included as a negative control. Bands at approximately 4.4 
and 4.7 kb when primer pairs RF826/RF22 and RF33/RF21, respectively, were used and a lack of a band 
when primer pair RF33/RF826 were used indicates successful insertion of the plasmid into the 
chromosome. The single recombinants were restreaked to non-selective BHI and incubated for 72 h. Cells 
were then harvested and incubated with an excess of Avidocin-CD 291.2 for 1 h, prior to being plated onto 
CDMM containing 5-Fluorocytosine. After 96 h incubation eight colonies arose and were restreaked to 
BHI. Plasmid loss was confirmed via sensitivity to thiamphenicol. The eight restreaked colonies were used 
to inoculate O/N cultures and S-layer extracts isolated. S-layer extracts were analysed by SDS-PAGE (C) 
and western blotting using an anti-SLCT-7 LMW SLPA antibody (D). No isolates were shown to express 
SLCT-7 SlpA, although two new slpA deficient mutants were isolated (lanes 2 and 3). One isolate also 
showed poor growth and an abnormal S-layer (colony 5). The LMW and HMW SLPs are labelled with a 
black arrow, CwpV is labelled with a red arrow, and unidentified proteins are labelled with a green arrow.  
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4.2.4.2 Characterisation of the slpA Promoter 
Complementation of FM2.5 with native levels of SlpA, using mutant variants of slpA or 
variants from different S-layer cassettes, may be achievable by inserting slpA, under control of 
its native promoter, into the pyrE locus. This, however, would require characterisation of the 
slpA promoter. SlpA is one of the most abundantly expressed proteins in C. difficile, constituting 
approximately 15% of the total protein content of the cell suggesting that slpA expression is 
driven by an extremely strong promoter (Fagan and Fairweather, 2011). Therefore, 
characterisation of the slpA promoter may also have practical applications such as high-level 
expression of proteins for use in in vitro analysis.  
4.2.4.2.1 In silico Analysis of the slpA Promoter 
Firstly, DNA sequences upstream of all 13 recorded slpA cassettes (Dingle et al., 2013) 
were subjected to BPROM promoter prediction and sequence alignment. Distinct promoter 
families were identified via the alignments (Fig.4.7A). slpA cassettes 1-8 and H2/6, contain near 
identical sequences upstream of slpA (>90% identity). Cassettes 10 and 12 showed greater 
identity between them than when compared to others (approximately 89%) and Cassettes 9 and 
11 showed relatively poor sequence identity to other cassettes types (<80%). 
BPROM analysis of sequences from cassettes 1-8 identified conserved -10 and -35 
promoter regions. This region, although differing in sequence relative to cassettes 1-8, was also 
quite well conserved within cassettes 9-12 (Fig.4.7B). 
The sequence immediately upstream of the -35 region (-42 to -64) in cassettes 1-8 
showed sequence similarity to the consensus sequence of upstream promoter elements (UPE) 
of E. coli (nnAAA(A/T)(A/T)T(A/T)TTTTnnAAAAnnn) (Fig.4.7B) (Estrem et al., 1998). This 
sequence was not identified in cassettes 9-12, which may suggest that cassettes contain weaker 
promoters, or increase promoter activity using a different mechanism.  
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4.2.4.2.2 The slpA promoters contains a UPE 
To confirm the presence of an upstream promoter element within the slpA promoter, a 
promoter activity assay was performed. The promoter was cloned to either include up to the -
40 or -80 regions and introduced into pRPF185 between the KpnI and BamHI restriction site. This 
placed gusA under control of the slpA promoter without the potential UPE (pJAK106, referred 
to as PslpA-SHORT) or with the potential UPE (pJAK107, referred to as PslpA-LONG). β-
glucuronidase assays were performed using R20291/PslpA-SHORT and R20291/PslpA-LONG to 
determine whether the sequence upstream of the -35 region increased promoter activity. 
pRPF144, a plasmid bearing gusA under the control of the constitutive cwp2 promoter, was used 
as a positive control. 
As expected, pRPF144 resulted in greater enzyme activity relative to the negative 
control, pSEW027, which lacks gusA (P<0.0005). PslpA-SHORT resulted in significantly higher 
enzyme activity relative to pRPF144 (P<0.0005). PslpA-LONG resulted in significantly higher 
enzyme activity (approximately 7-fold) compared to PslpA-SHORT (P<0.0005). This result 
strongly suggests that the slpA promoter contain an UPE. It is worth noting that before 
measuring the enzyme activity samples were centrifuged to remove cell debris and GusA activity 
seemed to be localised to the pellet. This could have led to localised substrate saturation in the 
PslpA-LONG samples, meaning the difference in enzyme activity between samples of PslpA-
SHORT and PslpA-LONG may be greater than recorded.  
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Fig.4.7: Characterisation of the slpA promoter. (A) Sequence identity between the sequences upstream 
of slpA from all 13 documented slpA cassettes. The entire non-coding region upstream of the slpA from 
all SLCTs were aligned using the Geneious ClustalW alignment tool. Numbers across the top and sown the 
left correspond to the SLCT and the % sequence identity is presented. (B) Sequence alignment of the 
cassette 1-8 sequences reveals high sequence conservation near the predicted promoter regions. The 
region immediately upstream of the -35 region resembles an UPE from E. coli promoters (Estrem et al., 
1998). (C) The slpA promoter was cloned to include up to the -35 region using primer pair RF1052/RF1053, 
or to approximately -80 of the transcriptional start site using primer pair RF1051/RF1053. These fragments 
were ligated into pRPF185 via the KpnI and SacI restriction sites, creating PslpA-sHORT and PslpA-LONG 
respectively, placing gusA under the control of the slpA promoters. These plasmids were conjugated into 
R20291. pRPF144, in which gusA is under the control of the cwp2 promoter, was included as a positive 
control, and pSEW027, which lacks gusA, was used as a negative control. R20291 strains bearing these 
plasmids were grown O/N in biological duplicate and subcultured to OD600nm 0.05 and were harvested 
at approximately OD600nm 0.7. Bacterial pellets were then used in a β-glucuronidase assay as previously 
described (Dupuy and Sonenshein, 1998). PslpA-SHORT did result in significantly higher enzyme activity 
relative to pRPF144. PslpA-LONG, containing the putative UPE, resulted in an even greater GusA 
expression. The mean from experiments using biological duplicates performed in technical triplicate are 
plotted. Error bars correspond to the standard deviation. Statistical significance was calculated using two-
tailed T-tests using Welch’s correction (* P<0.0005).  
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4.2.5 S-layer Pore Size and Innate Immune Effector Resistance 
The SlpA deficient mutant, FM2.5, shows increased sensitivity to the innate immune 
effectors LL37 and lysozyme (Kirk, 2017). To investigate the mechanism(s) behind this resistance, 
LL37 and lysozyme sensitivity assays were performed using FM2.5RΔD2 (Banerji, 2017). This 
strain lacks the variable domain in the LMW subunit of SlpA (Fig.4.8A), causing an apparent 
increase in S-layer pore size (Banerji, 2017).  
Growing cultures of R20291, FM2.5 and FM2.5RΔD2 were treated with lysozyme (500 
µg/ml) or LL37 (5 µg/ml), and the optical density of the culture was recorded hourly. As 
previously observed, treatment of FM2.5 with lysozyme results in significantly slowed growth 
relative to R20291 and treatment with LL-37 completely killed FM2.5 (Fig.4.8B). Treatment of 
FM2.5RΔD2 with lysozyme results in slowed growth, comparable to the effect of seen with 
FM2.5 (Fig.4.8B). In contrast, treatment of growing cultures of FM2.5RΔD2 with LL37 did not 
result in complete killing as with FM2.5. However, a larger drop in cell density was observed 
when FM2.5RΔD2 was treated with LL37 relative to R20291. 
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Fig.4.8: Sensitivity of FM2.5RΔD2 to the innate immune effectors, lysozyme and LL37. (A) 3D model of 
the native R20291 S-layer at 2 Å generated using data from electron diffraction experiments (Banerji, 
2017) showing the structure of the S-layer of R20291 (blue mesh) compared to the S-layer from 
FM2.5RΔD2 (blue). Broth based killing assays were performed where the OD600nm of growing cultures of 
R20291, FM2.5, and FM2.5RΔD2 was monitored every hour after addition of lysozyme (500 µg/ml.) or 
LL37 (5 µg/ml). LL37 and lysozyme were added to cultures 2.5 h post-inoculation (black arrow). (B) 
Addition of lysozyme to growing cultures of FM2.5RΔD2 results in a reduced growth rate comparable to 
that of FM2.5. (C) Addition of LL37 to growing cultures of FM2.5RΔD2 results in impaired growth relative 
to R20291. However, addition of 5 µg/ml of LL37 to growing cultures of FM2.5 results in complete cell 
death, suggesting increased LL37 resistance in FM2.5RΔD2 relative to FM2.5. LL37 and lysozyme challenge 
experiments were performed in triplicate using biological duplicates. Error bars show the standard 
deviation of the data. 
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4.3 Discussion  
Unlike other bacterial species, the S-layer of C. difficile is essential for growth in vitro (Dembek 
et al., 2015), although the reasons for this remain unknown. Due to the lack of slpA mutants, the 
functions of the S-layer are poorly understood. Recently, spontaneous slpA mutants of C. 
difficile, have been isolated (Kirk et al, 2017). These strains present a unique opportunity to study 
the functions of the S-layer and attempt to understand why the S-layer appears to be essential 
in WT C. difficile. Here we have made attempts to understand the effects of slpA loss to gain 
understanding on S-layer function.  
The most obvious difference observed with the SlpA deficient mutants was increased 
CwpV expression.  Interestingly this was observed in all four independent slpA mutants (FM2.5, 
FM2.6, JK1, and JK2). As cwpV is under the control of a phase variable promoter, where 
expression of CwpV is dependent on the orientation of a 195 bp switch region upstream of the 
cwpV ORF, we explored the possibility that the cwpV switch is biased towards the ON orientation 
in populations of FM2.5. It was confirmed that in FM2.5 the switch region is found more 
frequently in the ON orientation. We originally hypothesised that this observation was due to 
increased growth rate of FM2.5 cwpV ON variants, which would result in higher proportions of 
cwpV ON cells within a population. However, no difference in growth rate or cell morphology 
was observed in recV insertional mutants with cwpV expression locked either ON or OFF. This 
suggests that the overexpression of CwpV in populations of FM2.5 is due to changes in 
regulation of RecV-dependent site-specific recombination. Interestingly, the cwpV region is 
found in the ON orientation in FM2.5RW at similar frequencies to R20291, suggesting that SlpA 
expression may influence switching of the cwpV switch. Surprisingly, the colony morphology of 
FM2.5 and FM2.5RW cwpV ON and OFF strains did not match the previously reported colony 
morphologies (Reynolds et al., 2011). This may be due to the orientation of the CDR20291_3128 
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switch as the its orientation differs between FM2.5RW cwpV ON and R20291 cwpV ON, which 
theoretically have the same surface architecture. 
The genome of FM2.5 has previously been sequenced using illumina (Kirk et al, 2017). 
This method was chosen due to its routine use and relatively low cost. As no obvious suppressor 
mutations were observed in the illumina sequence, SMRT sequencing was employed. This 
method provides much larger read-lengths, averaging 10 kb, enabling easier identification of 
large insertions, deletions and inversions within the genome (Rhoads and Au, 2015). This is 
particularly useful as the C. difficile genome contains many repeat sequences. Using this method 
additional mutations were found within the FM2.5 genome. Although most of these mutations 
occur in genes of unknown function, a SNP within the gene encoding the regulatory protein, 
CodY, was identified. CodY is a negative regulator of both toxin production and sporulation 
(Dineen et al., 2010; Nawrocki et al., 2016), and it would be interesting to see whether this 
mutation contributes to the inability of FM2.5 to efficiently sporulate and produce toxins. 
As FM2.5 shows increased CwpV expression, it was unsurprising that the orientation of 
the cwpV switch was observed in the ON orientation in the FM2.5 genome. Interestingly 
however, other phase variable regions were found to be in their inverse orientations relative to 
the published R20291 genome. This includes the putative phase variable switch upstream of 
CDR20291_1514 and a previously undescribed phase variable region upstream of 
CDR20291_3128. The presence of these switches in both orientation within populations of C. 
difficile was confirmed via PCR analysis and the switch inversion was shown to be dependent on 
RecV. RecV has been shown to control the orientation of the cwpV switch (Emerson et al., 2009) 
and the flgB switch (Anjuwon-Foster and Tamayo, 2017), meaning that this recombinase is 
responsible for the phase switching of all switch regions identified to date. This is particularly 
interesting as the inverted repeat regions flanking these genetic switches share little sequence 
similarity. Asymmetric digest analysis also shows that the orientations of the switch regions are 
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regulated differently. cwpV switch regulation is, as previously mentioned, abnormal in FM2.5 
and corrected in FM2.5RW. flgB orientation regulation also seems to be abnormal in FM2.5, but 
is not corrected in FM2.5RW. Finally, both the CDR20291_3128 and CDR20291_1514 orientation 
switching are not affected by loss of slpA.  It is worth mentioning, that while asymmetric digests 
are useful for comparing different samples, they may not be sensitive enough to detect rare 
inversion events. Therefore, the reported proportion of CDR20291_3128 ON and 
CDR20291_1514 ON cells within a population may not accurately reflect the actual proportions. 
It may therefore be necessary to use more sensitive techniques, such as reverse-transcription 
PCR, to determine the frequency of CDR20291_3128 and CDR20291_1514 being in the ON 
orientations. As the orientation of the flgB switch has been shown to change over time within a 
population (Anjuwon-Foster and Tamayo, 2017), it may also be necessary to calculate phase 
switching at different stages of the bacterial growth. The difference in inverted repeat sequence 
may provide some insight into the mechanism(s) in which these regions are regulated. As the 
orientation switching of the different regions seem to differ, as not all switches are affected by 
SlpA loss, it is likely that they are regulated by different mechanisms. One possible explanation 
is the presence of co-factors which may be required for RecV function. Co-factors required for 
orientation switching may differ for the different switches. As c-di-GMP is known to be involved 
in regulation of expression of the flgB operon and CDR20291_1514 encodes a c-di-GMP PDE, c-
di-GMP may act as a co-factor for RecV-dependent orientation switching. This would allow 
coupling of expression of the regulatory CDR20291_3128 operon, surface antigen expression, 
motility, and c-di-GMP degradation to levels of intracellular c-di-GMP and, therefore, virulence 
and biofilm production (Bordeleau and Burrus, 2015).  
With the confirmation that two other phase variable regions, other than cwpV and flgB, 
were under control of RecV, the orientations of the four genetic switches in the recV inactivated 
mutants were determined. As FM2.5 cwpV OFF and FM2.5RW cwpV ON were created using 
allele exchange, the orientations of the other switches were the same between the ON and OFF 
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strains. However, R20291 cwpV ON was created through expression of recV from a plasmid. This 
means that the orientations of the other switches may not necessarily match R20291 cwpV OFF. 
In fact, in R20291 cwpV ON, CDR20291_3128 was also in the ON orientation, while in R20291 
cwpV OFF, CDR20291_3128 was in the OFF orientation. Interestingly CDR20291_3128 was also 
found to be in the ON orientation in the FM2.5RW recV::erm strains. This observation may 
explain why both FM2.5RW cwpV ON and OFF strains share a colony similar to that of R20291 
cwpV ON. Whilst this trait was assumed to be due to expression of CwpV, it now seems more 
likely to be due to expression of the CDR20291_3128 operon. To confirm this, it would be 
necessary to show that the orientation of the CDR20291_3128 switch assumed to be ON does 
result in transcription of the downstream genes. In addition, it would be necessary to show that 
expression of the CDR20291_3128 operon alone is sufficient to result in altered colony 
morphology. This could easily be performed using R20291 cwpV OFF, as all genetic switches in 
this strain are in the OFF orientation. The orientation of the CDR20291_3128 switch is in the OFF 
orientation in the FM2.5 recV::erm strains, which do show a small, smooth edged colony 
morphology. However, this may be explained by the huge alteration of surface architecture of 
these strains relative to wild-type.  
Manipulation of the slpA locus is notoriously difficult. Previous attempts to inactivate 
slpA have proven unsuccessful, and it is now known that slpA is essential for growth (Dembek et 
al., 2015). The isolation of FM2.5 raised hopes that the slpA locus may now be more easily 
manipulated. This has proven to be true to some extent. Insertion of slpA, encoding a functional 
protein, into the native locus has been successful, e.g. insertion of intact slpA containing a 
watermark allowed construction of strain FM2.5RW. Additionally, through insertion of slpA 
lacking the coding region for domain 2 of the LMW subunit, strain FM2.5RΔD2 was created. This 
demonstrates that we are now able to introduce mutant variants of SLCT-4 slpA into the FM2.5 
genome, potentially only if the gene expresses a functional SlpA. This strain has allowed us to 
further probe the functions of the S-layer. Treatment of growing cultures of FM2.5RΔD2 with 
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lysozyme resulted in slowed growth, similar to the effect seem in FM2.5 However, addition of 
LL37 to growing cultures of FM2.5RΔD2 did not result in complete cell death, as observed in 
FM2.5. As FM2.5RΔD2 has been reported to contain larger pores in the S-layer (Banerji, 2017) it 
may therefore be hypothesised that S-layer-dependent resistance to lysozyme may be caused 
by the S-layer acting as a physical barrier to lysozyme, preventing the enzyme from reaching the 
cell wall. The S-layer therefore acts as a molecular sieve, as previously hypothesised (Fouet et 
al., 1999). However, as increasing the pore size of the S-layer had minor effects on resistance to 
LL37, the S-layer may confer resistance to LL37 by altering the charge of the cell surface, 
preventing the CAMPs from reaching the cell membrane. This is a similar mechanism to 
lipopolysaccharide dependent CAMP resistance seen in Gram negative bacteria (Band and 
Weiss, 2015). 
This exemplifies how manipulation of slpA may help further understand the functions of 
the S-layer and the underlying mechanisms. However, even in FM2.5, manipulation of the native 
slpA locus has proven difficult. The slpA promoter has now been identified in R20291 which 
seems to include a UPE. Due to the sequence similarity between the R20291 promoter region 
and those from strains bearing S-layer cassettes 1-8, it is very likely this promoter region is 
conserved between these strains. However, it is still not understood how the promoters of 
cassettes 9-12 are so apparently strong, without an apparent UPE. High levels of slpA expression 
in these strains may be attributed to the presence of an additional promoter, although 
experimental evidence is still required. Identification and characterization of the slpA promoter 
may allow deletion of native slpA in FM2.5, and insertion of slpA under control of its native 
promoter into the pyrE locus. This would enable the study of all thirteen different SLCTs using 
an isogenic expression system. 
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Chapter V 
SecA2 and Biogenesis of the S-layer 
5.1. Introduction 
In addition to poor understanding of its function, little is known about the biogenesis of 
the S-layer.  SlpA is secreted via the accessory Sec secretion pathway. C. difficile expresses two, 
independently functional SecA proteins. SecA1 is thought to be responsible for the secretion of 
the majority of proteins while SecA2 secretes a small subset of proteins. SlpA is dependent on 
SecA2 for secretion (Fagan and Fairweather, 2011). However, the reason for C. difficile 
expressing two, functionally independent SecA proteins is unknown. As SlpA is so abundant, it 
is possible that an additional SecA is required to prevent saturation of the Sec secretion pathway. 
However, due to the lack of an additional SecY, it is likely that SecA2 uses the canonical channel 
for protein translocation. There is also the possibility that SecA2 provides temporal regulation 
on SlpA secretion. However, this is unlikely as SlpA is expressed constitutively and is essential 
for growth in vitro (Dembek et al., 2015). Another possibility is that SecA2 enables localised 
secretion. SecA2 mediated secretion is a poorly understood process and M. tuberculosis is the 
only organism to date for which the structure of both SecA2 and SecA1 is known (Sharma et al., 
2003; Swanson et al., 2015). 
In rod-shaped bacteria, synthesis of the cell wall occurs along the long axis of the cell 
and at the septum (Vollmer and Bertsche, 2008). There are two multi-enzyme complexes 
responsible for peptidoglycan synthesis, the elongasome and the divisome. These complexes 
are organised by the cytoskeletal proteins, the actin homologue MreB and the tubulin 
homologue FtsZ, respectively. MreB is thought to localise around the long axis of the cell, 
ensuring peptidoglycan synthesis occurs at these sites, maintaining cell shape and integrity (as 
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reviewed in (Errington, 2015)). However, the exact pattern of localisation is disputed. There are 
two C. difficile MreB homologues, MreB1 and MreB2, both of which are essential for growth in 
vitro (Dembek et al., 2015). FtsZ undergoes GTP-dependent polymerisation forming filamentous 
arches which form the Z-ring at the mid cell, the molecular scaffold essential for the localisation 
of at least 10 proteins involved in cell division (as reviewed in (Ortiz et al., 2016)).  
To further understand the mechanisms behind SecA2 substrate specificity and function, 
we have performed X-ray crystallisation of SecA2. SecA proteins are composed of several 
functional domains. NBD1 and NBD2 form the DEAD motor box domain which binds and 
hydrolyses ATP providing energy for protein transport, the PPXD domain is involved in substrate 
binding, the HSD links the specificity domain to the motor domain, the HWD links the IRA1 
domain thought to insert the substrate into the channel, and the CTD which interacts with SecB 
in Gram-negative bacteria and phospholipids (Feltcher and Braunstein, 2012). We have 
identified differences in SecA2 structure when compared to the structure of Mycobacterium 
tuberculosis SecA1 (MtbSecA1). Some of these differences are conserved between C. difficile 
SecA2 and M. tuberculosis SecA2 (MtbSecA2). In addition, we provide evidence for MreB and 
FtsZ involvement in SecA2 dependent secretion and suggest that S-layer biogenesis is localised 
to areas of cell wall synthesis.  
 5.2 Results 
5.2.1 3D Modelling of SecA Proteins 
5.2.1.1 Purification of SecA1 and SecA2 
Before in vitro analysis was performed, SecA1 and SecA2 were purified from C. difficile 
lysates. Plasmids expressing N-terminally strep-tagged variants of C. difficile strain 630 SecA2 
and SecA1, pRPF186 and pRPF193 respectively (Fagan and Fairweather, 2011), were conjugated 
into 630. The resulting strains were used to over-express the two proteins that were then 
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purified using Strep-tag affinity chromatography. However, the resulting yields of SecA2 and 
SecA1 were very low (approximately 2 mg and 0.3 mg, from 10 l of C. difficile culture, 
respectively). SecA1 and SecA2 preparations were very pure, although SecA1 samples were 
contaminated with a protein with a MW of approximately 45 kDa (Fig.5.1A). 
As SecA1 is mainly localised at the membrane (Fagan and Fairweather, 2011), the effect 
of treatment of cell lysates with detergent on the solubility of SecA1 was investigated. 
Supernatants of cell lysates treated with varying concentrations of N-lauroylsarcosine were 
analysed via western blot. None of the treatments substantially increased the solubility of SecA1 
(Fig.5.1B).   
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Fig.5.1: Purification of SecA1 and SecA2. (A) 10 L of TYG was inoculated with 630/pRPF186 or 
630/pRPF193 and grown to an approximate OD600 of 0.5. Protein expression was then induced through 
addition of 700 ng/ml of Atc. The cultures were then incubated anaerobically for a further 5-6 h, at which 
point cells were harvested via centrifugation (4,700 x g, 10 min). Cells were resuspended in 2x StrepTactin 
purification buffer and lysed using the CD27L bacteriophage endolysin (Mayer et al., 2008). The soluble 
fraction of the resulting lysates were diluted using 1x binding buffer and loaded onto two 1 ml StrepTactin 
columns. Protein was eluted from the column through the addition of an increasing gradient of elution 
buffer containing desthiobiotin. SDS-PAGE showing purified SecA2 and SecA1. Little contamination is seen 
in preparations of SecA2, although SecA1 contains a contaminating protein with a MW of approximately 
45 kDa. (B) Cell lysates of 630/pRPF193 were incubated without detergent or with 2% SDS or 0.5, 0.75, 1, 
and 2% N-lauroylsarcosine. Samples were then incubated at 4°C for 30 min and centrifuged to remove 
cell debris (20,000 x g, 2 min). Supernatants were resolved by SDS-PAGE and analysed via western blotting 
using an anti-Strep-tag antibody. A pellet of untreated cell debris was also treated with detergent to 
determine protein content of the non-soluble fraction (lane Pellet). Although some SecA1 is lost in the 
non-soluble fraction, more SecA1 is present in the soluble fraction when not treated with detergent.  
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5.2.1.2 SecA1 and SecA2 X-Ray Crystallography 
Purified samples of SecA1 and SecA2 were concentrated using Amicon centrifugation 
filters. However, neither protein could reach concentrations above approximately 1 mg/ml 
before precipitation was observed. Protein samples, at approximately 1 mg/ml, were used in 
four 96-well crystal screen trials. No crystal growth was observed for SecA1. However, SecA2 
crystals were observed in five different conditions in the PACT crystal screen. The largest, non-
needle like crystals were observed in conditions B10 (0.2 M magnesium chloride, 0.1 M MES pH 
6.0, 20 % w/v PEG 6000) and C10 (0.2 M magnesium chloride 0.1 M HEPES pH 7.0, 20 % w/v PEG 
6000) (Fig.5.2A). X-ray diffraction data was obtained to approximately 3.3 Å using these crystals. 
Optimisation of crystal growth conditions, data analysis, and 3D model assembly were 
performed by Dr Paula Salgado (University of Newcastle). Optimisation of crystal growth 
resulted in several conditions that yielded crystals. The structure of SecA proteins vary 
dependent on the presence of bound ATP or ADP. Crystallisation trials containing the 
unhydrolysable ATP analogue, AMP-PNP, or ADP were also performed. Different conditions 
were used to obtain crystals of SecA2 in its unbound, ADP bound, and AMP-PNP bound forms. 
Diffraction data was collected for all these SecA2 isoforms. Diffraction data was collected to 2.65 
Å for SecA2-ADP. Phasing was inferred by molecular replacement using the SecA structure of 
Thermatoga maritima.  Although we now have a complete model of SecA2, further refinement 
is still necessary as some areas do not fit within the electron density plot. This is especially true 
for residues 230-335 which correspond to the PPXD domain (Fig.5.2B and C).  
The structure of SecA2 contains all domains expected for a SecA protein including the 
HSD, HWD, IRA1, PPXD, and a DEAD box motor domain consisting of NBD1 and NBD2, although 
as expected, no CTD was identified within the model as this domain is believed to be very 
flexible. As the structure of SecA1 could not be determined, MtbSecA1 is shown for comparison 
(Fig.5.2D). When compared to MtbSecA1, there is a striking difference in the conformation of 
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the PPXD domain, which is rotated towards NBD2 in SecA2. In addition, NBD2 lacks the two 
alpha helices that form the VAR domain.  
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Fig.5.2: X-ray crystallography of SecA2. (A) Purified and concentrated samples of SecA1 and SecA2 were 
used in four different 96-well crystallisation screens. Although no crystal growth was recorded for SecA1, 
five different conditions resulted in SecA2 crystal growth. Of these conditions the best were PACT B10 
(0.2 M magnesium chloride, 0.1 M MES pH 6.0, 20 % w/v PEG 6000) and C10 (0.2 M magnesium chloride 
0.1 M HEPES pH 7.0, 20 % w/v PEG 6000). Using these crystals, diffraction data was collected to 
approximately 3.3 Å. Analysis of diffraction data was performed by Dr Paula Salgardo (The University of 
Newcastle). Optimisation of crystal growth was performed, including the addition of either AMP-PNP or 
ADP. Diffraction data was collected for three SecA2 isoforms. The most complete structure with the 
highest resolution resulting from these data was SecA2-ADP, however further refinement is required. (B) 
Although the model fits in the electron density map well in most areas, (C) other areas are poorly 
modelled. This may be due to bias introduced by using the Thermotoga maritima SecA structure for 
molecular replacement. (D) M. tuberculosis is the only organism to date for which the structures of both 
SecA1 and SecA2 have been resolved (Sharma et al., 2003; Swanson et al., 2015).The C. difficile SecA2 
structure clearly contains the domains associated with SecA proteins; the walker box containing NBD1 
(blue), NBD1 (cyan), PPXD (magenta), HSD (green), HWD (yellow), and IRA1 (orange). The two helices that 
form the VAR domain, absent in SecA2, are labelled (black arrows). Images were created using PyMOL 
molecular graphics system. SecA1 structural data was obtained from the protein data bank. PBD ID1NKT. 
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5.2.2 SecA2 Interacts with Members of the CWP family and Cell Wall 
Synthesis Machinery 
SecA2K106, a mutant variant of the protein unable to hydrolyse ATP (Fagan and 
Fairweather, 2011), was purified as before. However, SDS-PAGE analysis of purified Strep-tagged 
SecA2K106R showed many protein contaminants in the sample. (Fig.5.3A). Protein samples 
were analysed via western blots, using anti-strep tag and anti-LMW SLP antibodies (Fig.5.3B). 
Strep-tagged SecA2K106R and the major SecA2 substrate, SlpA, were identified in the sample. 
As SecA2K106R is unable to hydrolyse ATP, it is likely trapped in the secretion complex, bound 
to its substrate and other proteins involved in secretion. The contaminating protein bands were 
therefore hypothesised to be SecA2 interacting proteins.   
Peptide mass fingerprinting was used to identify the potential SecA2 binding partners. 
Mass spectrometry was performed by Dr Richard Beniston (The University of Sheffield BioMicS 
facility). Proteins of interest that were identified in the protein sample included eight members 
of the Cell Wall Protein family including the known SecA2 substrates SlpA and CwpV, SecA1, and 
the cell wall synthesis machinery; MreB2, MreB1, and FtsZ. Although this experiment proved 
useful for identifying potential SecA2 binding partners, it is worth noting that there seemed to 
be cross contamination between samples, likely due to insufficient washing between each 
analysis. 
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Fig.5.3: Pull down assay identifying SecA2 interacting proteins. (A) SecA2K106 was purified using Strep-
tag affinity chromatography. Protein containing fractions were pooled and analysed using SDS-PAGE. 
When SecA2 is purified in this manner, the resulting protein solution is very pure. SecA2K106R 
preparations however, contain many contaminating proteins. (B) Western blot analysis of the SecA2K106 
preparations confirms the presence of Strep-tagged SecA2K106R and SlpA (LMW SLP), the major substrate 
of SecA2. 
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5.2.3 MreB2 and SecA2 secretion 
5.2.3.1 SecA2 Interaction Experiments 
To investigate the potential interaction between SecA2 and the MreB proteins, bacterial two-
hybrid experiments were performed. Interaction between T18-tagged bait proteins and T25-
tagged prey protein results in functional complementation of adenylate cyclase (Karimova et al., 
1998). Co-expression of these proteins in an E. coli strain that lacks an endogenous adenylate 
cyclase and contains a cAMP responsive lacZ, results in blue colonies when grown in the 
presence of X-gal. Proteins were N and C terminally tagged with either the T18 or T25 fragments 
of CyaA. mreB1 and mreB2 were amplified using primer pairs RF200/RF201 and RF196/RF197 
respectively, and cloned into pUT18 between KpnI and XbaI. secA1 and secA2 were amplified 
using primer pairs RF194/RF195 and RF192/RF193 respectively, and cloned into pKNT25 and 
pKT25 between KpnI and XbaI. No interaction was observed between SecA1 or SecA2 with 
MreB1 or MreB2 using this method (data not shown).  
A similar experiment was performed using split-SNAP. This method involves tagging proteins 
with the N (nSNAP) or C (cSNAP) terminal half of SNAP, a variant of human O6-alkylguanine-DNA-
alkyltransferase that binds to a small fluorescent substrate. Interaction between cSNAP and 
nSNAP-tagged proteins results in complementation of SNAP, enabling binding of the fluorescent 
marker (Mie et al., 2016). This method was chosen as it can be performed in C. difficile. This is 
beneficial as SecA2 may only bind to MreB when bound to its substrate, SlpA, not present in E. 
coli. pRPF150 encodes an N-terminally Strep-tagged SecA2. This plasmid was linearised using 
primer pair NF1957/NF1958 and ligated, to introduce an XhoI site between secA2 and the strep-
tag, resulting in pJAK012. SNAP was amplified from pFT46 using primer pair RF208/RF209 and 
was introduced into pJAK012 between SacI and XhoI, resulting in pJAK013. Primer pair 
RF430/RF431 was used to amplify a 1.2 kb fragment, upstream of the secA2 start codon, from 
630 gDNA. Primer pair RF432/RF433 was used to amplify a 1.7 kb fragment from pJAK013 
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containing the SNAP tag coding sequence and 1.2kb downstream of the secA2 start codon. These 
fragments were ligated into pMTLSC7315 using Gibson assembly. The resulting plasmid, 
pJAK047, was used to N-terminally SNAP tag chromosomal secA2 (described below). To generate 
n-SNAP-secA2, cSNAP was deleted from pJAK047 by inverse PCR using RF464/RF466. The 
resulting plasmid, pJAK052, was used to insert nSNAP into the 5’ end of chromosomal secA2 via 
allele exchange mutagenesis. Expression of cSNAP fused prey proteins was induced in this strain 
(630 nSNAP-secA2) from plasmids. SNAP functional complementation was investigated using 
epifluorescence microscopy and in-gel fluorescence analysis (performed by Alice Lanne, 
personal communication). Again, no interaction was observed between SecA1 or SecA2 and 
MreB1 or MreB2 (data not shown). However, this method also failed to demonstrate an 
interaction between nSNAP-SecA2 and cSNAP-SecY suggesting that this method may not be 
suitable for investigating SecA2 protein-protein interaction (data not shown).  
5.2.3.2 Creation of a Conditional MreB2 C. difficile 
As direct interaction between SecA2 and MreB2 was not observed using the above 
methods, the effect of MreB perturbation on SlpA secretion was investigated. Creation of an 
mreB2 conditional lethal C. difficile strain was attempted. mreB2, under control of a tetracycline 
inducible promoter, was inserted into the pyrE locus using allele exchange mutagenesis (Fig.5.4A 
and B). Attempts to knock-out the native mreB2 were then performed in the resulting strain, 
630 pyrE::Ptet-mreB2. However, despite numerous attempts a successful knock-out mutant was 
not isolated.  
5.2.3.3 A22 Treatment affects SlpA secretion 
A more indirect route to study the role of MreB in SlpA secretion was performed using 
A22. A22 is a small MreB perturbing compound that interacts with the MreB nucleotide-binding 
pocket, preventing ATP binding and MreB polymerisation (Bean et al., 2009). A22 was added to 
exponentially growing cultures of 630 and its effect on SlpA secretion was investigated 
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(performed by Alice Lanne, personal communication). Western blot analysis revealed an 
increase in the concentration of intracellular, unprocessed SlpA in the presence of A22 (Fig.5.4C), 
suggesting that MreB perturbation inhibits SlpA secretion. Interestingly, an increase in 
intracellular processed SlpA was also observed which suggests that Cwp84, the protease 
responsible for SlpA cleavage, is also secreted by SecA2. 
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Fig.5.4: Investigating the role of MreB2 in SecA2 dependent secretion. (A) To investigate MreB2’s role in 
SecA2 secretion, creation of a conditional lethal 630 strain was attempted. 1.2 kb upstream and 
downstream of the non-coding region downstream of pyrE were amplified from 630 gDNA using primer 
pairs RF837/RF838 and RF841/RF842. mreB2 under control of a tetracycline inducible promotor was 
amplified from pAMBL019 using RF839/RF840. These three fragments were inserted into PCR linearised 
pMTLSC7315 by Gibson assembly. The resulting plasmid, pJAK080, was conjugated into 630 and allele 
exchange mutagenesis performed. (B) Mutants were screened via PCR using RF874/RF863. An increase in 
size of approximately 2 kb confirmed insertion of the conditional mreB2 in the pyrE locus. Deletion of the 
native mreB2 in the resulting strain was attempted, to create a conditional lethal strain. However, we 
failed to isolated a successful deletion mutant. Without a conditional-lethal mutant, more indirect 
methods for investigating the role of MreB2 in SecA2 dependent secretion were used. (C) 630 was grown 
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to approximately OD600nm 0.6 and A22 (400 µg/ml) was added to the culture. After 1 h incubation, cells 
were treated with low pH glycine to remove the S-layer, then washed, and lysed. Cell lysates were then 
used in western blot analysis using anti-LMW SLP antibodies (performed by Alice Lanne, data 
unpublished). Bands corresponding to the Cwp84-processed and unprocessed SlpA are labelled.  
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5.2.4 Localisation of SecA2 Secretion 
5.2.4.1 SNAP and CLIP-Tagged SecA2 and SecA1 
We hypothesised that SecA2-dependent secretion is localised to particular areas of the 
cell. To test this, SecA1 and SecA2 were tagged with fluorescent reporters and localisation of 
these proteins was investigated microscopically.  
To determine the effect of tagging SecA2 on its function, N and C terminally tagged 
SecA2 was constitutively expressed in a conditional lethal 630 strain (630 Ptet-secA2). Although 
C-terminally tagged SecA2 did not fully restore growth in the mutant strain when grown without 
Atc, N-terminally tagged SecA2 did (data not shown). Due to the lack of a conditional-lethal 
secA1 strain in which to test tagged protein function, N-terminal tagging was chosen for both 
proteins. Allele exchange mutagenesis was performed to add SNAP and CLIP to the 5’ end of 
secA2 and secA1 on the chromosome respectively (Fig.5.5A and B), although mutants were 
difficult to isolate. These mutants grew normally in TY broth, 630 SNAP-secA2 did show 
abnormal growth on solid media, growing as a mixture of large and small colonies.  
Brightfield and epifluorescence microscopy was performed using these mutants. The 
morphology of 630 SNAP-secA2 appeared normal and, although there was a strong signal from 
SNAP-SecA2, the protein did not seem to show any organised localisation (Fig.5.6). Cells of 630 
CLIP-secA1 however, formed long chains and little signal was observed from CLIP-SecA1. As 630 
SNAP-secA2 showed abnormal growth on agar and 630 CLIP-secA1 showed altered cell 
morphology, tagged SecA1 and SecA2 may be only partially functional.  
  
 Chapter V. SecA2 and Biogenesis of the S-layer 
 159 
 
 
Fig.5.5: Creation of 630 SNAP-secA2 and 630 CLIP-secA1. (A) secA1 was amplified using primer pair 
RF234/RF235 and inserted into pJAK013 via the XhoI and BamHI restriction sites, resulting in pJAK015. C. 
difficile codon optimised CLIP tag (Integrated DNA Technologies) was amplified using primer pair 
RF226/RF227 and inserted into pJAK015 via the SacI and XhoI restriction sites, resulting in pJAK034. 1.7 
kb, containing the CLIP tag and 1.2 kb of the secA1 ORF, was amplified using RF436/RF437. 1.2 kb 
upstream of secA1 was amplified using RF434/RF435. These fragments were assembled into RF311/RF312 
linearised pMTLSC7315 using Gibson assembly. The resulting plasmid, pJAK049, and pJAK047 were used 
to add CLIP and SNAP with triple alanine linkers, to the chromosomal secA1 and secA2, respectively, by 
allele exchange mutagenesis. (B) An increase of approximately 600 bp when analysed by PCR, using 
primers flanking the insert site, confirms successful insertion of the tags into the chromosome. 
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Fig.5.6: Microscopic analysis of SecA1 and SecA2 localisation. Brightfield and fluorescence microscopic 
analysis was performed using 630 SNAP-secA2 and 630 CLIP-secA1, which revealed that although the 
cellular morphology of 630 SNAP-secA2 appeared normal, 630 CLIP-secA1 formed long chains. In addition, 
the signal from CLIP-SecA1 was very weak. SNAP-SecA2 however gave very strong signal, although no 
organised protein localisation was observed.   
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5.2.4.3 S-layer Biogenesis Co-localises to Areas of Cell Wall Synthesis 
Although localisation studies focusing on the SecA proteins have resulted in non-
conclusive results, the localisation of newly synthesised SlpA proved to be an easier target for 
study. 
 To determine if SlpA biogenesis is localised to areas of cell wall synthesis as 
hypothesised, a fluorescently labelled D-amino acid (HADA) was employed (Kuru et al., 2015). 
Growing C. difficile in the presence of HADA results in saturation of the cell wall with this 
fluorescent marker. When cells are washed of excess HADA and allowed to grow for 30 min, 
areas of newly synthesised cell wall are non-fluorescent (Fig.5.7A). pSEW027, a plasmid bearing 
SLCT-7 slpA under control of a tetracycline inducible promoter, was introduced into R20291. As 
the LMW SLP is variable amongst strains, antibodies against these subunits show high specificity. 
When induced for 5 minutes with Atc, newly secreted SLCT-7 SlpA was visualised using 
immunofluorescence microscopy, which resulted in punctate staining of the cell (Fig.5.7B).  
Combination of these staining methods revealed co-localisation of cell wall synthesis 
with S-layer biogenesis. However, immunostaining of the cells was not efficient and further 
optimisation of this experiment is required to validate the results obtained. 
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Fig.5.7: Co-localisation of cell wall synthesis and S-layer biogenesis. (A) Incubation of growing cultures 
of C. difficile with the fluorescently labelled D-amino acid HADA resulted in saturation of the cell wall with 
this fluorescent marker. These cells were then washed and allowed to grow for a further 30 minutes. 
Areas of new cell wall growth appeared dark, this was especially apparent at new septa. (B) 
R20291/pSEW027 was treated with HADA as described. 5 min prior to harvesting, SLCT-7 SlpA expression 
was induced using 100 ng/ml Atc. Harvested cells were fixed and immunostained using an anti SLCT-7 
antibody. Newly created septa (white arrows) were obvious in the HADA images which also seemed to 
contain large amounts of newly secreted SLCT-7 SlpA, suggesting that cell wall synthesis and S-layer 
biogenesis are co-localised.  
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5.3 Discussion 
As with many elements of C. difficile physiology, SecA2-dependent secretion and S-layer 
biogenesis are poorly understood. Using a combination of structural biology, microscopy, and 
biochemical analysis we have taken the first steps towards understanding the function of SecA2 
and its role in S-layer biogenesis.  
Over-expression of SecA2 and SecA1 in C. difficile allowed isolation of very pure samples 
of these proteins using a simple one-step affinity chromatography protocol. This also allowed 
isolation of these proteins from a native expression system. Although we were unable to 
crystallise SecA1, we have now solved the crystal structure of SecA2 in its holo and apo forms, 
the highest resolution structure being the ADP-bound form. When compared to SecA from other 
organisms, including M. tuberculosis for which both the SecA1 and SecA2 structures are known, 
SecA2 shares all structural features expected for a SecA protein, including the HWD, HSD, IRA1, 
HSD, DEAD box motor domain composed of NBD1 and NBD2, and PPXD domains although it 
lacks a CTD. In addition, NBD2 is truncated, lacking the pair of alpha helices that compose the 
VAR subdomain of other SecA proteins. The VAR domain forms a cap on the nucleotide binding 
site, suggesting that the nucleotide binding motif of SecA2 is more solvent-exposed. The VAR 
domain modulates the function of the DEAD motor box, loss of which results in rapid ADP 
dissociation and increased ATPase activity (Das et al., 2012). The PPXD of SecA2 is also rotated 
towards NBD2 relative to the positioning of the MtbSecA1 PPXD. A similar lack of the VAR and 
C-terminal domains, and a shift in the positioning of the PPXD have also been observed for SecA2 
from Mycobacterium tuberculosis (Swanson et al., 2015). These features may therefore be 
common characteristics of SecA2 proteins and may provide some insight into SecA2 function 
and specificity. However, as our model still requires refinement, the structure reported here is 
likely to change upon further scrutiny.  
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The purpose of having two independently functioning SecA proteins is not understood. 
As SecA2 likely uses the canonical SecY (Fagan and Fairweather, 2011), it is unlikely that the 
additional SecA is required to prevent saturation of the Sec secretion pathway with the highly 
abundant substrate SlpA. It is therefore logical to hypothesis that SecA2 is required for localised 
secretion of a small subset of proteins. The pull-down experiment using SecA2K106R supports 
this hypothesis. When this protein, unable to hydrolyse ATP, was isolated, several proteins were 
co-purified. This included the cell wall synthesis machinery MreB1, MreB2 and FtsZ. These 
experiments have since been repeated using both SecA2K106R and SecA1K106R (Peter Oatley, 
personal communication). FtsZ and MreB2 were only co-purified with SecA2K106, MreB1 was 
not identified. Tagged MreB has been reported to show abnormal behaviour in many studies, 
the most famous of which demonstrated that YFP-MreB mis-localises in E. coli (Margolin, 2012).  
It also appears that the N-terminal tags applied to C. difficile SecA proteins in this study result in 
partial loss of function. This may explain the failure of the split-SNAP and bacterial two-hybrid 
experiments to demonstrate an interaction between either MreB1 or MreB2 with SecA2. In vitro 
binding experiments such as thermophoresis or isothermal titration calorimetry may therefore 
be more suitable for studying the interactions between these proteins. Although split-SNAP and 
bacterial two-hybrid experiments failed to demonstrate an interaction between SecA2 and 
MreB2, A22 perturbation of the MreB cytoskeleton did inhibit SlpA secretion, suggesting MreB 
is involved in SecA2-dependent secretion. However, A22 is known to cause MreB-independent 
toxicity (Karczmarek et al., 2007) and the inhibition of SlpA synthesis cannot, therefore, 
conclusively be linked to MreB perturbation. A conditional-lethal MreB strain would be ideal to 
study the effect of MreB perturbation on SlpA secretion. Although attempts to create this 
mutant were unsuccessful, insertion of the entire operon containing MreB, under control of an 
inducible promoter, into the pyrE locus may be necessary to facilitate deletion of the native 
mreB2. Although localisation of SecA2 and SecA1 could not be directly observed, through a 
combination of immunofluorescence and HADA labelling of the cell wall, we have shown co-
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localisation of cell wall synthesis and S-layer biogenesis. However, immunostaining of SlpA was 
not optimal and further study is necessary to validate these experiments.  
In addition to the cell wall synthesis machinery, several members of the Cell Wall Protein 
family were also identified in the pull-down samples, including the only confirmed SecA2 
substrates, SlpA and CwpV (Fagan and Fairweather, 2011). SecA2 dependent secretion may 
therefore be a characteristic of members of this protein family, or a small subset. Experiments 
performed by Peter Oatley also identified Cwp2 and Cwp6 in later SecA2K106R samples 
(personal communication). The presence of intracellular, processed SlpA in A22 treated samples 
may also suggests Cwp84 secretion is SecA2 dependent. 
Work presented here represents a huge step in understanding the role of SecA2 and the 
mechanisms behind its specificity. The structure of SecA2, although requiring further 
refinement, is one of only two SecA2 structures reported to date and may provide insights into 
SecA2 function. This is also the first instance of the cell wall machinery being implicated in S-
layer biogenesis, and further study will hopefully confirm this hypothesis.   
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Chapter VI 
Discussion 
The S-layer of C. difficile completely encases the cell and its protein constituents 
represent approximately 15% of the total protein content of the cell. It is therefore likely that S-
layer biogenesis is associated with a high metabolic cost and it likely provides vital functions to 
the cell, especially as this structure is essential for C. difficile growth in vitro (Dembek et al., 
2015). Exposing cultures of C. difficile to excess Avidocin-CD allowed the isolation of 
spontaneous mutants lacking a functional S-layer. The S-layer mutants and subsequent 
revertant strains have provided a unique opportunity to study the function of the C. difficile S-
layer, showing the complex to be multi-functional (Fig.6.1). The properties of these mutants 
allowing their growth, whilst lacking a gene essential for growth in wild-type strains, remain 
elusive. It is likely, however, that these mutants contain suppressor mutations in their genome 
to allow their growth. The genome sequence of FM2.5 revealed several differences compared 
to the wild-type. Although many of these differences occur in genes of unknown function, a 
substitution within codY results in a change in the primary sequence of the resulting protein. 
CodY is a regulatory protein that regulates expression of toxins, sporulation and metabolism 
(Dineen et al., 2010; Nawrocki et al., 2016). This is a particularly interesting observation as we 
have demonstrated that FM2.5 has diminished ability to sporulate and produce toxins. However, 
as FM2.5RW does not show diminished sporulation or toxin production and likely contains the 
same mutation in codY, the phenotypes observed in FM2.5 are unlikely to be due to codY. 
Avidocin-CDs use the S-layer as a binding receptor. As these structures are created using 
bacteriophage RBPs mined from the genomes of C. difficile, we have also shown that the S-layer 
acts as a receptor for bacteriophage binding. These findings suggest that antigenic variation of 
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SLCTs is largely due to selective pressure from bacteriophage predation rather than evasion of 
the host immune system and may help determine the host-range of C. difficile bacteriophage 
(Nale et al., 2016). 
FM2.5 is avirulent in the hamster model of infection, likely due to decreased toxin 
production. Surprisingly FM2.5 was still able to persist in the gut, right up to the experimental 
end-point 14 days after initial infection. This observation suggests that SlpA does not function 
as a colonisation factor as previously suggested (Merrigan et al., 2013). Alternatively, the 
presence of several adhesins on the cell surface may represent functional redundancy, meaning 
loss of one adhesin form the surface may not result in loss of adherence to the host. FM2.5 is 
also able to persist in the gut despite showing increased sensitivity to killing by innate immune 
effectors such as LL-37 and lysozyme. LL-37 is present in the gut, being secreted by immune cells 
and gut epithelial cells, at concentrations of up to 5 µg/ml. This may be further increased in 
response to infection (Bowdish et al., 2005). Infection with FM2.5 also did not result in any 
symptoms of C. difficile disease. Taken together, these observations suggest that FM2.5 is 
unable to stimulate an immune response. As toxins can stimulate the immune system, causing 
release of inflammatory cytokines (Shen, 2012), the toxin synthesis defect displayed by FM2.5 
will likely prevent host immune activation. SlpA is also able to stimulate the immune response 
via TLR4 (Ryan et al., 2011). Perhaps, therefore, loss of toxin production and/or SlpA loss is 
sufficient to prevent the excessive activation of the host immune system that characterises 
severe C. difficile infection.  
Although it is difficult to speculate on the exact causes, FM2.5 shows significantly 
reduced sporulation rates. As the spore acts as the transmissive agent, it is likely that FM2.5 will 
show lower transmission rates, although this needs to be confirmed experimentally. As FM2.5 
is avirulent, and has lower sporulation rates, it represents little clinical threat. This highlights the 
promise Avidocin-CDs show as treatment for CDI, as C. difficile must trade virulence for 
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resistance to these agents. As Avidocin-CDs have been shown to not affect the composition of 
the microbiota, the use of these agents as either prophylactics or treatment would allow the 
recovery of the microbiota from previous damage (Gebhart et al., 2015). It is unlikely that 
resistant mutants such as FM2.5 would be able to persist in the gut in the presence of a healthy 
microbiota, although this would be interesting to investigate experimentally. In addition, we 
have demonstrated that killing of C. difficile with Avidocin-CDs does not results in the release of 
intracellular toxin in vitro. This is an important observation as treatments that result in the 
release of toxin may exacerbate disease symptoms. However, as Avidocin-CDs kill C. difficile in 
a strain-specific manner, depending on the SLCT of the strain, treatment using these compounds 
poses a serious problem. To be effective treatments, either the SLCT of the infecting strain must 
be known, or a cocktail of different Avidocin-CDs covering all SLCTs must be administered. This 
highlights the need to develop Avidocin-CDs that target SLCT-3 and SLCT-5, which we currently 
lack. Ideally a broad range RBP would be used that interacts with all SLCTs, although due to the 
variation between SLCTs, discovery of such a RBP seems unlikely.  
The isolation of FM2.5 also presents a unique opportunity to study the contributions of 
the different SLCTs to virulence. Although we have demonstrated that manipulation of the 
native slpA locus is difficult, further understanding of the slpA promotor region and SlpA 
expression may enable insertion of slpA under control of its native promotor into the pyrE locus 
of FM2.5, allowing deletion of the native slpA. This would allow insertion of any of the SLCT slpA 
into the genome of FM2.5, resulting in a library of isogenic strains expressing different SlpAs at 
native levels. This method would also allow the insertion of mutant variants of slpA which would 
allow us to study the contributions of the different components of the SlpA complex to virulence 
and its other functions. 
Indeed, one mutant, whose creation would likely have not been possible without the 
isolation of FM2.5, allowed further insight into the mechanisms behind S-layer-dependent 
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resistance to lysozyme and LL-37. FM2.5RΔD2, presumed to contain an S-layer with larger pores 
than usual, shows increased sensitivity to lysozyme relative to wild-type but is resistant to LL-
37. As lysozyme is so large, it is possible that the S-layer excludes this enzyme by acting as a 
physical barrier; the S-layer may not contain pores large enough for passage to the cell wall. 
Increasing the pore size of the S-layer may therefore allow lysozyme to pass through the S-layer. 
LL-37 on the other hand is a very small peptide. It is unlikely that the S-layer can exclude this 
molecule simply through size exclusion. It is more likely that, as with the LPS of Gram-negative 
bacteria, the S-layer is able to sequester this cationic peptide at the cell surface via ionic 
interactions. Increasing the pore size of the S-layer would therefore have little to no effect on 
the sensitivity of the cell to LL-37. It would be interesting to determine if overexpression of one 
of the CWPs, such as CwpV, could functionally complement the loss of SlpA in FM2.5 for 
resistance to innate immune effectors.  
We have also demonstrated that SlpA contributes to the regulation of CwpV expression 
as FM2.5, but not FM2.5RW, shows increased CwpV expression due to larger proportion of the 
population containing the cwpV switch in the ON orientation. CwpV expression does not result 
in a growth benefit to FM2.5, which would otherwise result in higher proportions of CwpV ON 
cells within a population. These results suggest that CwpV expression is regulated by SlpA. It 
seems unlikely that extracellular SlpA could regulate phase switching and so I propose that 
intracellular SlpA down-regulates expression either through interaction with RecV or indirectly.  
In addition to allowing investigation of S-layer function, isolation of FM2.5 and 
sequencing of its genome led to the identification of two additional RecV-dependent phase 
variable regions. One of these regions was upstream of CDR20291_1514, and has been 
previously suggested to be phase variable. CDR20291_1514 encodes a c-di-GMP PDE which 
controls the turnover of the nucleotide secondary messenger, c-di-GMP, and its expression has 
previously been shown to increase motility in strain 630 (CD630_1616) (Bordeleau et al., 2011). 
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The phase variable region upstream of CDR20291_3128 has not been previously described. 
CDR20291_3128 is the first gene in an operon that encodes a histidine sensor kinase and two 
response regulators likely to form a three-component regulatory system. Although the function 
of this three-component system is unknown, its expression seems to affect colony morphology 
of C. difficile. Experiments to determine the effect of expression of this operon on colony 
morphology are required to confirm this hypothesis. However, colony morphology is often 
associated with changes in motility. CwpV expression causes aggregation (Reynolds et al., 2011), 
expression of the flgB operon is essential for motility (Anjuwon-Foster and Tamayo, 2017), and 
c-di-GMP is a secondary messenger that regulates motility and aggregation (Purcell et al., 2012). 
Therefore, we hypothesis that RecV-dependent phase variation is involved in the regulation of 
genes responsible for switching from sessile to motile lifestyles in C. difficile. During infection C. 
difficile switches from a motile to a surface adherent state, and it would be interesting to 
determine whether RecV-dependent phase variation is involved in this change and if RecV 
activity is affected by c-di-GMP. 
Another interesting question posed by the identification of these additional phase 
variable regions is how RecV recognises their different inverted repeats and why their regulation 
is different. One possibility is the presence of specific co-factors required for RecV activity. Pull 
down experiments using RecV may be used to identify RecV binding partners. 
As the S-layer is bound to the cell wall, growth of the cell wall would result in the 
formation of gaps in the S-layer which could potentially be fatal to the cell as this structure is 
essential for growth (Dembek et al., 2015). We propose a new model for S-layer biosynthesis in 
which interaction of SecA2 with MreB or FtsZ localises SecA2-dependent secretion, and 
therefore S-layer biogenesis, to areas of peptidoglycan growth (Fig.6.1). This localisation of S-
layer biogenesis was observed microscopically. Further optimisation of these experiments and 
utilisation of super-resolution methodologies will allow more accurate observations of S-layer 
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growth in situ. Investigation of the localisation of SecA1 secretion was not performed and 
secretion of SecA1 substrates may also be localised to areas of cell wall growth, as these areas 
have transient gaps in the S-layer. This may be required for large secreted proteins to pass 
through the S-layer. 
We were unable to show direct interaction between SecA2 and MreB or FtsZ of the cell 
wall synthesis machinery. This may be due to the methods employed to investigate these 
interactions which are dependent on tagging the proteins of interest which can result in loss of 
function or cause steric hindrance at the interaction interfaces. In vitro investigation into the 
interactions between SecA2 and its binding partners may therefore be better suited.  
Using X-ray crystallography, we have also created a 3D model of SecA2, the second 
SecA2 structure to date (Swanson et al., 2015). Interestingly, this structure demonstrated 
structural difference to MtbSecA1, similar to MtbSecA2, including loss of the VAR domain and a 
spatial rearrangement of the PPXD domain. However, unlike MtbSecA2, the SecA2 of C. difficile 
does contain a HWD. Although the significance of these changes are not understood, it is likely 
that they contribute to the specificity of these proteins for their substrates. 
In conclusion, we have now identified several functions of the S-layer including 
sporulation, toxin production, virulence, and growth. In addition, we also propose a new model 
for SecA2 dependent secretion, which may be a characteristic of members of the CWP family, in 
which its secretion is localised to areas of new peptidoglycan synthesis.   
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Fig.6.1: Biogenesis and function of the C. difficile S-layer. The S-layer is the receptor for binding of 
Avidocin-CDs and some bacteriophages, and its loss results in resistance to Avidocin-CDs. The S-layer also 
provides resistance to the innate immune effectors LL-37 and lysozyme. The mechanisms behind these 
resistances are unclear but are likely due to size exclusion and sequestering the antimicrobials at the cell 
surface. Loss of SlpA results in diminished sporulation efficiency, toxin production, altered growth and 
increased CwpV expression. The reasons for these observed phenotypes are unknown. SlpA is secreted 
by the accessory secretion pathway. This secretion is localised to areas of cell wall growth (light grey area) 
via interaction of SecA2, for which the structure is now known, with the cell wall synthesis machinery 
MreB and FtsZ. The S-layer is attached to the cell wall and is assembled in the gaps formed by cell wall 
growth. 
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Appendix I 
Table A1: Bacterial strains used in this study 
C. difficile 
Strain Description Source 
R20291 Ribotype 027 strain responsible for 
the 2004 Stoke-Mandeville outbreak. 
(Stabler et al., 2009) 
R20291 recV::erm cwpV ON R20291 containing a ClosTroin 
inactivated recV, with the cwpV 
switch locked in the ON orientation. 
(Sekulovic et al., 
2015) 
R20291 recV::erm cwpV OFF R20291 containing a ClosTroin 
inactivated recV, with the cwpV 
switch locked in the OFF orientation. 
(Sekulovic et al., 
2015) 
FM2.5 Spontaneous mutant resistant to 
killing by Avidocin-CDs. This strain 
contains a single base insertion early 
in the slpA gene resulting in a frame 
shift and loss of slpA function. 
AvidBiotics 
FM2.5RW FM2.5 in which a functional copy of 
slpA, containing a silent mutation, has 
been returned to the chromosome. 
This study 
FM2.5 recV::erm cwpV ON FM2.5 containing a ClosTroin 
inactivated recV, with the cwpV 
switch locked in the ON orientation. 
This study 
FM2.5 recV::erm cwpV OFF FM2.5 containing a ClosTroin 
inactivated recV, with the cwpV 
switch locked in the OFF orientation. 
This study 
FM2.5RW recV::erm cwpV 
ON 
FM2.5RW containing a ClosTroin 
inactivated recV, with the cwpV 
switch locked in the ON orientation. 
This study 
FM2.5RW recV::erm cwpV 
OFF 
FM2.5RW containing a ClosTroin 
inactivated recV, with the cwpV 
switch locked in the OFF orientation. 
This study 
FM2.5RΔD2 FM2.5 in which a functional copy of 
slpA, in which the coding region for 
the domain 2 of the LMW subunit has 
been deleted, has been returned to 
the chromosome. 
(Oishik Banerji, 2017) 
FM2.6 Spontaneous mutant resistant to 
killing by Avidocin-CDs. This strain 
contains a single base substitution 
early in the slpA gene resulting in a 
stop codon and loss of slpA function. 
AvidBiotics 
FM2.6RW FM2.6 in which a functional copy of 
slpA, containing a silent mutation, has 
been returned to the chromosome. 
This study 
630 Isolated from the stool of a healthy 
infant during an outbreak in Zurich. 
(Wüst et al., 1982) 
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630 pyrE:: Ptet-mreB2 630 in which mreB2 under control of 
a tetracycline inducible promotor has 
been inserted into the pyrE locus on 
the chromosome. 
This study 
E. coli strains 
NEB-5α Chemically competent cells 
used for routine cloning and 
plasmid propagation.  
New England Biolabs 
CA434 Strain HB101 carrying 
the IncPβ conjugative 
plasmid, R702. Used as a 
conjugation donor.  
(Purdy et al., 2002) 
Top10 Chemically competent cells 
used for routine cloning and 
plasmid propagation. 
Lab stock 
 
Appendix II 
Table A2: Primers used in this study 
Name Sequence 5’-3’ Restriction 
site 
NF823 GCATTTTTCCATCCATCTTG  
NF825 TTTAAGGTAAGTTTGATTTTTATGTTAATGAAT  
NF826 ATTCATTAACATAAAAATCAAACTTACCTTAAA  
NF863 GTAAAAAGAGTAGCACTTTTAATTCTAAAGG  
NF1215 CTTAATCACATATATCACACTTGTATAAGTTTACTGG  
NF1957 GAGTCAGTTATAGATTCGATACTTGAC  
NF1958 GAGTTTTTCAAATTGTGGATGACTCCAC  
RF21 GGATTTCACATTTGCCGTTTTGTAAAC  
RF22 GATCTTTTCTACGGGGTCTGAC  
RF33 GGCTTCTATAGCTTGGTGAA  
RF110 GACATAACTGCAGCACTACTTG  
RF111 CAGGATTAACAGTATTAGCTTCTGC  
RF192 GATCTCTAGAGATGTCAGTTATAGATTCGATACTTGAC XbaI 
RF193 GATCGGTACCGCGTTAAATTTATATAAGTATTGCACTGTTGC KpnI 
RF194 GATCTCTAGAGATGAGCTTTATGGATAATTTATTCAACATG XbaI 
RF195 GATC GGTACCGCTCTTCCACAACAGTTTTTATATTTTTTACC KpnI 
RF196 GATCTCTAGAGATGGCTAAGGAAAAAAAGAAAGAAAAAAAAG XbaI 
RF197 GATCGGTACCGCATTCTTAGTATTCATCATTAATACTTTTTC KpnI 
RF200 GATCTCTAGAGATGGCTGGAGCTGATATAGG XbaI 
RF201 GATCGGTACCGCTTTTCTTTTGAAAGACCCACCAG KpnI 
RF208 GATCGAGCTCGGAGGAACTACTATGG SacI 
RF209 GATC CTCGAGAGCAGCTGCCCCAAGTCCTGGTTTCCCCAAAC XhoI 
RF226 GATCGAGCTCGGAGGAACTACTATGGATAAAGATTGTGAAATGAA
AAG 
SacI 
RF227 GATCCTCGAGAGCAGCTGC TCCTAATCCTGGTTTTCCTAATC XhoI 
RF234 GATCCTCGAGAGCTTTATGGATAATTTATTCAACATGG XhoI 
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RF235 GATCGGATCCGCCATCTGCTCCATACTATGTTTATAC BamHI 
RF311 TAGGGTAACAAAAAACACCG 
RF312 CCTTTTTGATAATCTCATGACC 
RF430 CGTAGAAATACGGTGTTTTTTGTTACCCTAGTAGTAAATATTATAAT
TCTGATGATAAAAATG 
RF431 ACAATCTTTATCCATATAAGTACCTCCTTTTCTATTGTC 
RF432 AAAGGAGGTACTTATATGGATAAAGATTGTGAAATG 
RF433 GGGATTTTGGTCATGAGATTATCAAAAAGGAATCAGCTCTAATAAC
TGGTCTATTAG 
RF434 CGTAGAAATACGGTGTTTTTTGTTACCCTAAGTAAGTTAATTATAAT
TTGGGTATATG 
RF435 ACAATCTTTATCCATATTTTACATCTCTCCTCGTTC 
RF436 GGAGAGATGTAAAATATGGATAAAGATTGTGAAATG 
RF437 GGGATTTTGGTCATGAGATTATCAAAAAGGTAAGTCTTCCCTTATCA
TAAGC 
RF438 CATTAATAGCTTGCTGAGTTACTCTTATATATCGC 
RF464 TTGTTGAAATACAGGATGGTGAAG 
RF466 GCAGCTGCTCTCGAGTCAG 
RF655 CGTAGAAATACGGTGTTTTTTGTTACCCTATAGTGATAAGTCTGTAC
TTAGAAGTGC 
RF656 ATTTTTCTTATTCATTTCTTAAATTCCTCCCAAC 
RF658 ATTATATTTATATTACATATCTAATAAATCTTTCATTTTGTTTATAAC 
RF659 GATTTATTAGATATGTAATATAAATATAATAATATAAAAAGGCTTC 
RF660 GGGATTTTGGTCATGAGATTATCAAAAAGGTTTCTATCCATCTCAAA
GTCTTC 
RF750 CGTAGAAATACGGTGTTTTTTGTTACCCTAATGAATAAGAAAAATAT
AGCAATAGC 
RF779 CGTAGAAATACGGTGTTTTTTGTTACCCTATTATAGAGATGTGAGAA
ATATTAGGAATATATG 
RF780 AACTACAGTATAACCTTGTGTTCCAGTAGTTGCTGCAAACACAGGT
GC 
RF798 GATCGTTTAAACCAAACAGAGTTATAAAACCTATGGAAAGG PmeI 
RF799 GATCGTTTAAACCTTCTTTAACCTCACTAGTTGGCTTAAAG PmeI 
RF826 GGTTATCAATTAGTAGATGCAGTTGC 
RF835 GATCGGTACC TAGTGATAAGTCTGTACTTAGAAGTG KpnI 
RF836 GATCGGATCC TTTCTATCCATCTCAAAGTCTTCTTC BamHI 
RF837 CGTAGAAATACGGTGTTTTTTGTTACCCTAAATATATCTTGCCCAAA
TGTC 
RF838 TTGATGCAGAATTCGTTATTACATCCCTAATTCCTTG 
RF839 TTAGGGATGTAATAACGAATTCTGCATCAAGCTAG 
RF840 TAAATAATTAAGTTTAAATAAAAAAGACTTCTCATGAGAG 
RF841 AAGTCTTTTTTATTTAAACTTAATTATTTATAGTGTTACTTAAAAAAT
G 
RF842 GGGATTTTGGTCATGAGATTATCAAAAAGGATAGTATATAACATTA
ATAAAATTTAAAATCAATAATTATC 
RF863 CAGCTAACCTTCATTTATAAGGCTAAC 
RF874 GTACAGTTGTTGAACAAATAAAAGACTTAG 
RF901 GGTACCATAAAAATAAGAAGCCTGC 
RF902 GAATAAAAATGGATTATTATAGAGATGTG 
RF963 TGGCATAGCATCATTTAATGTTTCTTC 
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Table A3: Plasmids used in this study 
Plasmid Name Description Source 
pASF75 ClosTron vector carrying a group II intron targeted 
to recV. 
(Emerson et al., 
2009) 
pJAK012 pMTL960 based vector containing strep-tagged 
secA2 under control of Pcwp2. There is a XhoI 
restriction site between the strep-tag and secA2. 
This study 
pJAK013 pJAK012 in which the strep tag has been replaced 
with a SNAP tag. 
This study 
pJAK015 pJAK012 in which secA2 has been replaced with a 
secA1. 
This study 
pJAK034 pJAK015 in which the SNAP tag has been replaced 
with a CLIP tag 
This study 
pJAK047 pMTLSC7315 based vector to insert a SNAP tag to 
the 5’ of chromosomal secA2 
This study 
pJAK049 pMTLSC7315 based vector to insert a CLIP tag to 
the 5’ end of chromosomal secA1 
This study 
pJAK052 pMTLSC7315 based vector to insert nSNAP tag to 
the 5’ of chromosomal secA2 
This study 
pJAK072 pMTLSC7215 based vector to replace the native 
R20291 slpA with a SLCT-7 slpA 
This study 
pJAK073 pMTLSC7215 based vector to lock the cwpV switch 
in the OFF orientation 
This study 
pJAK074 pMTLSC7215 based vector to lock the cwpV switch 
in the ON orientation 
This study 
pJAK076 pMTL960 based vector to replace the native 
R20291 slpA with a SLCT-7 slpA 
This study 
pJAK080 pMTLSC7315 based vector to insert mreB2 under 
control of a tetracycline inducible promoter into 
the pyrE locus on the chromosome 
This study 
pJAK084 pMTLSc7315 based vector to knock out the native 
mreB2 
This study 
pJAK086 pJAK076 with a truncated left homology arm This study 
RF964 AGGCAACTTTATAAAGAAATATTTAAATTTATATTAAAATATTTTTAT
ATTTTTATTAGG 
RF966 GTATACTTAAGTTAAAACTAAATAGGCAAATC 
RF990 CAACATCATCATCTACAACCAG 
RF991 GATAGGTGAAATTTTGGCTTTTAAAGTAG 
RF992 CATTGAGATGCAAAATATAAACCTTTTG 
RF994 GTTTCATTTATGTAATGAAAATGTTATATAAATG 
RF995 GTAGCATATTCATTGTCTTAACTATTG 
RF997 GCAAATAAGTACATCTCAAAAGTTTCC 
RF1051 GATC GGTACC CTCATATGCTTGGGAAAAATAATAATTTC KpnI 
RF1052 GATCGGTACCGACTTGCAAAAAGAATAAAAATGGATTATTATAG KpnI 
RF1053 GATCGAGCTCCATTATATTAAAATTACATCTCTTCATTATGTAC SacI 
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pJAK106 pMTL960 based vector containing gusA under 
control of the slpA promoter (to the -35 region) 
This study 
pJAK107 pMTL960 based vector containing gusA under 
control of the slpA promoter (to include the 
potential UPE) 
This study 
pMTLSC7215 codA allele exchange vector for use in strain 
R20291 
(Cartman et al., 
2012) 
pMTLSC7315 codA allele exchange vector for use in strain 630 (Cartman et al., 
2012) 
pRPF144 pMTL960 based vector containing strep-tagged 
secA2 under control of Pcwp2 
(Fagan and 
Fairweather, 
2011) 
pRPF185 pMTL960 based vector containing gusA under 
control of the tetracycline inducible promoter.  
(Fagan and 
Fairweather, 
2011) 
pRPF186 pMTL960 based vector containing strep-tagged 
secA2 under control of the tetracycline inducible 
promoter. 
(Fagan and 
Fairweather, 
2011) 
pRPF187 pMTL960 based vector containing strep-tagged 
secA2K106R under control of the tetracycline 
inducible promoter. 
(Fagan and 
Fairweather, 
2011) 
pRPF193 pMTL960 based vector containing strep-tagged 
secA1 under control of the tetracycline inducible 
promoter. 
(Fagan and 
Fairweather, 
2011) 
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Appendix IV 
As part of my PhD thesis I am including my published paper “Heat shock increases conjugation 
efficiency in Clostridium difficile”, which was originally published in Anaerobe, 
https://doi.org/10.1016/j.anaerobe.2016.06.009 
All work presented in this paper was performed by myself. I also wrote all sections of the paper, 
which was then edited by my supervisor and the corresponding author, Dr Robert Fagan. 
This work is under a creative commons licence (https://creativecommons.org/licenses/by/4.0/) 
and I therefore have permission to use this article in my thesis. 
Yours sincerely, 
Joseph Kirk (PhD candidate) 
Dr Robert Fagan 
lable at ScienceDirect
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Clostridium difﬁcile infection has increased in incidence and severity over the past decade, and poses a
unique threat to human health. However, genetic manipulation of C. difﬁcile remains in its infancy and
the bacterium remains relatively poorly characterised. Low-efﬁciency conjugation is currently the only
available method for transfer of plasmid DNA into C. difﬁcile. This is practically limiting and has slowed
progress in understanding this important pathogen. Conjugation efﬁciency varies widely between
strains, with important clinically relevant strains such as R20291 being particularly refractory to plasmid
transfer. Here we present an optimised conjugation method in which the recipient C. difﬁcile is heat
treated prior to conjugation. This signiﬁcantly improves conjugation efﬁciency in all C. difﬁcile strains
tested including R20291. Conjugation efﬁciency was also affected by the choice of media on which
conjugations were performed, with standard BHI media giving most transconjugant recovery. Using our
optimised method greatly increased the ease with which the chromosome of R20291 could be precisely
manipulated by homologous recombination. Our method improves on current conjugation protocols and
will help speed genetic manipulation of strains otherwise difﬁcult to work with.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Clostridium difﬁcile poses a signiﬁcant threat to human health
and is the most common cause of antibiotic associated diarrhoea
[1]. Both incidence and mortality has increased over the last
decade. This is due, at least in part, to the emergence of epidemic
lineages such as ribotype 027 and 078 [1]. Despite the increase
incidence and severity of C. difﬁcile infections, relatively little is
known about the molecular basis of disease. However, an increased
recognition of the importance of C. difﬁcile in human health has led
to an increased interest in this bacterium. Despite this, genetic
manipulation of C. difﬁcile remains in its infancy. One limitation in
C. difﬁcile research is the reliance on low-efﬁciency conjugation, as
this is the only useable method for DNA transfer into C. difﬁcile [2].
This is less of a problem when using strains with relatively high
conjugation efﬁciencies such as the laboratory strain CD630.
However, clinically relevant epidemic strains, such as the ribotype
027 strain R20291, display very low conjugation efﬁciencies. This
makes genetic manipulation of these strains particularly difﬁcult.
Conjugation efﬁciencies of other bacteria, such as Campylobactere by Elisabeth Nagy.
irk), r.fagan@shefﬁeld.ac.uk
r Ltd. This is an open access articlejejuni and Corynebacterium glutamicum, have been shown to in-
crease in response to heat treatment [3,4]. Here we demonstrate
that conjugation efﬁciency in a panel of C. difﬁcile strains is
increased in response to heat treatment and we provide an opti-
mised conjugation protocol that will increase the ease with which
the species may be genetically manipulated.
2. Materials and methods
2.1. Growth and handling of organisms
C. difﬁcile strains, outlined in Table 1, were propagated either in
TY broth without thioglycolate [5] or on BHI agar. Cultures were
incubated at 37 C in an anaerobic environment composed of 80%
nitrogen,10% hydrogen and 10% carbon dioxide. Escherichia coliwas
routinely grown in LB broth or on LB agar. E. coli strain CA434
(HB101 carrying R702) was used as the conjugation donor
throughout. NEB5a (New England Biolabs) was used for cloning and
plasmid propagation. Growth media was supplemented with
chloramphenicol (15 mg/ml), thiamphenicol (15 mg/ml) or cyclo-
serine (250 mg/ml) as appropriate.
2.2. Viability of C. difﬁcile after heat treatment
C. difﬁcile strain R20291 was grown overnight in TY broth. 200 mlunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
C. difﬁcile strains used in this study including their respective clade, ribotype, and S-
layer type.
C. difﬁcile strain Clade Ribotype S-layer type
Ox858 1 029 2
Ox1437a 1 026 5
Ox1896 1 018 6
630 1 012 7
Ox1396 1 012 8
Ox1533 1 129 10
R20291 2 027 4
R7404 4 017 7b
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or 60 min. An unheated control was included. Samples were then
serially diluted and 10 ml of each dilution was spotted onto well-
dried BHI plates and incubated overnight. Enumerations were
performed in triplicate on biological duplicates. Colonies of C.
difﬁcile were counted and viability calculated as CFU/ml.2.3. Plasmid conjugations
A previously described and widely used conjugation protocol
was used as the starting point for development of our improved
method [2]. 200 ml samples of C. difﬁcile overnight cultures were
heated, as above, and incubated at 37 C for 2min.1 ml of overnight
E. coli conjugant donor (CA434) culture was harvested by centri-
fugation at 4000g for 2 min and transferred into the anaerobic
workstation. E. coli cell pellets were then gently resuspended in
200 ml of heat treated or untreated C. difﬁcile culture. This mixed cell
suspension was then pipetted onto well-dried, non-selective agar
plates (10  10 ml spots) and allowed to dry. BHI agar was used
routinely but BHIS (BHI agar supplemented with 0.1% (w/v)
cysteine and 0.5% (w/v) yeast extract), TY [5] and Brazier’s (Brazier’s
CCEY media, 1% (v/v) deﬁbrinated horse blood, 4% (v/v) egg yolk
emulsion) agar were also tested. All solid media contained 1.5%
agar. Conjugationswere then incubated for 8e24 h followingwhich
growth was harvested using 900 ml of TY broth, serially diluted and
spread on plates containing either cycloserine (for total C. difﬁcile
CFU counts), or cycloserine and thiamphenicol (to select for
transconjugants). Approximate conjugation efﬁciency was then
calculated as transconjugant CFU/total C. difﬁcile CFU. These ex-
periments were performed using biological duplicates with tech-
nical triplicates. Statistical signiﬁcance of these results was
determined using either individual student t-tests or in combina-
tion with one way analysis of variance (ANOVA), performed using
GraphPad Prism 6. P values of<0.05 were considered statistically
signiﬁcant.2.4. Creation of a chromosomal divIVA-SNAP fusion mutant and
ﬂuorescence microscopy
1.2 kb upstream and downstream of the 30 region of divIVAwere
ampliﬁed using RF439 (CGTAGAAA-
TACGGTGTTTTTTGTTACCCTACTGTAGCAATATTAAATTCTACAAATG)
with RF440 (CAGCAGCTGCCTCGAGTTCTAAAGTTGTAGCAGCTTC)
and RF443 (CCAGGACTTGGGTAAGCTTGTAATTTGTTTATTTTTTATG)
with RF444 (GGGATTTTGGTCATGAGATTATCAAAAAGGA-
CATTTGATGGTAAAGTCCATG) respectively. A C. difﬁcile codon-
optimised SNAP-tag coding sequence was cloned from pFT46 [6]
using RF441 (GCTACAACTTTAGAACTCGAGGCAGCTGCTGAT) and
RF442 (AAACAAATTACAAGCTTACCCAAGTCCTGGTTTCC). pMTL-
SC7215 [7] was linearized using RF311 (TAGGGTAACAAAAAA-
CACCG) and RF312 (CCTTTTTGATAATCTCATGACC). These fragmentswere then combined using a combination of SOEing PCR [8] and
Gibson assembly [9] using the HiFi DNA assembly kit (New England
Biolabs). The resulting plasmid (pJAK050) was then conjugated into
C. difﬁcile strain R20291 and mutants selected using the method
previously described [7]. Correct insertion of the SNAP-tag coding
sequence into the chromosome was conﬁrmed by PCR using RF445
(GGTTTAAGAGGGTATAGAGATG) and RF545 (CGAGTTA-
TAAATCGCGTTACCACC). For ﬂuorescent labelling of DivIVA-SNAP,
1 ml of exponentially growing R20291 and R20291 divIVA-SNAP
was incubated anaerobically with 250 nM SNAP TMR-star (New
England Biolabs) for 30 min before slides were prepared for stan-
dard ﬂuorescence microscopy, or lysates prepared. Proteins in the
lysates were resolved on 12% SDS-PAGE gels and visualised using a
BioRad ChemiDoc MP imaging system. Slides were visualised using
a Nikon Ti Eclipse inverted epiﬂuorescence microscope.
3. Results and discussion
3.1. Heat treatment of R20291 increases conjugation efﬁciency
C. difﬁcile strain R20291 was chosen for these experiments due
to its clinical relevance and relatively low conjugation efﬁciency.
The effect of heat treatment on conjugation efﬁciency was tested.
R20291 cultures were heated to 44e52 C for 15 min prior to
conjugation with the E. coli donor CA434 bearing the plasmid
pRPF185 [10]. pRPF185 was chosen as it is a commonly used
plasmid in C. difﬁcile research and contains the native C. difﬁcile
replicon pCD6. A clear increase in conjugation efﬁciency was
observed with increasing temperatures, from 46 C to 50 C
(Fig.1A). However, no transconjugants were observedwhen treated
at 52 C for 15 min. Additionally, although conjugation efﬁciency
was increased at 50 C relative to 48 C, lower total CFUs and
transconjugant CFUs were recorded. To test the effect of the heat
treatment on C. difﬁcile viability, cultures were heated to 44e52 C
for 5e60 min and viable cells enumerated (Fig. 1B). Viability was
unaffected by incubation at 44 C but there was a signiﬁcant
reduction in viability at temperatures above this and viability
further decreased with increasing incubation time. Based on these
data it is clear that the total number of transconjugants recovered is
a compromise between increasing conjugation efﬁciency and
decreasing viability. Although heat treatment at 52 C for 15 min
resulted in recovery of no transconjugants, this treatment did
reduce viability by more than four orders of magnitude. As shorter
heat treatments minimised the impact on viability, conjugationwas
tested following a 52 C heat treatment for 5 min. This treatment
almost doubled the recovery of transconjugants compared to the
next best condition (approx. 2800 CFU/ml following 52 C, 5 min
compared with 1500 CFU/ml following 50 C, 15min). These con-
ditions were used as standard for the remainder of the experiments
described below unless otherwise stated.
3.2. Conjugation efﬁciency is affected by media choice
There appears to be no standard media choice for C. difﬁcile
conjugations in the current literature. For this reason, the effect of
media choice on conjugation efﬁciency, after heat treatment, was
investigated. Conjugations were performed on BHI, BHIS, TY, and
Braziers agar (Fig. 2). The highest conjugation efﬁciency was
recorded when conjugations were performed using BHI agar.
Although conjugation efﬁciency was lower when using BHIS rela-
tive toTY, higher numbers of transconjugants were recoveredwhen
using TY due to a higher total CFU count recorded when using this
growth medium. Total C. difﬁcile CFUs recovered from Brazier’s was
the lowest of all tested media, and resulted in the recovery of no
transconjugants. While this observation is unlikely to be due to the
Fig. 1. Effect of heat treatment on conjugation efﬁciency and viability of C. difﬁcile
strain R20291. (A) Conjugation efﬁciency of unheated and heat treated (44e52 C for
15 min) C. difﬁcile strain R20291. Asterisks (*) denote statistical signiﬁcance between
heat treatment conditions (P < 0.05). Each bar represents the mean and standard
deviation of data collected from experiments performed in triplicate using biological
duplicates. (B) Viability of R20291 after heat treatment at varying temperatures
(44e52 C) and incubation times (5e60 min). Each bar represents the mean and
standard deviation of data collected from experiments performed in triplicate using
biological duplicates.
Fig. 2. Effect of media choice on conjugation efﬁciency of C. difﬁcile strain R20291 after
heat treatment. BHI, BHIS, TY and Brazier’s agar were tested in 8 h conjugations
following a 52 C, 5 min heat treatment. Use of Brazier’s agar resulted in the recovery
of no transconjugants. Each bar represents the mean and standard deviation of data
collected from experiments performed in triplicate using biological duplicates.
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is likely that population equilibrium between C. difﬁcile and E. coli is
affected, which may in turn impact overall conjugation efﬁciency.3.3. Heat treatment improves conjugation efﬁciency of a plasmid
containing a non-native replicon
The precise manipulation of the genome of R20291 can be
achieved through the use of the allele-exchange vector pMTL-
SC7215. This pseudosuicide vector contains the pBP1 replicon,
which replicates at a rate lower than that of the host cell chro-
mosome. The result is non-exponential growth, limited by the rate
of plasmid replication, when under antibiotic selection [7]. How-
ever, plasmids based upon this vector are difﬁcult to conjugate into
strain R20291 and the number of publications describing the use of
this plasmid remains low. For this reason a pMTL-SC7215 based
vector was created to add the SNAP-tag coding sequence to the
chromosomal divIVA gene. This plasmid, pJAK050, was then used in
heat treated and unheated conjugations. Due to the extremely low
conjugation efﬁciency when using this plasmid, 24 h conjugations
were performed following a 50 C for 15 min heat treatment. No
transconjugants were recovered using the standard unheated
conjugation protocol. However, using our optimised heat treatment
protocol large numbers of transconjugants were recovered, allow-
ing a divIVA-SNAP mutant to be isolated in little over 2 weeks after
the plasmid was constructed. Correct insertion of the SNAP-tag
coding region into the C. difﬁcile genome was conﬁrmed by PCR
(Fig. 3A). Fluorescence imaging of lysates of SNAP TMR-star treated
R20291 divIVA-SNAP resolved by SDS-PAGE shows a band at
approximately 40 kDa, the estimated size of DivIVA-SNAP (Fig. 3B).
SNAP TMR-star treated R20291 divIVA-SNAP displayed mostly
septal and some polar localisation of ﬂuorescence (Fig. 3C and D),
similar to DivIVA localisation observed in other bacterial species
[11]. Taken together, these results suggest correct insertion of the
SNAP-tag coding sequence into the C. difﬁcile chromosome at the
appropriate genetic locus.
3.4. Heat treatment increases conjugation efﬁciency in a panel of C.
difﬁcile strains
In order to determine whether the improved conjugation pro-
tocol was more widely applicable, conjugations were performed
with pRPF185 on a panel of C. difﬁcile strains. The strains tested
represented a further 6 ribotypes and the majority of C. difﬁcile
clades and S-layer types [12]. All strains tested displayed an in-
crease in conjugation efﬁciency after heat treatment, although the
observed improvement was greatest for strain R20291 (Fig. 4).
Although efﬁciency was improved, heat treatment did not result in
a signiﬁcant increase in the number of transconjugants recovered
for strains Ox1396 and Ox1437a. This is likely due to a decrease in
viability following heat treatment and may be improved by
extending the conjugation time. Using the standard 52 C for 5 min
heat treatment, conjugation efﬁciency into strain R7404 was too
low to accurately measure after an 8 h conjugation and no signif-
icant increase in conjugation efﬁciency was observed when con-
jugations were extended to 24 h. R7404 conjugation was then
tested after incubation at 50 C for 15 min followed by a 24 h in-
cubation. This resulted in a signiﬁcant increase in both conjugation
efﬁciency (Fig. 4) and in the number of transconjugants recovered.
These results indicate that our heat treatment conjugation protocol
is broadly applicable to themajority of C. difﬁcile strains andmay be
further optimised for speciﬁc applications.
4. Conclusions
C. difﬁcile shows considerable strain-to-strain variation in
conjugation efﬁciency. Conjugation efﬁciency is improved in a
panel of strains, representing the majority of clades and S-layer
types, through heat treatment of the recipient C. difﬁcile prior to
Fig. 3. Precise manipulation of the R20291 genome accelerated by the use of optimised conjugation. (A) 0.8% Agarose gel showing PCR fragments ampliﬁed using primers ﬂanking
the SNAP-tag coding sequence insertion site in the chromosomal divIVA gene. The increase of approximately 550bp from 885 bp (R20291) to 1443 bp (R20291 divIVA-SNAP) suggests
the correct insertion of the SNAP-tag coding sequence. (B) 12% SDS-PAGE gel imaged using a ﬂuorescence imager, showing resolved lysates from SNAP TMR-star treated R20291 and
R20291 divIVA-SNAP. A band at approximately 40 kDa in the mutant corresponds to the addition of a SNAP-tag on DivIVA. (C) Brightﬁeld and (D) ﬂuorescence microscopy of
exponentially growing R20291 divIVA-SNAP stained with 250 nM SNAP TMR-star for 30 min, showing mostly septal and some polar localisation of ﬂuorescence. This demonstrates
successful modiﬁcation of the R20291 genome. Scale bar represents 5 mm.
Fig. 4. Effect of heat treatment on the conjugation efﬁciency of a panel of C. difﬁcile
strains. A panel of C. difﬁcile strains was used in unheated (dark grey) and heat treated
(light grey, 52 C for 5 min) 8 h conjugations. Strain R7404 showed no signiﬁcant
increase in conjugation efﬁciency with this treatment and was therefore used in a 24 h
conjugation after a more stressful heat treatment (50 C for 15 min). Each bar repre-
sents the mean and standard deviation of data collected from experiments performed
in triplicate using biological duplicates. All strains displayed a statistically signiﬁcant
(P < 0.05) increase in conjugation efﬁciency after heat treatment.
J.A. Kirk, R.P. Fagan / Anaerobe 42 (2016) 1e54conjugation. Conjugation efﬁciency is dependent on the media
choice on which the conjugation is performed, with the highest
number of transconjugants being recovered from BHI agar in this
study. Using an optimised heat treatment conjugation protocol
signiﬁcantly improved the ease in which a pMTL-SC7215 based
plasmid was introduced into R20291, facilitating chromosomal
manipulation of the R20291 genome by homologousrecombination. Heating the recipient C. difﬁcile to 52 C for 5 min
prior to conjugation proved to be optimum for an 8 h conjugation,
although conjugation efﬁciency can be increased by coupling more
stressful heat treatments with longer conjugation times.
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